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Abstract
In many species a developmentally related increase in Cortisol production
from the fetal adrenal gland brings about the progressive maturation of
fetal organ systems and triggers the onset of parturition. The fetal
hypothalamus is thought to play a pivotal role in this process by secreting
the neuropeptides, CRH and AVP which act upon the fetal pituitary gland
to cause the secretion of ACTH. However, little is known about the
ontogeny and neuroendocrine regulation of CRH and AVP secretion
from the fetal hypothalamus. The experiments described in this thesis
were therefore designed to investigate the maturation of CRH and AVP
secretion from the fetal hypothalamus during fetal development.
In order to study the secretion of CRH and AVP from the fetal
hypothalamus a method for the serum-free culture of fetal sheep
hypothalamic neurones was developed. The system was optimised in
terms of plating density and substrate requirements and cells were
maintained in vitro for up to 35 days. The functional capacity of these
cells was demonstrated by measuring enhanced AVP secretion after
potassium-induced depolarization, a response which was time- and
calcium-dependent.
To investigate the ontogeny of CRH and AVP secretion, cultured
fetal sheep hypothalami removed at day 70, day 100 and day 130 of
gestation (Term = day 145) were incubated with control and 56 mM
potassium-containing medium. The results showed an overall reduction
in basal and potassium-stimulated CRH and AVP release with advancing
gestational age. These data suggested that hypothalamic secretion of CRH
and AVP was reduced with advancing gestation.
To relate these results to the intact hypothalamus, the
concentrations of immunoreactive and bioactive CRH and AVP were
measured in age-matched fetal sheep hypothalami by RIA and pituitary
cell bioassay respectively. In contrast to the reduction in CRH and AVP
secretion observed in vitro, the concentrations of CRH and AVP in the
fetal hypothalamus increased with advancing gestational age. These
results suggest that extrahypothalamic inputs regulate the secretion of
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CRH and AVP from the hypothalamus in vivo. Alternatively, changes
in peptide secretion in vitro may reflect inherent maturational
differences between hypothalamic cells removed at each gestational age.
The functional capacity of cultured fetal hypothalamic cells was
assessed by studying the effects of Cortisol and opioid peptides on AVP
secretion at day 70 and day 100 of gestation. Cortisol inhibited basal and
potassium-stimulated AVP secretion in day 70 but not in day 100 cells.
Similarly, the kappa opioid agonist [D-Pro10] Dynorphin (1-11) inhibited
AVP secretion from day 70 cells via a naloxone-insensitive pathway, yet
had no effect in day 100 cultures or in cells pre-treated with Cortisol.
These results suggest that both Cortisol and opioid inhibition are
diminished with advancing gestation and that there may be interactions
between these inhibitory influences during development.
In conclusion, these studies have demonstrated the viability of an
in vitro culture system for investigating developmentally related changes
in neuropeptide secretion from the fetal sheep hypothalamus. As a result
of these studies it is possible to conclude that CRH and AVP secretion
from the fetal hypothalamus is likely to be under extrahypothalamic
inhibitory control early in gestation. The gradual decline in this
inhibition during fetal development would allow activation of the fetal
pituitary-adrenal axis, the maturation of fetal organs and the onset of
parturition.
[~ 45,000 words in main text]
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In the United Kingdom, 5-8% of all births occur preterm, and prematurity
with immaturity accounts for the majority of perinatal mortality and
morbidity in this country. However, the precise mechanisms which
underlie the onset of prenatal maturation and the timing of parturition
are unknown. The experimental evidence suggests that sequential
maturation of fetal endocrine systems, specifically the adrenal axis, plays a
significant role in prenatal development. Thus the developing fetal
hypothalamus secretes corticotrophin-releasing hormone (CRH) and
arginine vasopressin (AVP). These factors provoke the release of
adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland,
which stimulates Cortisol secretion from the fetal adrenal (Norman, Lye,
Wlodek & Challis, 1985; Challis & Brooks, 1989). Cortisol thus secreted by
the fetal adrenal cortex late in gestation enhances neonatal viability by
stimulating the maturation of the fetal lung and gut. Further, high
concentrations of fetal Cortisol observed just before term induce specific
biochemical changes in the placenta which cause a decline in
progesterone and increase in oestrogen production. This ultimately leads
to the enhanced myometrial contractility which culminates in birth.
Therefore, increasing hypothalamic input to the fetal pituitary-adrenal
axis late in gestation may play a pivotal role in the fetal preparations for
extrauterine life.
In pioneering studies to examine the contribution of the fetal
hypothalamo-pituitary-adrenal axis to the onset of parturition in the
sheep, Liggins and colleagues determined the effects of various endocrine
and surgical manipulations in the fetus on the timing of birth (see
Liggins, Fairclough, Grieves, Kendall & Knox, 1973, for review).
Separation of the fetal hypothalamus from the fetal pituitary by
infundibular stalk section lead to prolonged pregnancy, and this was
mimicked by electrocoagulation of the fetal pituitary gland
(hypophysectomy). By contrast, intrafetal administration of ACTH or
Cortisol reliably brought about preterm delivery of the fetus within a few
days. Recent studies have reported that disconnection of the
hypothalamus from the pituitary gland in the fetal sheep prevents the
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onset of labour at the normal time (Antolovich, Clarke, McMillen, Perry,
Robinson, Silver & Young, 1990). Furthermore, specific ablation of the
fetal hypothalamic paraventricular nucleus, which contains the cell
bodies of the CRH and AVP neurones, invariably results in a failure of
parturition at term (see Palca, 1991). However it is not known whether an
increase in hypothalamic drive to ACTH secretion by the fetal pituitary
accounts for these maturational processes.
The observations presented above lead to a general hypothesis
regarding the function of the fetal sheep hypothalamus during
development. It was considered that maturation of the fetal sheep
hypothalamus gave rise to changes in hypothalamic secretion of CRH
and AVP, and that these changes might underlie the preparurient
increase in fetal plasma ACTH and Cortisol. The purpose of this thesis
was therefore to investigate the regulation of AVP and CRH secretion in
the fetal sheep hypothalamus during development. However, it was not
possible to measure AVP and CRH secretion directly. Therefore, the first
experimental chapter describes the optimisation of the culture conditions
required to maintain fetal sheep hypothalamic neurones in vitro.
Subsequently, the development of fetal hypothalamic CRH and AVP was
followed at several gestational ages by measuring CRH and AVP secretion
in vitro and by assessing hypothalamic CRH and AVP content in fresh
tissues. Later, the functional maturation of the fetal hypothalamus was
investigated by assessing the responses to Cortisol or an opioid peptide at
different gestational ages.
The results of the above investigations are presented in chapters 4-
8, each of which contains a discussion of the results relevant to that
chapter. A synthesis of these results is presented in chapter 9, in which
methodological limitations are discussed, along with those areas which
warrant further investigation.
2. Review of the Literature.
The studies described in this thesis are centred around an investigation
of corticotrophin-releasing factors in the developing fetal sheep
hypothalamus. To illustrate the relationship of these studies to the
general physiology of the hypothalamo-pituitary-adrenal axis, the
following chapter describes the functional development of this axis in the
fetal sheep. Moreover, detailed reviews are given of those aspects of
hypothalamic biology most relevant to material presented in ensuing
chapters of this thesis. Many of the reports concerning the hypothalamic
secretion of corticotrophin-releasing factors have described data gathered
in adult animals and in species other than the sheep. In order to present
a more complete description of hypothalamic function in the fetal sheep,
references have been made to these reports where the corresponding
studies had not been carried out in the sheep fetus.
This chapter is divided into two general areas. The first part
comprises sections 2.1 and 2.2, which contain information relating to the
physiology of the hypothalamo-pituitary-adrenal axis in the fetal sheep.
Therefore, an overview of the functional maturation of the pituitary-
adrenal axis in the sheep fetus is presented in section 2.1, and in section
2.2, the interplay between hypothalamic releasing factors, pituitary ACTH
and adrenal steroids during fetal development is discussed. The second
part of this review comprises sections 2.4 to 2.5 and examines those areas
of hypothalamic function most relevant to specific chapters in this thesis.
Therefore, these sections examine factors such as the neuropeptides and
adrenal steroids which regulate secretion of corticotrophin-releasing
factors from the hypothalamus. These sections are not intended to be
exhaustive documents of all research carried out in these fields. Instead,
they serve to highlight areas of investigation which are most relevant to
the subject matter of this thesis.
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2.1 Overview of the Fetal Pituitary-Adrenal axis in
development
2.1.1. Historical Perspective.
The significance of the fetal pituitary gland in fetal maturation and in the
timing of parturition in the sheep came to be appreciated in the 1960's.
Until this time, the question of whether the fetus or the mother
originated the signal for parturition had remained a matter for
speculation, though a paper by Binns and colleagues in 1960 had
highlighted a fortuitous natural experiment implicating the fetus as the
origin for this signal (Binns, Anderson & Sullivan, 1960). These
researchers observed that certain sheep failed to deliver their fetuses at
the normal gestational age. On examination, the unborn lambs were
found to bear widespread lesions of the central nervous system and
pituitary gland, which had been induced by maternal ingestion of
teratogenic shrubs during early pregnancy. Reports appearing in the
literature of the time had made parallel observations in guernsey cows, in
which the fetuses had genetically-induced dysgenesis of the central
nervous system and pituitary gland, and the mothers had greatly
extended pregnancies (Kennedy, Kendrick and Stormont, 1957).
Therefore, these data provided good evidence that the fetal central
nervous system and pituitary were implicated in the initiation of
parturition, in contrast to the role of the mother, which was essentially
passive in this regard.
The observations described above lead Liggins and co-workers to
investigate the role of the fetal hypothalamus and pituitary in parturition
in the sheep. These authors removed hypothalamic input to the fetal
pituitary gland by performing pituitary stalk section, and showed that
fetuses were not delivered at term after this treatment (see Liggins et al.
1973, for review). In parallel, electrocoagulation of the fetal sheep
pituitary gland significantly delayed parturition in fetuses in which 70%
or more of the gland had been destroyed (Liggins, Kennedy & Holm,
1967). These studies did not, however, account for the many active
principles contained in the fetal pituitary, and so could not determine
which was responsible for normal parturition. Later experiments by
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Liggins (1968) determined that administration of growth hormone,
luteinising hormone, follicle-stimulating hormone and prolactin to the
sheep fetus had no effect on the duration of pregnancy. However,
administration of these hormones plus ACTH, or of ACTH alone, reliably
gave rise to parturition within a few days. By contrast, concomitant
administration of ACTH and metyrapone, the corticosteroid synthesis
inhibitor, did not result in premature labour (Liggins, 1968).
The efficacy of intrafetal ACTH to induce premature delivery, and
the dependence of this phenomenon on adrenal steroid synthesis,
suggested that the fetal pituitary-adrenal axis formed an essential
component in the initiation of parturition. In support of this, Drost &
Holm (1968) showed that fetal adrenalectomy abolished parturition in the
sheep, complementing the observation that intrafetal administration of
Cortisol, but not oestradiol, precipitated preterm delivery in this species
(Liggins, 1968). The physiological significance of fetal adrenal activation
was then confirmed in studies showing that fetal adrenal Cortisol
secretion was increased with advancing gestation in the sheep
(Alexander, Britton, James, Nixon, Parker, Wintour & Wright, 1968), and
that parturition was associated with dramatic elevations in fetal plasma
Cortisol levels, which preceded delivery by several days (Basset &
Thorburn, 1969). These early studies laid the foundations for the current
understanding, which holds that activation of the hypothalamo-pituitary-
adrenal axis in the fetal sheep gives rise to parturition (see Challis &
Brooks, 1989).
2.1.2. The preparturient activation of the fetal pituitary-adrenal axis.
The basic hypothesis outlined above suggests that pituitary drive to the
fetal adrenal is increased with advancing gestation, and that it is this
drive which increases the secretion of Cortisol from the fetal adrenal.
Until recently, however, experimental observations suggested that the
progressive increase in fetal plasma Cortisol levels which occurs in the
last few weeks of gestation was not dependent on fetal plasma ACTH,
which remained unchanged during this time. Thus, Rose and colleagues
found that plasma ACTH concentrations in the fetal sheep between day 70
and day 140 of gestation showed no developmental trends, though they
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clearly demonstrated increasing plasma Cortisol levels over the last three
weeks of gestation (Rose, MacDonald, Heymann & Rudolph, 1978). Such
observations had lead other workers to consider that fetal ACTH was not
implicated in the adrenal activation which occurs in the maturing sheep
fetus (Rees, Jack, Thomas & Nathanielsz, 1975; Jones, Boddy & Robinson,
1977).
Recent improvements in assay techniques, coupled with more
stable chronically instrumented preparations, have permitted a re¬
examination of fetal ACTH during the preparturient activation of the
fetal adrenal axis. These studies have lead to the current appreciation that
fetal plasma ACTH levels begin to increase around day 110-120 of
gestation, well before fetal Cortisol begins to rise at day 125, and that fetal
ACTH continues to rise in parallel with Cortisol as gestation proceeds
towards term (Norman et al. 1985). Around day 140 of gestation, fetal
plasma ACTH and Cortisol undergo a further coincident elevation, as
recorded by earlier workers (Rees et al. 1975; Jones et al. 1977; Rose et al.
1978). Ultimately, these endocrine developments stimulate fetal
maturation and bring about the marked changes in placental steroid
synthesis characteristic of the later stages of pregnancy and the onset of
parturition in this species.
2.1.3. Functions of Cortisol in the fetal sheep.
Early investigations were concerned with the function of the fetal
hypothalamo-pituitary-adrenal axis in parturition. It was clear that fetal
adrenal Cortisol was important in the mechanisms of parturition,
however, these studies did not elucidate how fetal Cortisol might act in
this regard. Serial plasma samples removed from the mother showed
that spontaneous or glucocorticoid-induced labour in the sheep was
preceded by a sharp rise in maternal plasma oestrogens and a concomitant
fall in plasma progesterone (Bassett, Oxborrow, Smith & Thorburn, 1969;
Challis, 1971; Flint, Anderson, Patten & Turnbull, 1974), suggesting that
removal of the "progesterone block" on uterine contractility may have
been involved (Csapo & Weist, 1969). Fetal placental membranes are the
site of progesterone synthesis in the sheep placenta (Anderson, Flint &
Turnbull, 1975), and fetal, but not maternal placental tissues collected
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after intrafetal administration of glucocorticoids or from term fetuses
during labour show much enhanced 17a-hydroxylase (Anderson et al.
1975) and C-17, 20 lyase activity (Steele, Flint & Turnbull, 1976). In concert
with placental aromatase, these enzymes catalyse the synthesis of
oestrone from progesterone (Steele et al. 1976). Therefore, glucocorticoids
acting in the fetal compartment transform the placenta from a
progesterone-synthesising organ to an oestrogen-synthesising organ near
term. Previous experiments had shown that oestrogens and
prostaglandin F2a (PGF2a) levels increase in parallel in uterine venous
blood, and that oestrogen infusion to fetuses stimulates PGF2a levels in
uterine venous blood (Flint et al. 1974). Therefore, fetal glucocorticoids
ultimately stimulated the release of a potent uterotonic prostaglandin,
which is believed to play a major role in the onset of labour and
parturition in many species (See Thorburn & Challis, 1979, for review).
In addition to the role of glucocorticoids in the placenta, it has
become clear that fetal corticosteroids have equally important actions
within the fetus, and are responsible for bringing about fetal organ
maturation in late gestation (see Silver, 1990, for review). Liggins (1969)
remarked on the precocious maturity of the lungs of fetal lambs infused
with dexamethasone in utero and hypothesised that this may be due to
increased production of pulmonary surfactant. It has since become clear
that glucocorticoids act to induce functional differentiation of the type 2
pneumocytes which synthesise surfactant (Wang, Kotas, Avery, &
Thurlbeck, 1971), and stimulate the activity of one of the key enzymes in
surfactant production, choline phosphotransferase (Farrell & Zachman,
1973). Glucocorticoids may also have potent stimulatory effects on the
maturation of other fetal organ systems. For example, Cortisol infusion to
the hypophysectomised fetal sheep restores hepatic glycogen levels
(Barnes, Comline & Silver, 1978), induces the expression of gut
disaccharidases, and enhances maturation of the fetal insulin response to
intravenous glucose administration (see Liggins, 1976, for review).
Therefore, the current understanding suggests that increasing fetal
plasma corticosteroids in late gestation induce fetal maturation, in
preparation for extrauterine survival. Subsequently, the further elevated
Cortisol levels observed in the last few days of pregnancy have a different
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function, which is to initiate the placental endocrine mechanisms which
bring about parturition.
2.2 Functional development of the fetal hypothalamo-
pituitary-adrenal axis.
The previous section has described the important functions of the fetal
adrenal gland as a glucocorticoid-synthesising organ. However, the
failure of parturition after fetal hypophysectomy clearly demonstrates the
importance of pituitary drive in the normal preterm activation of the
fetal adrenal gland. Therefore, increasing hypothalamic secretion of
ACTH-releasing factors, and hence ACTH secretion from the fetal
pituitary gland, are possibly more important factors in the timing of birth
than the activity of the adrenal gland alone. The purpose of this section is
therefore to examine pituitary ACTH secretion during fetal life, and to
illustrate how hypothalamic ACTH-releasing factors might act at the fetal
pituitary, to acutely stimulate ACTH release and to activate the pituitary-
adrenal axis near term.
2.2.1. ACTH in the developing fetal pituitary.
ACTH is a 39 amino acid peptide which is processed from a large
precursor in the corticotrophs of the anterior pituitary gland (Mains,
Eipper & Ling, 1977; Phifer, Orth & Spicer, 1977;). Transcription of the
pro-opiomelanocortin (POMC) gene gives rise to a high molecular weight
peptide, which is cleaved at several processing sites to yield mature ACTH
(1-39), in addition to several other bioactive peptides, such as (3-
lipotrophin and ^-endorphin (Nakanishi, Inoue, Kita, Nakamura, Chang,
Cohen, & Numa, 1979). Whilst the POMC gene product is synthesised in
both the anterior and intermediate lobes of the pituitary gland, only the
anterior pituitary contains substantial amounts of ACTH (see Eipper &
Mains, 1980, for review).
Recent studies have investigated the maturation of corticotrophs
in the fetal sheep pituitary gland. Using four antisera, each specific for a
different POMC product, corticotrophs were observed to contain all of
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ACTH, pro-ymelanocyte-stimulating hormone (pro-yMSH), yMSH and (3-
endorphin/p-lipotrophin by day 38 of gestation (Mulvogue, McMillen,
Robinson & Perry, 1986). The pituitary glands from more mature fetuses
showed the same staining pattern, however, the intensity of the
immunostaining was increased, which was suggestive of increased
pituitary content of the POMC peptides. In pituitary glands removed at
day 38 of gestation, the immunostaining reaction products were located in
large columnar cells (fetal corticotrophs). However, between day 87 and
127, small, immunoreactive stellate cells were found in increasing
numbers (adult corticotrophs). After day 132 of pregnancy, only the
stellate, adult-type corticotrophs were present.
Investigations carried out recently have suggested that maturation
of the fetal sheep corticotrophs is under hypothalamic neuroendocrine
control. Antolovich and colleagues reported that fetal ACTH-immuno-
reactive cells adopt the adult, stellate appearance in normal fetuses
between day 120 and day 135 of gestation (Antolovich, Perry, Trahair,
Silver & Robinson, 1989). However, the majority of ACTH-
immunoreactive cells in day 135 pituitaries show the columnar, fetal-type
morphology if surgical disconnection of the hypothalamus and pituitary
is carried out at day 108-112 of gestation (Antolovich, McMillen,
Robinson, Silver, Young & Perry, 1991). Therefore, aside from ACTH-
releasing activities, hypothalamic input to the fetal pituitary is likely to
play a significant part in the maturation of the fetal pituitary corticotrophs
during fetal life.
Development of adult-type corticotrophs may be associated with
developmental changes in the biochemistry of ACTH synthesis. Extracts
of anterior pitutiary glands removed from fetal and adult sheep contain
several molecular weight species which are immunoreactive in ACTH
radioimmunoassay (RIA) procedures (Silman, Holland, Chard, Lowry,
Hope, Rees, Thomas & Nathanielsz, 1979). In fetal sheep pituitary glands
removed around day 120 of gestation, most ACTH immuno-reactivity
was accounted for by high molecular weight (> 20 kD) ACTH molecules,
whereas the majority of ACTH-immunoreactivity in the adult pituitary
gland co-eluted with synthetic ACTH(l-39) on Sephadex chromatography
(Silman et al. 1979).
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Jones & Roebuck (1980) carried out experiments to examine the
bioactivity of the different ACTH peptides present in the fetal sheep
pituitary gland. These authors purified the ACTH-immunoreactive
substances in fetal pituitaries to yield 50-60 kD, 30 kD, 20 kD and 4.5 kD
(ACTH 1-39) molecular weight species. They incubated fetal sheep
adrenal cells removed at day 127 of gestation with the high molecular
weight ACTH peptides, in the presence and absence of ACTH(l-39). The
30 kD peptide stimulated Cortisol production to some degree, however,
there was no additive effect with ACTH(l-39). By contrast, the 50-60 kD
and 20 kD peptides had little effect alone but substantially inhibited
ACTH(l-39)-induced Cortisol secretion, suggesting that these substances
may act as ACTH antagonists at the fetal adrenal gland in vivo.
These studies investigated the ACTH peptides present in pituitary
extracts, and so did not reveal which ACTH-like molecules might exist in
the circulation to act at the fetal adrenal gland in vivo. However, Jones &
Roebuck (1980) pointed out that electrophoresis of fetal sheep plasma
proteins reveals ACTH immunoreactivity to be present as equal amounts
of "big" ACTH (50-60 kD, 30 kD and 20 kD) and small ACTH(l-39)
molecules. Interestingly, these authors found that the proportion of big
ACTH, relative to ACTH(l-39), was reduced in late pregnancy, and
showed that ACTH(l-39) became the principal ACTH-immunoreactive
species in fetal plasma in late gestation. These data are in agreement with
more recent studies, which have shown that increased ACTH bioactivity,
as secreted by fetal sheep pituitary cells, is associated with increasing
proportions of low molecular weight ACTH relative to total ACTH
immunoreactivity (Brieu & Durand, 1989). Therefore, the fetal sheep
pituitary gland may secrete more bioactive ACTH, and less of the high
molecular weight ACTH antagonists, and so provide increasing drive to
fetal adrenal corticosteriod secretion near term.
2.2.2. ACTH-Releasing Factors, ACTH, and adrenal steroids in fetal life.
The identification of the corticotropin-releasing factor in the ovine
hypothalamus by Vale's group in 1981 (Vale, Speiss, Rivier, & Rivier,
1981; Speiss, Rivier, Rivier & Vale, 1981) rapidly established the new
corticotropin-releasing hormone (CRH) as a potent stimulator of pituitary
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ACTH secretion in several species, including rat (Rivier, Brownstein,
Speiss, Rivier, & Vale, 1982), sheep (Donald, Redekopp, Cameron, Nicolls,
& Bolton, 1983), and man (Motomatsu, Takahashi, Ibayashi & Nobunaga,
1984). Ironically, the isolation of CRH permitted the identification of
Arginine Vasopressin (AVP), long suspected to be an ACTH-releasing
factor, as a physiologically significant peptide in the hypothalamic control
of ACTH secretion (Linton, Tilders, Hodgkinson, Berkenbosch, Vermes &
Lowry, 1985), which exhibited synergy in this regard with CRH (Gillies,
Linton, & Lowry, 1982; Giguere & Labrie, 1982). Recent evidence suggests
that AVP is a more potent ACTH-releasing factor in the sheep than CRH
(Familiari, Smith, Smith & Funder, 1989), however, both factors are
implicated in the physiological stimulation of ACTH release in this
species (Engler, Pham, Fullerton, Ooi, Funder & Clarke, 1989). In the fetal
sheep, it is not known whether hypophyseal portal plasma levels of AVP
and CRH are increased during the preparturient activation of the
pituitary-adrenal axis. However, administration of either of these
peptides to the fetus in vivo rapidly stimulates fetal plasma ACTH levels
(Norman & Challis, 1987a). Therefore, increasing hypothalamic secretion
of CRH and AVP during development may play a significant role in
stimulating ACTH secretion in the maturing sheep fetus.
To investigate releasing factor-induced ACTH secretion from the
developing fetal sheep pituitary gland, Brieu & Durand (1987) prepared
dispersed cell cultures from anterior pituitary glands, removed from fetal
sheep at day 63, day 125-138 and day 144 of gestation. Cells were incubated
with AVP, CRH, or AVP+CRH, and ACTH release was measured by RIA
and adrenal cell bioassay. These studies showed that incubation with
AVP or CRH elicited secretion of both immunoreactive and bioactive
ACTH, and that the magnitudes of the secretory responses were increased
with advancing gestational age. In cultures of rat anterior pituitary cells,
AVP and CRH are synergistic in their action to stimulate ACTH secretion
(Gillies et al. 1982). Similarly, AVP and CRH showed synergy in their
actions to stimulate ACTH secretion by fetal sheep pituitary cell cultures,
however, the magnitude of the synergistic effect appeared to be greatest in
the cells removed at day 63 of gestation (Brieu & Durand, 1987).
Evidence has accumulated to suggest that the degree of synergistic
interaction between AVP and CRH in the fetal sheep varies with
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gestational age. Plasma ACTH concentrations have been measured in
chronically catheterised fetal lambs treated with AVP, CRH, or AVP+CRH
at day 110-115, day 125-130 and day 135-140 of gestation (Norman &
Challis, 1987a). At day 110-115 of gestation, fetal plasma ACTH levels
were elevated for 240 minutes after administration of CRH, whereas the
fetal pituitary ACTH response to AVP lasted for 10 mintues, perhaps
reflecting the much shorter half-life of AVP in the circulation
(Wiriyathian, Porter, Naden & Rosenfeld, 1983; Brooks & Challis, 1988).
By contrast, the ACTH response to AVP+CRH was prolonged, and was
maintained at a level in excess of the response to CRH alone for the first
60 minutes. As gestation proceded, the ACTH responses to the various
treatments were decreased, such that by day 125-130, there was no
difference between the overall reponses to CRH and AVP+CRH. A little
later in gestation, at day 135-140, the magnitudes of the ACTH responses
were further diminished, though the patterns of response to the various
treatments remained similar to those observed at day 125-130.
These data suggest that the effects of ACTH-releasing factors are
diminished with advancing gestational age. Norman & Challis (1987b)
provided evidence to corroborate the studies described above, and
convincingly demonstrated the gestational reduction in pituitary ACTH
response to ACTH-releasing factors. It is worthy of note that these data
contrast with the in vitro studies discussed above (Brieu & Durand, 1987),
wherein the secretion of bioactive and immunoreactive ACTH in
response to CRH or AVP was increased with advancing gestation. In fact,
the presence of endogenous corticosteroids, the plasma levels of which
are elevated from day 125 onwards in the fetal sheep (Norman et al. 1985),
is likely to account for the reduced ACTH response to CRH or AVP
observed with advancing gestation in vivo. Previous studies have
shown that Cortisol or dexamethasone inhibits basal and AVP- or CRH-
stimulated ACTH release from cultured fetal sheep pituitary cells in vitro
(Durand, Cathiard, Dacheux, Naaman & Saez, 1986). In vivo,
dexamethasone infusion abolishes the ACTH response to AVP, CRH, or
AVP+CRH in the fetal sheep (Norman & Challis, 1987b). Re-examination
of the data presented by Norman & Challis (1987a) shows that basal
Cortisol levels in the experimental animals were elevated at day 135-140,
when compared to earlier gestational ages. Hence, the absence of a
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pituitary response to ACTH-releasing factors in late gestation may be
ascribed to the inhibitory effects of endogenous corticosteroids on ACTH
release.
It is most interesting to consider that endogenous corticosteroids
act to inhibit release of ACTH from the pituitary gland in response to
ACTH-releasing factors. The normal preterm rise in fetal plasma ACTH
in the sheep is dependent on hypothalamic input to the fetal pituitary
gland (Antolovich et al. 1991), and yet this elevation in plasma ACTH
occurs in the presence of increasing fetal plasma Cortisol levels (Norman
et al. 1985), which is at odds with an hypothesised inhibitory role for
glucocorticoids. To investigate the effects of Cortisol on endogenously-
stimulated ACTH release from the fetal pituitary gland, Wood &
Rudolph (1983) infused fetal sheep with either saline or Cortisol at day
117-131 of gestation. Subsequently, they determined the changes in fetal
plasma ACTH levels in these fetuses in response to nitroprusside-
induced hypotension. The results showed that plasma ACTH levels in
saline-pretreated fetuses were greatly elevated by hypotension. However,
Cortisol pretreatment completely abolished the fetal ACTH response to
hypotensive stress. By contrast, a more recent study carried out by Wood
(1988) used a similar protocol to reveal that Cortisol did not inhibit the
hypotension-induced release of ACTH in fetuses between day 132-142 of
gestation.
These data are at odds with the findings of Norman and Challis
(1987b), who showed that dexamethasone administration abolished fetal
ACTH release stimulated by exogenous ACTH-releasing factors between
day 110 and day 140 of gestation. However, Wood & Rudolph (1983) and
Wood (1988) investigated ACTH release induced by an endogenous
neural pathway, mediated by neurones in the fetal hypothalamic
paraventricular nucleus (McDonald, Rose, Figueroa, Gluckman &
Natanielsz, 1988). Furthermore, they used physiological levels of Cortisol
as the feedback stimulus, instead of the highly potent synthetic
glucocorticoid favoured by Norman and Challis (1987b). Therefore, these
data suggest that reductions in the negative feedback efficacy of Cortisol
may occur in the maturing fetal sheep. These observations may explain
the paradoxical coincident rise in fetal plasma ACTH and Cortisol which is
observed in the fetal sheep in late gestation.
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In contrast to the reduction in fetal pituitary responsiveness to
ACTH-releasing factors with advancing gestational age, fetal adrenal
sensitivity to ACTH increases in late pregnancy (Wintour, Brown,
Denton, Hardy, McDougall, Oddie, & Whipp, 1975; Manchester & Challis,
1982). Thus Rose and associates found that fetal plasma levels of Cortisol,
for a given concentration of ACTH, were significantly greater after day 125
of gestation than before day 125 (Rose et al. 1978) and more directly, the
increase in fetal plasma Cortisol levels in response to a fixed bolus of
ACTH becomes greater as fetuses mature (Rose, Meis, Urban & Greiss,
1982).
The mechanism which underlies the gestational increase in fetal
adrenal sensitivity to ACTH has received considerable attention, as this
pathway could serve to further elevate plasma Cortisol levels in the fetal
sheep in late gestation, in the absence of increased ACTH concentrations.
Experimental evidence has indicated that adrenal Cortisol itself may have
a priming action on the fetal adrenal, to enhance Cortisol secretion in
response to ACTH. For example, fetal adrenal cells isolated from fetuses
treated with ACTH and metyrapone, an ll(3-hydroxylase inhibitor,
accumulate less cyclic adenosine monophosphate (cAMP) in response to
ACTH than cells from fetuses treated with ACTH alone (Lye & Challis,
1984). However, concomitant administration of glucocorticoids with the
ACTH and metyrapone restores the cAMP response to ACTH of the
adrenal cells (Challis, Huhtanen, Sprague, Mitchell & Lye, 1985).
Similarly, fetal adrenal cells cultured for 48 hours in the presence of
glucocorticoids show a greater cAMP response to ACTH than those
maintained in control medium alone (Darbeida & Durand, 1987).
In conclusion, the fetal pituitary-adrenal axis undergoes
progressive maturational changes during fetal life. ACTH released from
the fetal pituitary becomes increasingly bioactive with advancing
maturity, and the fetal adrenal gland shows greater sensitivity to pituitary
ACTH in late gestation. It is not yet clear how plasma ACTH and
corticosteroid concentrations increase in parallel in late gestation, though
a reduction in the negative feedback effects of corticosteroids may permit
an escape of the axis from feedback control. Most likely, several different
mechanisms, including those described here, act in concert to bring about
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the increasing activity of the fetal pituitary-adrenal axis during
development.
2.2.3. Integrated function of the fetal hypothalamo-pituitary-adrenal axis.
The functional development of the hypothalamo-pituitary-adrenal
endocrine system has been investigated in the sheep fetus, primarily by
assessing the fetal plasma ACTH and steroid responses to various
physiological stressors, which require mature afferent and efferent neural
and endocrine pathways. Rose and associates (1978) demonstrated that
plasma ACTH was not affected by a haemorrhagic stress in the fetal sheep
before day 100 of gestation, but that fetal plasma ACTH was elevated after
fetal blood withdrawal in fetuses older than 100 days, suggesting that the
central mechanisms governing the pituitary ACTH response did not
mature until day 100. By contrast, fetal pituitary ACTH secretion was
shown to be powerfully stimulated by an hypovolaemic stress imposed
on fetal sheep at day 64-90 of gestation (Maclsaac, Congiu, Levidiotis,
McDougall & Wintour, 1989), providing good evidence that the fetal
neuroendocrine reflexes were fully competent as early as day 64 of
pregnancy.
The functional maturity of the fetal hypothalamo-pituitary-adrenal
axis has also been assessed by infusing hypothalamic releasing factors into
the sheep fetus, with a view to mimicking a hypothesised hypothalamic
input to the fetal pituitary gland. For example, Wintour and colleagues
have infused CRH into the the sheep fetus and reported that CRH
increasingly stimulates ACTH secretion with advancing gestational age
(Wintour, Bell, Fei, Southwell, Tregear & Wang, 1984). Furthermore,
continuous infusions of high doses of CRH to fetuses at day 125 of
gestation were reported by this group to induce parturition after 5-11 days
(Wintour, Bell, Carson, Maclsaac, Tregear, Vale & Wang, 1986).
To study the phenomenon of releasing factor-induced parturition
more closely, Brooks & White (1990) and Brooks, Challis & Norman
(1987) infused ACTH-releasing factors every four hours for seven days to
fetal sheep at day 117-120 of gestation. These authors found that AVP or
CRH alone stimulated ACTH and Cortisol release from the fetal pituitary
and adrenal respectively. However, the ACTH response to CRH and AVP
Chapter 2 Literature Review 16
combined was greater than the response to either peptide alone (Brooks &
White, 1990). In fact, only CRH+AVP treatment resulted in elevated basal
plasma ACTH and Cortisol levels. As expected, the fetal ACTH response
to CRH+AVP decreased as basal plasma Cortisol levels increased,
however, the Cortisol response to CRH+AVP was not attenuated by the
reduction in plasma ACTH, suggesting that an increase in adrenal
sensitivity to ACTH had occurred. Despite the marked increase in
pituitary-adrenal activity, as suggested by the increased adrenal weights in
all peptide-treated fetuses, parturition was not induced by any of the
experimental treatments (Brooks & White, 1990; Brooks et al. 1987).
Clearly, the results of Brooks & White (1990) and Brooks et al.
(1987), as described above, are at odds with the observations of Wintour et
al. (1984, 1986) who asserted that CRH increasingly stimulated plasma
ACTH and that CRH could induce parturition in the fetal sheep.
However, there are a number of differences evident between these
studies. Re-examination of the data presented by Wintour and colleagues
(1984) reveals that administration of CRH increasingly stimulated ACTH
secretion in only 3 out of 6 fetuses. Further, in only one animal were
plasma samples obtained for more than a few days before the animal was
removed from the study, which presumably occurred secondary to fetal or
maternal death, suggesting that elevated fetal plasma ACTH levels may
not have been due to CRH administration. With regard to the induction
of parturition by CRH, none of the experimental animals received a
uniform treatment schedule, and so it would be difficult to conclude
which particular dosage regime was most efficacious in the induction of
parturition (Wintour et al. 1986). Perhaps of greater significance,
maternal plasma progesterone levels did not fall prior to CRH-induced
parturition in this study (Wintour et al. 1986). If parturition had occurred
as a result of fetal pituitary-adrenal activation, then maternal plasma
progesterone levels would undoubtedly have fallen, as explained in
section 2.1.3. Therefore, these data suggest that parturition, as induced by
CRH administration, was dissimilar to the natural mechanism of
delivery in the sheep.
The data provided by Brooks and colleagues (Brooks et al. 1987;
Brooks & White, 1990), as reviewed above, suggest that increased ACTH-
releasing factor secretion by the fetal hypothalamus may not be
Chapter 2 Literature Review 17
responsible for the initiation of parturition, as it was not possible to
induce parturition by administering hypothalamic ACTH-releasing
factors to fetal sheep. However, recent evidence obtained by Antolovich
and associates serves to underline the significance of the fetal
hypothalamus in parturition. These authors utilised the technique of
fetal hypothalamo-pituitary disconnection (HPD), in which the neural
tissue of the median eminence is removed, leaving intact the vascular
supply of the anterior pituitary. After HPD had been performed on
fetuses at day 110 of gestation, the ewes did not go into labour at the
expected time (day 145), and showed no signs of labour when they were
sacrificed at day 153 (Antolovich, Clarke, McMillen, Perry, Robinson,
Silver & Young, 1990). More recent studies have repeated these findings
(Antolovich et al. 1991), which provides very good evidence that the fetal
hypothalamo-pituitary unit is intimately associated with the mechanisms
of parturition.
2.3 Hypothalamic Corticotrophin-Releasing Factors.
The previous sections have illustrated how releasing factors, pituitary
ACTH, and adrenal steroids may act as part of the fetal hypothalamo-
pituitary-adrenal endocrine system to bring about fetal maturation and
parturition in the sheep. ACTH-releasing factors were shown to have
stimulatory effects on the fetal pituitary-adrenal system, and could
substantially activate the pituitary-adrenal axis prior to term. The
importance of hypothalamic drive to the fetal pitutary gland was
indicated by the failure of normal endocrine changes prior to term, and
the abolition of parturition, in response to fetal hypothalamo-pituitary
disconnection. Available evidence, therefore, suggests that stimulatory
hypothalamic input is of crucial importance in the preparturient
activation of the fetal pituitary-adrenal axis. The purpose of the following
sections is to examine ACTH-releasing factors in the hypothalamus, and
to see how their secretion is controlled, with a view to understanding
how ACTH release may be regulated during fetal life in the sheep.
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2.3.1. Co-localisation of CRH and AVP in the hypothalamus.
The isolation of CRH (1-41) from ovine hypothalami (Vale et al. 1981)
lead rapidly to the development of immunocytochemical methods
capable of detecting CRH-containing cells (e.g. Pelletier, Desy, Cote,
Lefevre, Vaudry & Labrie, 1982; Olscowka, O'Donohue, Mueller &
Jacobowitz, 1982; Bloom, Battenberg, Rivier & Vale, 1982). Around 2000
CRH-immunopositive cells were detected in the hypothalamic
paraventricular nucleus (PVN), principally in the medial parvocellular
subdivisions which project massively to the median eminence
(Wiegrand & Price, 1980; Swanson, Sawchenko, Rivier & Vale, 1983).
CRH cells were also detected elsewhere in the CNS, however, in contrast
to the cells of the PVN, the CRH-immunoreactivity in these cell groups
was not increased by adrenalectomy (Swanson et al. 1983), indicating that
these neurones were less directly involved in the regulation of the
pituitary-adrenal axis.
Vandesande, Dierickx & De Mey (1977) had previously investigated
the dense fibre projection from the PVN to the external lamina of the
median eminence. In contrast to later work, their study showed that the
putative hypophysiotropic fibres originating in the PVN were AVP-
immunoreactive. Indeed, adrenalectomy caused a marked increase in
AVP immunoreactivity in these fibres (Vandesande et al. 1977; Stillman,
Recht, Rosario, Seif, Robinson & Zimmerman, 1977), however, these
studies could not establish the origins of the AVP fibres, as the
immunostaining methods were not sufficiently sensitive to detect cell
bodies.
More recently, double-labelling studies have revealed that medial
parvocellular CRH cell bodies in the PVN express AVP mRNA and
become AVP-immunopositive after adrenalectomy (Kiss, Mezey &
Skirboll, 1984; Tramu, Croix & Pillez, 1983; Sawchenko, Swanson & Vale,
1984; Wolfson, Manning, Davis, Arentzen & Baldino, 1985). Therefore, it
would seem that there is no anatomical distinction between parvocellular
CRH and AVP cells in the PVN. However, these investigations may be
criticised on the grounds that they do not show whether AVP and CRH
may exist in the same cell under normal conditions.
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Electron micrcroscopy, coupled with double-label immunocyto-
chemistry has recently been used to investigate the co-existence of AVP
and CRH. Whitnall, Mezey & Gainer (1985) have determined that AVP is
present in 50% of CRH neurosecretory vesicles in the external zone of the
median eminence in normal rats, providing good evidence for co-release
of these ACTH-releasing factors under physiological conditions. Further
studies by these researchers have shown that CRH/AVP+ and CRH/AVP-
cells have different distributions within the PVN (Whitnall and Gainer,
1988), and that stress selectively activates the AVP-containing subset of
CRH-immunopositive cells (Whitnall, 1989). Therefore, the normal
activation of the hypothalamo-pituitary-adrenal axis may involve the
release of a potent, synergistic mixture of ACTH-releasing factors into the
hypophysial portal vasculature.
2.3.2. Functional divisions within the PVN.
In addition to the fibres directed to the external zone of the median
eminence, cells located in different areas of the PVN project widely
throughout the neuraxis. Specific characteristics, such as cell size, afferent
input and immunohistochemical staining have been used to divide the
PVN into 3 magnocellular and 5 parvocellular subdivisions (Swanson &
Kuypers, 1980; Swanson & Sawchenko, 1980). In conjunction with the
supraoptic nucleus, the magnocellular areas contain the cell bodies of the
vasopressinergic and oxytocinergic neurones which project to the
posterior pituitary gland (Vandesande & Dierickx, 1975; Swanson &
Sawchenko, 1983). Fibres originating in the dorsal aspect of medial
parvocellular region project heavily to the external lamina of the median
eminence (Wiegrand & Price, 1980), and these are the fibres containing
CRH and AVP as discussed above. The PVN also projects to the spinal
cord (Kuypers & Maisky, 1975), more sepcifically to the intermediolateral
column of the cord (Saper, Loewy, Swanson & Cowan, 1976) and to the
nucleus of the solitary tract and the dorsal motor nucleus of the vagal
complex (Conrad & Pfaff, 1976; Saper et al. 1976). Therefore, efferent fibres
of the PVN project to sites containing preganglionic neurones of
sympathetic and parasympathetic nervous systems. The PVN is thus
implicated in the orchestration of both endocrine and autonomic
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responses to stress, and so is considered to function as an integrator of
humoural and neural reponses to stress (see Swanson & Sawchenko,
1980, for review).
2.3.3. Hypothalamic synthesis of CRH and AVP.
The messenger RNA (mRNA) species which code for the CRH and AVP
precursors have been sequenced in several species (Shibahara, Morimoto,
Furutani, Notake, Takahashi, Shimizu, Horikawa & Numa, 1983;
Furutani, Morimoto, Shibahara, Noda, Takahashi, Hoirose, Asai,
Inayama, Hayashida, Miyata & Numa, 1983; Jingami, Mizuno, Takahashi,
Shibahara, Furutani, Imura &Numa, 1985; Land, Schutz, Schmale &
Richter, 1982; Schmale, Heinsohn & Richter, 1983). The CRH mRNA
precursor in the sheep is approximately 1.2 kilobases in length and codes
for a polypeptide of 190 amino acids, which contains CRH (1-41) at amino
acid residues 148-188 (Furutani et al. 1983). Several proteolytic cleavage
sites exist within the precursor structure, as indicated by the presence of
paired basic amino acids (Arg-Arg or Arg-Lys) at positions 116-117,144-145
and 146-147. Post translational processing of the nascent polypeptide
involves transport to the Golgi apparatus, where it is packaged into
secretory vesicles ready for transport to the axon terminal. En route to the
median eminence, the peptide precursor is appropriately cleaved and
undergoes C-terminal amidation, in order to yield fully bioactive CRH (1-
41) (see Gainer, Russell, & Loh, 1985).
Data obtained from the fetal human hypothalamus indicate the
presence of a high molecular weight CRH in early gestation (Ackland,
Ratter, Bourne & Rees, 1986). This may reflect incomplete post-
translational processing during development, as an 9kD peptide
containing the CRH sequence would be liberated if cleavage were to occur
at the Arg-Arg present at positions 123-124. A similar cleavage site is
present in the sheep CRH precursor, at amino acids 116-117. In contrast to
the human hypothalamus, available data indicate that CRH (1-41) is the
sole immunoreactive CRH species present in the fetal sheep
hypothalamus (Brooks, Power, Jones, Vang & Challis, 1989; Watabe,
Levidiotis, Oldfield & Wintour, 1991).
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Prepro-AVP mRNA is approximately 0.6 kilobases in length (Land
et al. 1982). The 147 amino-acid polypeptide contains AVP at amino acids
1-9, and the AVP-binding protein, neurophysin-II, at positions 13-107.
During transport to the median eminence, the C-terminal amino acids of
AVP-Gly10-Lys11 are cleaved, and the amino group from the glycine is
sacrificed to form a carboxy-terminal amide, which is required for AVP
bioactivity (Eipper & Mains, 1988). There have been no reports of
purification of AVP immunoreactive species from fetal sheep or rat
hypothalami, and so it is not clear whether AVP is present in the mature
1-9 form, or whether during development, AVP-Gly10-Lys11 is present in
measurable quantities. It is therefore not known whether bioactvity of
fetal hypothalamic AVP varies at different fetal ages.
2.3.4. Development of CRH and AVP cells in the fetal sheep PVN.
The stereotaxic atlas of the fetal sheep brain shows the PVN as a paired
midline structure, lying either side of the third cerebral ventricle
(Gluckman & Parsons, 1983). At its most rostral extent, the PVN lies
above and in close proximity to the optic chiasm. The nucleus passes
dorsally and caudally over several millimetres, with the major part of the
nucleus approaching the dorsal extent of the third ventricle.
To examine the development of hypothalamic neurones in the
fetal sheep PVN, Levidiotis, Oldfield & Wintour (1987) used
immunocytochemical techniques to visualise CRH and AVP cells in fetal
sheep hypothalami removed at different gestational ages. AVP-
immmunoreactive terminals were present in the external layer of the
fetal median eminence at day 42 of gestation, whereas CRH-containing
cells did not arise in the PVN until day 90, with fibres projecting to the
median eminence by day 105. These data supported a more significant
role for AVP in early gestation, in agreement with previous studies
which had shown AVP to be a more potent ACTH-releasing factor than
CRH in fetal sheep pituitary cells removed at midgestation (Brieu &
Durand, 1987).
In contrast to the immunocytochemical data cited above, CRH was
detected by radioimmunoassay (RIA) procedures in the extracts of fetal
sheep hypothalami removed at day 63 of pregnancy (Brieu, Tonon, Lutz-
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Bucher & Durand, 1989), suggesting the presence of CRH cells in the fetal
hypothalamus by midgestation. In a re-appraisal of CRH-immuno-
reactive cells in the fetal sheep hypothalamus, Watabe et al. (1991) used
more sensitive immunocytochemical techniques and found CRH-
immunopositive cells in the fetal sheep hypothalamus at day 49 of
pregnancy. These data do not reveal whether CRH or AVP is the more
important ACTH-releasing factor in the fetal sheep hypothalamus.
However, they do show that the anatomical and biochemical maturation
of the hypothalamic ACTH-releasing cells is complete around day 50 of
gestation in the sheep, which is very early in the development of this
species. This is in contrast with observations made in the human fetus,
in which immunoreactive CRH-immunoreactive cell bodies are detected
in the fetal hypothalamus at week 19 (Term = 39 weeks; Bugnon,
Fellman, Gouget, Bresson, Clavequin, Hadjiyiassemis & Cardot, 1984).
2.3.5. CRH and AVP immunoreactivity in the fetal sheep hypothalamus.
The fetal hypothalamic contents of CRH and AVP have been measured by
RIA at different gestational ages in several species (Rundle & Funder,
1988; Ackland et al. 1986; ). In the fetal sheep at midgestation, AVP and
CRH levels in the hypothalamus are approximately 5% of the
concentrations observed near term (Brieu et al. 1989). AVP and CRH
concentrations rise slowly until day 100, and then increase more rapidly
as gestation proceeds towards term (Brieu et al. 1989; Brooks et al. 1989),
perhaps as a result of maturation of trophic neural input to the fetal
peptidergic neurones (see Brooks & Challis, 1988). Further to the sharp
increases in the hypothalamic contents of CRH and AVP in late gestation,
CRH and AVP levels in the fetal sheep hypothalamus fall dramatically in
the last few days of pregnancy. This has been attributed to increased
glucocorticoid feedback late in gestation (Brooks et al. 1989), or to a
massive increase in hypothalamic secretion of the two neuropeptides
immediately before parturition (Brieu et al. 1989). Interestingly, extracts
prepared from term fetal hypothalami do not show greatly reduced
ACTH-releasing bioactivity (Brieu et al. 1989), despite the greatly reduced
AVP and CRH content. However, the factors which are responsible for
the ACTH-releasing activity present in the hypothalamic extracts have
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not yet been determined, and so the significance of these observations is
not clear.
The reduction in CRH and AVP immunoreactivity in the fetal
sheep hypothalamus near term may reflect hypothalamic maturation,
such that immunoreactive, but not bioactive, forms of AVP and CRH are
selectively diminished in late development. In the human fetus prior to
20 weeks of gestation, hypothalamic CRH is present as two molecular
species, one with a high molecular weight which is not bioactive, and
another bioactive peptide which co-elutes with CRH (1-41) on Sephadex
chromatography (Ackland et al. 1986). In contrast, the high molecular
weight CRH species is absent from hypothalami collected after 20 weeks
gestation. Immunoreactive CRH in the fetal sheep and rat hypothalamus
has been fractionated using sephadex chromatography (Watabe et al. 1991;
Chatelain, Boudouresque, Chautard, Dupouy & Oliver, 1988). In contrast
to the human data, immunoreactive CRH in fetal sheep and rat
hypothalami co-eluted with the synthetic CRH(1-41). However, neither
of these studies assessed the bioactivity of the chromatography fractions,
and so it remains to be determined whether the bioactivity of fetal
hypothalamic CRH, or AVP, is enhanced with fetal maturation.
In conclusion, the data presented here have shown that AVP- and
CRH-containing cells are present in the fetal sheep hypothalamus by day
50 of development. Whilst immunoreactive CRH and AVP have been
detected by RIA in the fetal sheep hypothalamus at day 63 of gestation, it
is not clear whether these peptides correspond to the genuine, mature
forms of the ACTH-releasing factors. Evidence exists in other species that
post-translational processing of ACTH-releasing factors may develop with
increasing fetal maturity. This suggests that the biologically active forms
may arise relatively late in development in the fetal sheep hypothalamus.
Irrespective of the biological activity of hypothalamic CRH and AVP
during fetal life, it is clear that fetal sheep hypothalamic contents of CRH
and AVP increase dramatically through gestation, suggesting that the
preparturient activation of the fetal pituitary-adrenal axis is accompanied
by sharply increasing hypothalamic activity.
Chapter 2 Literature Review 24
2.4. Neural control of CRH and AVP secretion.
The interface between the central nervous system and the anterior
pituitary gland is formed by the neuroendocrine hypothalamus. Thus,
neural signals converge on the hypothalamic peptidergic neurones and
are transduced into a neuroendocrine signal, which then acts at the
anterior pituitary to stimulate an endocrine response. Therefore, the
central nervous system relays signals in the form of neurotransmitters
and neuropeptides to the peptidergic cells. Recently, the endogenous
opioid peptides have gained support as central regulators of the
hypothalamo-pituitary-adrenal axis, in addition to the many other
neuropeptides and neurotransmitters, such as neuropeptide Y,
noradrenaline and serotonin, which act to stimulate or inhibit CRH and
AVP release. The purpose of this section is to discuss the various
regulatory substances which act at the AVP and CRH cells to control the
activity of the pituitary-adrenal axis.
2.4.1. The effects of opioids on the secretion of ACTH-releasing factors.
The endogenous opioids are a family of peptides, each of which contains
the sequence Tyr-Gly-Gly-Phe at the amino terminus (Hughes, Smith,
Kosterlitz, Fothergill, Morgan & Morris, 1975; Li & Chung, 1976; Chavkin,
James & Goldstein, 1982). The prototypical endogenous opioids are
[Met5]- and [Leu5]-enkephalin, dynorphin (1-17) and [^-endorphin, each of
which is derived from a separate gene (Kakidani, Furutani, Takahashi,
Noda, Morimoto, Hirose, Asai, Inayama, Nakanishi & Numa, 1982;
Noda, Furutani, Takahashi, Toyosato, Hirose, Inayama, Nakanishi &
Numa, 1982; Nakanishi et al. 1979), and interacts respectively with either
delta 0), kappa (k) or mu (p) opioid receptors (Patterson, Robson &
Kosterlitz, 1983). Compared to other brain regions, the hypothalamus
shows remarkably high concentrations of the opioids (Bloom, Rossier,
Battenberg, Bayon, French, Henriksen, Siggins, Segal, Browne, Ling &
Guillemin, 1978; Miller, Chang & Cuatrecasas, 1978; Zamir, Palkovits &
Brownstein, 1984). This is understood to reflect the presence of
numerous opioid neurones in this region of the brain (Khachaturian,
Lewis, Schafer & Watson, 1985).
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Early investigations of the effects of opioids indicated that
morphine was stimulatory to the pituitary-adrenal axis (Briggs & Munson
1955), however, this effect was blocked in rats bearing hypothalamic
lesions (George & Way, 1959), suggesting, with hindsight, that morphine
acts to enhance the secretion of ACTH-releasing factors. More recently,
this issue has been addressed directly by measuring the release of CRH or
AVP from hypothalamic tissue pieces in the presence of opioid receptor
agonists and antagonists.
Tsagarakis and colleagues investigated the effects of 202-250, U50,
488H or [D-Pen2'5]-enkephalin, which are highly specific |i-, k- and 3-
receptor agonists respectively, on the secretion of CRH from rat
hypothalamic tissue during short-term incubations (Tsagarakis, Rees,
Besser & Grossman, 1990). These authors found no effects of the (i-, k-
and 3-receptor agonists on basal CRH release from the rat hypothalamus.
However, CRH release evoked by 28 mM potassium stimulation was
inhibited in a dose-dependent fashion by the p- and k- agonists, but
remained unaffected by the 3-agonist. These effects were shown to be
opioid receptor-mediated when p- and k-receptor antagonists selectively
reversed the inhibitory effects. Previous authors had carried out similar
investigations using a perifusion system to maintain rat hypothalami
(Yajima, Suda, Tomori, Sumitomo, Nakagami, Ushiyama, Demura &
Shizume, 1986). Interestingly, the results from the perifusion studies
were in close agreement to those of Tsagarakis et al. (1990); the p- and k-
agonists ^-endorphin and dynorphin(l-17) inhibited CRH release,
whereas [D-Ala2, D-Ala5]-enkephalin, a specific 3-agonist, had no effect.
The effects of opioids on AVP secretion by the hypothalamus
in vitro was recently assessed by Knepel & Reimann (1982). Superfused
hypothalami secreted AVP under basal conditions, and responded to
electrical stimulation with elevated AVP secretion, an effect which was
calcium-dependent and tetrodotoxin-sensitive. The inclusion of
morphine in the superfusate reduced AVP released in response to
stimulation, and this effect was naloxone-reversible, suggesting that
morphine inhibition was mediated via opioid receptors. The data also
suggested that naloxone enhanced AVP release overall, however, the
responses were too variable to reach statistical significance.
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The data presented so far are at odds with the early findings of
Briggs & Munson (1955), which suggested that hypothalamic drive to
pituitary ACTH release was stimulated by opioid agonists. However,
recent studies carried out in vivo have examined hypothalamic secretion
of AVP and CRH into the portal vasculature, and the results from these
investigations are in agreement with the inhibitory effects reported
above. Thus, Plotsky (1986) showed that portal plasma CRH levels in
anaesthetised rats were decreased in response to intravenous
administration of (3-endorphin or dynorphin(l-17). Similarly, Koenig
and colleagues demonstrated that peripheral infusions of morphine to
rats resulted in a naloxone-reversible decrease in portal plasma AVP
concentrations (Koenig, Metlzer, Devane & Gudelsky, 1986).
The inhibitory actions of the opioids as described here conflict
considerably with a number of reports from Buckingham, all of which
support the hypothesis that opioids act to enhance the secretion of
hypothalamic ACTH-releasing factors. Using an in vitro incubation
system, Buckingham (1982; 1986) has shown that morphine, [Met5]- or
[Leu5]-enkephalin and ^-endorphin all stimulate the release of bioactive
ACTH-releasing factors from the rat hypothalamus in vitro. The
incubation system was very similar to that used by Tsagarakis et al. (1990),
and careful scrutiny of the experimental procedures does not reveal a
reason as to why the results should differ from Tsagarakis and colleagues.
An explanation could be that Buckingham utilised a pituitary fragment
bioassay to measure secretion of bioactive ACTH-releasing factors, rather
than direct CRH and AVP RIA procedures as employed by other workers
(Koenig et al. 1986; Yajima et al. 1986; Plotsky, 1986; Tsagarakis et al. 1990).
Therefore, the effects of the opioids on the release of CRH or AVP may be
obscured by the opioid-stimulated secretion of other hypothalamic
ACTH-releasing factors.
2.4.2. Opioid peptides and pituitary-adrenal activity in vivo.
In contrast to the data obtained in vitro, a considerable body of evidence
suggests that administration of opioids to rats in vivo is stimulatory to
the hypothalamo-pituitary-adrenal axis. Intraperitoneal infusion of
morphine rapidly results in elevation of plasma ACTH levels
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(Buckingham, 1982). Similarly, in rats treated with either morphine, a p-
agonist, or U50, 488H, a K-agonist, plasma corticosterone levels increase
dramatically, and peak around 20 minutes after subcutaneous opioid
administration (Ignar & Kuhn, 1990). These data are in agreement with a
number of previous studies, which have shown that opioid receptor
agonists stimulate ACTH and corticosterone release (von Voightlander,
Lahti and Ludens, 1983; Hayes and Stewart, 1985; Pfeiffer, Hertz, Loriaux
and Pfeiffer, 1985), and that these effects are probably mediated at a central
site, as the anterior pituitary gland does not contain opioid receptors
(Herkenham, Rice, Jacobson and Rothman, 1986).
Perhaps of greater physiological relevance are the effects of opioid
receptor antagonists on the secretion of ACTH and corticosteroids.
Administration of low doses of naloxone, the opioid antagonist, to rats
has little effect on plasma ACTH levels (Eisenberg, 1980; Siegel, Chowers,
Conforti, Feldman and Weidenfeld, 1982; Jezova, Vigas & Jurcovicova,
1982). However, when higher doses of naloxone are administered,
plasma ACTH and corticosterone are greatly increased (Eisenberg, 1980;
Siegel et al. 1982; Jezova et al. 1982), suggesting that endogenous,
naloxone-resistant opioid pathways, such as d- or k- (Patterson et al. 1983),
are involved in a tonic inhibition of the pituitary-adrenal axis.
In order to investigate whether endogenous opioids were active in
regulating hypothalamo-pituitary-adrenal activity under basal and
stressed conditions, Cover & Buckingham (1989) pretreated rats with p-, d-
or k- receptor selective antagonists and then subjected the animals to
laparotomy stress. Whilst the d- antagonist had no effect on basal plasma
levels of ACTH, the p- and K-antagonists stimulated basal ACTH release.
The p-antagonist, however, attenuated the pituitary and adrenal
responses to stress, an effect opposite to the K-antagonist, which enhanced
the stress-induced ACTH and corticosterone secretion. By contrast, the d-
antagonist had no effect on stress-induced activity of the pituitary-adrenal
axis (Cover & Buckingham, 1989).
The data presented above suggest a very complex opioid regulation
of the hypothalamo-pituitary-adrenal axis. However, taking these
findings together, one can hypothesise that there are both stimulatory and
inhibitory K-receptor and p-receptor pathways, whereas there is less
evidence for the role of 5-opioids. In an effort to resolve the paradoxical
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similarities between the effects of opioid agonists and antagonists on the
pituitary-adrenal axis, Nikolarakis and associates investigated the effects
of opioid administration in rats pretreated with saline or CRH-antiserum
(Nikolarakis, Pfeiffer, Stalla & Herz, 1987). These authors showed that the
stimulatory effects of the opioid antagonist naloxone and the k-agonist
MR 2034 on ACTH secretion were abolished by CRH antiserum, whereas
the stimulatory effects of morphine, the p-agonist, were still present after
antiserum pretreatment. These findings suggested that there was a tonic,
inhibitory opioid pathway(s) regulating CRH release, whereas there may
have been k- and p-mediated stimulatory pathways, in which the
secretion of either CRH or another ACTH-releasing factor was stimulated
by opioid administration. These data served to emphasise the complexity
of opioid regulation of the hypothalamo-pituitary-adrenal axis, and
suggest that futher studies should utilise specific RIA procedures, and
highly specific opioid agonists and antagonists to clarify the physiological
actions of these substances.
2.4.3. Opioids and the fetal sheep hypothalamo-pituitary-adrenal axis.
The pronounced activation of the fetal sheep pituitary-adrenal axis in late
gestation may be driven by a stimulatory endogenous opioid input to the
fetal hypothalamus. In order to determine whether endogenous opioids
could act to elevate plasma ACTH and Cortisol in the fetal sheep, [Leu5]-
enkephalin was administered to fetuses at day 120-125 of pregnancy
(Bousquet, Lye & Challis, 1984). The results clearly showed a marked
stimulation of plasma Cortisol levels in the fetus in response to opioid
administration. In view of the absence of opioid receptors in the fetal
sheep pituitary gland (Yang & Challis, 1991), and the absence of an effect
of [Leu5]-enkephalin on fetal adrenal Cortisol secretion (Bousquet et al.
1984), these data suggested that [Leu5]-enkephalin stimulated the release
of CRH and AVP into the fetal hypophysial portal blood. Furthermore,
these results provided evidence that endogenous opioids might stimulate
fetal ACTH and Cortisol secretion during the preparturient phase, and so
may participate in the initiation of parturition.
To investigate the development of opioid pathways in the fetal
hypothalamus, Yang & Challis (1991) determined the binding of tritiated
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naloxone to homogenates of fetal sheep hypothalami removed at day 110-
115, day 125-130 and day 135-140 of gestation. Opioid receptors at all
gestational ages investigated showed similar dissociation constants,
suggesting that the same receptor type was present at each gestational age.
However, opioid-binding capacity increased two-fold between day 110-115
and day 125-130, providing good evidence that opioid systems in the fetal
sheep undergo maturational changes at this point in fetal life.
In order to examine the functional maturation of fetal sheep opioid
systems, Brooks & Challis (1988) measured fetal plasma ACTH levels after
opioid administration at day 110-115, day 125-130 or day 135-140 of
gestation. These authors demonstrated that fetal plasma ACTH levels
were stimulated by intrafetal administration of FK 33,824, a p-selective
enkephalin analogue (Roemer, Buescher, Hill, Pless, Cardinaux, Closse,
Hauser & Huguenin, 1977), at day 125-130 and day 135-140 of gestation,
and that this effect was abolished by naloxone pretreatment. However,
there was no effect of the opioid on plasma ACTH concentrations at day
110-115. It is notable that the appearance of the fetal ACTH response to
opioid administration coincides with the sharp increase in hypothalamic
opioid receptors as described by Vang & Challis (1991).
The functional significance of endogenous opioid systems in the
fetal sheep has been much clarified in a very recent study by Brooks &
Challis (1991). These authors measured plasma ACTH levels in fetal
sheep infused with saline or naloxone in the last few days of pregnancy.
They clearly demonstrated that whilst the elevated fetal plasma ACTH
levels present at this time were unaffected by saline treatment, chronic
naloxone infusion caused a marked reduction in fetal ACTH levels,
which provided good evidence that endogenous opioids in the fetal sheep
are stimulatory to the fetal hypothalamo-pituitary-adrenal axis near term.
Taking the above studies together, the data suggest that there is a
maturation of fetal hypothalamic opioid systems during fetal life and that
activation of the fetal opioid pathways in late gestation may drive the
fetal hypothalamo-pituitary-adrenal axis towards term.
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2.4.4. Neuropeptide Y as a regulator of pituitary-adrenal activity.
Neuropeptide Y (NPY), a 36 amino acid peptide, has recently been isolated
from mammalian brain using a chemical assay for the the C-terminal
amide group (Tatemoto, Carlquist, & Mutt, 1982), which it possesses, in
common with a number of biologically active peptides (Eipper & Mains,
1988). Purification of the peptide, and the development of RIA
procedures and immunolocalisation techniques, has revealed that NPY is
widely distributed throughout the central nervous system (Allen, Adrian,
Allen, Tatemoto, Crow, Bloom & Polak, 1983). More specifically, NPY-
immunoreactivity is found in brainstem neurones in which NPY is co-
localised with catecholamines (Everitt, Hokfelt, Terenius, Tatemoto, Mutt
& Goldstein, 1984). There is also a population of NPY-immunoreactive
cells in the arcuate nucleus of the hypothalamus which does not contain
catecholamines (Bai, Yamano, Shiotani, Emson, Smith, Powell &
Tohyama, 1985). Both groups of cells project heavily to the PVN (Bai et
al. 1985; Sawchenko, Swanson, Grzanna, Howe, Bloom & Polak, 1985), in
which NPY-immunoreactive structures innervate CRH-containing cell
bodies (Liposits, Sievers & Paull, 1988), and may therefore be involved in
the regulation of ACTH-releasing factors.
Recently, data have been obtained which support the function of
NPY as a regulator of neuroendocrine input to the anterior pituitary
corticotrophs. NPY infusion to the lateral cerebral ventricles of awake
rats had a small stimulatory effect on circulating levels of corticosterone,
however, direct administration of NPY to the PVN caused a massive
increase in plasma ACTH and corticosteroid concentrations (Wahlstedt,
Skagerberg, Ekman, Heilig, Sundler & Hakanson, 1987). Investigations of
the effects of NPY on CRH release from hypothalami in vitro have
shown that NPY is stimulatory to CRH release (Tsagarakis, Rees, Besser &
Grossman, 1989). These data complement observations made in the
sheep, which show that intracerebroventricular administration of NPY is
a potent stimulator of plasma Cortisol levels (Porter, 1988).
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2.4.5. Neurotransmitter regulation of ACTH-releasing factors.
Presently, data are accumulating which describe the functions of the
endogenous neuropeptides in the regulation of the hypothalamo-
pituitary-axis. However, considerably more data are available regarding
neurotransmitter control of this axis, presumably because central
neurotransmitter pathways were described over 25 years ago (Dahlstrom
& Fuxe, 1964; Anden, Dahlstrom, Fuxe, Larsson, Olson & Ungerstedt,
1966) and neurotransmitter systems have continued to receive attention
since then. It has become clear that the parvocellular PVN receives
catecholaminergic inputs which originate in the nucleus tractus solitarius
(NTS), and in the CI and C3 cell groups of the brainstem (Cunningham
and Sawchenko, 1988; Cunningham, Bohn & Sawchenko, 1989). At the
ultrastructural level, CRH- and AVP-immunoreactive neurones in the
medial parvocellular subdivision of the PVN have been observed to form
synapses with adrenergic and noradrenergic processes (Kitazawa, Shioda
& Nakai, 1987; Ochia, Iwai & Nakai, 1988). Electrical stimulation of the
brainstem catecholaminergic nuclei results in enhanced electrical activity
of the PVN neurones (Day, Ferguson & Renaud, 1985), which suggests
that the aminergic fibres form stimulatory junctions with CRH and AVP
cells of the PVN.
In support of a stimulatory role for catecholamines, noradrenaline
has been shown to elevate the release of CRH and AVP from serum-free
cultures of fetal hypothalamic cells (Clarke & Gillies, 1988; Widmaier,
Lim & Vale, 1989) and from hypothalamic tissue pieces incubated over
the short term in vitro (Tsagarakis, Holly, Rees, Besser & Grossman, 1988;
Hillhouse & Milton, 1989a). Furthermore, administration of
noradrenaline or adrenaline into the third cerebral ventricle of the sheep
stimulates ACTH release from the anterior pituitary gland (Liu, Clarke,
Funder & Engler, 1991). This study did not reveal the mechanism of
action of the catecholamines, however, the hypophysiotropic CRH and
AVP neurones lie on either side of the third ventricle (Swanson and
Sawchenko, 1983). In view of the small effect of catecholamines on the
secretion of ACTH from anterior pituitary cells in culture (Liu et al. 1991),
the stimulatory effects are probably mediated by the paraventricular CRH-
and AVP-containing neurones.
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In the fetal sheep, available evidence suggests that central
catecholamine pathways are functional relatively early in gestation.
Hypotensive stimuli cause massive increases in plasma ACTH in the fetal
sheep from midgestation onwards (Maclsaac et al. 1989; Hargrave & Rose,
1985). The afferent fibres which relay arterial baroreceptor information
pass to the NTS (Sumal, Blessing, Joh, Reis, & Pickel, 1983), which sends
catecholaminergic fibres to the PVN (Cunningham &Sawchenko, 1988;
Cunningham et al. 1989). Ablation of the NTS abolishes the ACTH
response to hypotension (Darlington, Shinsako & Dallman, 1986).
Therefore, these data suggest that in the fetal sheep, brainstem aminergic
inputs to the fetal PVN are functionally mature by mid-gestation.
In addition to the catecholamines, there are proposed roles for
other neurotransmitter substances in the central control of CRH and AVP
secretion. In vivo, 5-HT agonists cause elevations of plasma ACTH and
glucocorticoids in rat and man (Koenig, Gudelsky & Meltzer, 1987; Fuller
& Snoddy, 1990; Petraglia, Faccinetti, Martignoni, Nappi, Volpe &
Genazzani, 1984). Data gathered in the rat indicate that this effect is
mediated at a supra-pituitary site, as administration of a CRH-antiserum
blocks this response (Calogero, Bagdy, Szemeredi, Tartaglia, Gold &
Choursos, 1990). These data suggest the hypothesis that endogenous 5-HT
is stimulatory to the secretion of ACTH-releasing factors. In support of
this hypothesis, the 5-HT reuptake inhibitor Fluoxetine increases
hypophyseal portal plasma concentrations of CRH and AVP (Gibbs &
Vale, 1983). Further, the ACTH reponse to insulin-induced
hypoglycemia is attenuated by 5-HT receptor blockers or prior depletion
of brain 5-HT (Yehuda & Meyer, 1984). Furthermore, 5-HT enhances the
release of bioactive ACTH-releasing factors from hypothalamic tissue
pieces (Jones, Hillhouse & Burden, 1976; Hillhouse & Milton, 1989a), and
stimulates CRH release from fetal hypothalamic cell cultures in vitro
(Clarke, 1988). Thus, considerable evidence favours the stimulatory role
of 5-HT in the central regulation CRH and AVP secretion.
In contrast to the facilitatory effects of 5-HT, the inhibitory
neurotransmitter y-Amino Butyric Acid (GABA) is reported to have little
effect on the basal release of CRH and AVP, either from cultured
hypothalamic cells (Clarke, 1988), or from hypothalamic tissue pieces
(Suda, Yajima, Tomori, Sumitomo, Nakagami, Ushiyama, Demura and
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Shizume, 1987; Hillhouse & Milton, 1989b). On the other hand, GABA
significantly inhibited the acetyl choline (ACh)-stimulated release of
ACTH-releasing factors (Buckingham & Hodges, 1979) or CRH or AVP
(Suda et al. 1987, Hillhouse & Milton, 1989b). Furthermore, the GABA
antagonists bicuculline and picrotoxin stimulated the release of both AVP
and CRH from cultured hypothalamic cells (Clarke, 1988). In vivo,
administration of bicuculline and picrotoxin rapidly increases plasma
ACTH levels (Ixart, Cryssogelou, Szafarczyk, Malaval & Assenmacher,
1983) and corticosterone concentrations (Makara & Stark, 1974). These
data suggest that GABA can inhibit CRH and AVP secretion, and that a
tonic inhibitory effect of GABA in vivo may act to antagonise stimulatory
inputs as described above.
In conclusion, there are a large number of neuropeptide and
neurotransmitter systems which act to stimulate and inhibit the function
of the pituitary-adrenal axis by modulation of hypothalamic CRH and
AVP. The central control of ACTH-releasing factors in the fetal sheep has
received relatively litle attention, compared to other animal models,
however, available data indicate the presence of a stimulatory opioid
input to hypothalamic ACTH-releasing factors and that this input may be
tonically active in late gestation.
2.5. Negative Feedback Regulation of ACTH-Releasing Factors.
Stimulatory drive to fetal ACTH secretion is provided by hypothalamic
CRH and AVP. However, Cortisol secreted by the fetal adrenal gland is
able to act at both hypothalamic and pituitary sites to regulate the activity
of the axis, in the manner of an endocrine negative feedback loop. In
view of the parallel increase in fetal plasma ACTH and Cortisol levels
which are observed during the preparturient phase of gestation in sheep,
it may be that mechanisms exist within the fetal hypothalamo-pituitary-
adrenal system which override normal glucocorticoid negative feedback.
Therefore, the purpose of this section is to assess the effects of
glucocorticoids on hypothalamic CRH and AVP, and to discuss the effects
of glucocorticoids on the fetal sheep hypothalamus in development.
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2.5.1. Central distribution of glucocorticoid receptors.
It now accepted that glucocorticoids may only act to regulate gene
expression, and hence secretion of CRH and AVP, after binding to the
glucocorticoid receptor (see Gustaffson, Carlstedt-Duke, Poellinger, Okret,
Wikstrom, Bronnegard, Gillner, Dong, Fuxe, Cintra, Harfstrand & Agnati,
1987, for review). To examine whether glucocorticoids could act directly
at the level of hypothalamic neurones, Okret and colleagues raised a
monoclonal antibody against rat liver glucocorticoid receptors (Okret,
Wikstrom, Wrange, Andersson & Gustaffson, 1984). Immunocyto-
chemical studies were then carried out to visualise glucocorticoid
receptors in the telencephalon and diencephalon of the rat brain (Fuxe,
Wikstrom, Okret, Agnati, Harfstrand, Yu, Granholm, Zoli, Vale &
Gustaffson, 1985). The monoclonal antibody detected large numbers of
glucocorticoid receptor-containing cells throughout the brain, with the
most intensely staining cells located in the hypothalamic PVN, the
mediobasal hypothalamus and in the CA1 and CA2 subregions of the
hippocampal formation (Fuxe et al. 1985).
Glucocorticoid receptor immunoreactivity in the PVN was most
concentrated in the medial parvocellular region, where the receptor-
immunoreactivity overlapped the distribution of CRH-immunoreactive
cells (Swanson et al. 1983; Fuxe et al. 1985). However, these studies did
not show whether the peptidergic neurones themselves expressed
glucocorticoid receptor. To address this issue, double-labelling
immunocytochemistry was carried out using the monoclonal anti-
glucocorticoid receptor antibodies and conventional anti-CRH antiserum.
Again, intense glucocorticoid receptor immunostaining was detected in
the hypothalmamic PVN. In addition, cells of the medial parvocellular
PVN, which expressed glucocorticoid receptor immunoreactivity, were
intensely immunostained with the anti-CRH antiserum (Gustaffson et al.
1987). These data clearly showed that circulating adrenal corticosteroids
may act directly at the level of the paraventricular neurones to regulate
stimulatory drive to anterior pituitary ACTH release.
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2.5.2. Glucocorticoid regulation of CRH and AVP synthesis.
Primary evidence for the inhibitory effects of glucocorticoids on peptide
synthesis has been provided in studies which sought to establish the co-
localisation of CRH and AVP in hypothalamic cells. Several workers
reported that hypothalamic AVP immunostaining was much enhanced
in adrenalectomised animals (Vandesande et al. 1977; Stillman et al.
1977), and that the effects were specific to the parvocellular regions of the
PVN (e.g. Tramu et al. 1983; Kiss et al. 1984). Furthermore, adrenalectomy
permitted the co-localisation of AVP mRNA and CRH peptide within the
same hypothalamic neurones (Wolfson et al. 1985). Therefore, the
hypothalamic cells which control the pituitary-adrenal axis are disinhibited
by diminished glucocorticoids, in keeping with the hypothesis of
glucocorticoid negative feedback regulation.
More recent investigations have directly assessed the effects of
glucocorticoid treatment on the expression of mRNA species coding for
CRH or AVP. Using quantitative in situ hybridisation techniques, Davis
and colleagues investigated the effects of adrenalectomy on the
hypothalamic levels of AVP mRNA (Davis, Arentzen, Reid, Manning,
Wolfson, Lawrence & Baldino, 1986). These workers clearly showed that
removal of endogenous corticosteroids was associated with a doubling of
AVP mRNA signal intensity in the hypothalamus. However, this effect
was only observed in the parvocellular regions of the PVN, and was not
present in adrenalectomised animals treated with dexamethasone.
Similar studies have been carried out to examine the responses of
hypothalamic CRH mRNA to glucocorticoid removal. Jingami and co¬
workers showed that adrenalectomy induced an increase in hypothalamic
CRH mRNA levels, which could be reversed by glucocorticoid
administration (Jingami, Matsukura, Numa & Imura, 1985).
Interestingly, these authors found that extrahypothalamic CRH mRNA
levels were unaffected by either adrenalectomy or by glucocorticoid
administration (Jingami et al. 1985). Further studies of CRH mRNA
regulation in the rat central nervous system have confirmed the precise
nature of the anatomical locus at which glucocorticoids act to inhibit CRH
mRNA. Thus Beyer, Matta & Sharp (1988) showed that levels of CRH
mRNA in the parvocellular PVN, but not in the bed nucleus of the stria
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terminalis or the central nucleus of the amygdala, were decreased by
glucocorticoid administration. Kovacs & Mezey (1987) utilised implants
of dexamethasone to show that glucocorticoids act within the
hypothalamus, but not in the hippocampus, cerebral cortex or amygdala,
to reduce CRH mRNA levels.
Complementary investigations have been carried out to assess the
effects of glucocorticoids on the peptide content of the hypothalamus
under conditions of altered glucocorticoid negative feedback. Plotsky &
Sawchenko (1987) found that after pharmacological adrenalectomy, in
which adrenal corticosteroid synthesis was prevented by administration
of metyrapone + aminoglutethimide, hypothalamic levels of CRH and
AVP were initially decreased at 24 hours post treatment, and were then
increased 72 hours later. These data were taken to mean that there was an
initial outpouring of AVP and CRH, which accounted for the diminished
peptide content in the first 24 hour period, followed by an adrenalectomy-
induced elevation in hypothalamic peptide synthesis and storage. The
reports of several authors indicate that the hypothalamic contents of CRH
and AVP are greatly enhanced by adrenalectomy, as CRH and AVP
immunostaining in the rat PVN are much more intense several days
after removal of endogenous adrenal steroids (Swanson et al. 1983;
Plotsky & Sawchenko, 1987). These data provide good evidence that
physiological levels of glucocorticoids may exert a potent inhibitory
influence on the synthesis of the hypothalamic factors which stimulate
ACTH release.
2.5.3. Negative feedback regulation of CRH and AVP secretion.
In support of a direct inhibitory effect of glucocorticoids on the secretion
of CRH and AVP, chronic glucocorticoid treatment has been shown to
reduce CRH and AVP output from cultured rat hypothalamic cells in
vitro (Clarke & Gillies, 1988). By contrast, the levels of AVP in
hypophysial portal blood are rapidly elevated by adrenalectomy (Koenig et
al. 1986; Eckland, Todd & Lightman, 1987), an effect which is paralleled by
the increased portal levels of CRH observed under these conditions
(Plotsky & Sawchenko, 1987). Furthermore, hypothalami removed from
adrenalectomised animals secrete increased quantities of CRH and AVP
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in vitro (Suda, Yajima, Tomori, Demura, & Shizume, 1985; Knepel,
Nutto, Meyer & Vlaskovska, 1984). These changes in hypophysial portal
ACTH-releasing factors may well underlie the massive elevation in
peripheral plasma ACTH concentrations observed in adrenalectomised
animals (Plotsky & Sawchenko, 1987), as surgical ablation of PVN
projections to the median eminence abolishes the post-adrenalectomy
increase in plasma ACTH (Levin, Shinsako & Dallman, 1988).
2.5.4. Glucocorticoid feedback regulation in the fetal sheep hypothalamus.
Glucocorticoid negative feedback in the hypothalamo-pituitary system of
the fetal sheep is apparently diminished in late gestation, as plasma
ACTH levels escalate in parallel with circulating Cortisol concentrations
towards term (Norman et al. 1985). However, it is not clear whether such
a hypothetical reduction in glucocorticoid feedback occurs at a
hypothalamic site, as data are not available which describe hypothalamic
release of CRH and AVP in the fetal sheep in vivo. To determine how
the efficacy of glucocorticoid negative feedback at the fetal hypothalamus
might vary during development, Yang, Jones & Challis (1990) examined
glucocorticoid receptor binding in the fetal sheep hypothalamus at
different gestational ages. These authors found that between day 60 of
gestation, the earliest gestational age studied, and term, there were no
appreciable changes in the binding characterisitics of the fetal
hypothalamic glucocorticoid receptor. In contrast, the glucocorticoid
binding capacity of the fetal hypothalamus varied markedly with fetal
development. Binding was dramatically elevated at day 100-110 of
gestation when compared to other gestational ages. These observations
suggested that there were maturational changes occurring in the
expression of glucocoricoid receptors in the fetal sheep hypothalamus,
and that this might be associated with an increase in the negative
feedback effects of glucocorticoids around day 100-110.
To examine the developing negative feedback effects of
glucocorticoids on CRH secretion by the fetal sheep hypothalamus,
Brooks and co-workers (1989) measured CRH release from perifused fetal
hypothalamic pieces removed at day 100 and day 140 of gestation. These
workers found that the spontaneous release of CRH from day 140
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hypothalami was greater than from day 100 tissues, suggestive of an
increasing hypothalamic drive to ACTH release with advancing
gestational age. In addition, they found that dexamethasone inhibited
basal CRH release from hypothalami removed at day 140 of gestation, but
had no effect on release from day 100 tissues. These data are at odds with
the binding studies carried out by Yang and colleagues (1990), which
showed very high levels of hypothalamic glucocorticoid receptors at day
100-110 of gestation. However, there are no studies which have
determined the functionality of the hypothalamic glucocorticoid
receptor in the developing fetal sheep. In a number of studies in which
the effects of glucocorticoids on the fetal sheep hypothalamus have been
assessed, the data are clearly supportive of a negative feedback effect of
glucocorticoids. Thus, intrahypothalamic inplants of dexamethasone at
day 108-111 of gestation cause marked reductions in AVP and CRH
immunostaining in the fetal median eminence, and abolish the fetal
ACTH response to stressors such as hypotension and hypoxaemia
(McDonald, Hoffman, Myers & Nathanielsz, 1990). By contrast,
adrenalectomy in the fetal sheep at day 118-121 of gestation gives rise to
greatly elevated CRH mRNA levels in the fetal PVN (Myers, Ding &
Nathanielsz, 1991). Therefore, the available evidence suggests that
endogenous glucocorticoids are inhibitory to hypothalamic ACTH-
releasing factors, though it is still not clear whether the efficacy of
glucocorticoid feedback varies during fetal life.
2.5.5. Extrahypothalamic glucocorticoid negative feedback.
The original studies which described the distribution of glucocorticoid
receptors in the CNS showed that receptors were present in several cell
groups within the hypothalamus and in several brainstem nuclei (Fuxe et
al. 1985). In addition to the direct inhibitory effects of glucocorticoids on
the paraventricular CRH and AVP neurones, corticosteroid negative
feedback on the hypothalamo-pituitary-adrenal axis may therefore
include a component mediated by the cells which project to the PVN.
Noradrenergic, adrenergic and serotoninergic projections from the
brainstem to the paraventricular cells of the PVN originate in the Al,
C1-C3 and raphe nuclei respectively (Cunningham & Sawchenko, 1988;
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Cunningham et al. 1989; Sawchenko, Swanson, Steinbusch & Verhofstad,
1983). These neurones may be differentiated in immunocytochemical
procedures by their contents of specific enzymes or neurotransmitters.
For example, noradrenergic fibres contain tyrosine hydroxylase (TH), but
not phenylethanolamine-N-methyltransferase (PNMT), which is present
in adrenergic cells, whereas serotonin (5-HT) may be visualised directly by
conventional immunocytochemistry. A recent study by Harfstrand and
colleagues investigated the presence of glucocorticoid receptor
immunoreactivity in the brainstem nuclei, and further assessed whether
TH, PNMT or 5-HT were co-localised in these cells. The vast majority of
brainstem cells which contained TH, PNMT or 5-HT showed pronounced
glucocorticoid receptor immunoreactivity (Harfstrand, Fuxe, Cintra,
Agnati, Zini, Wikstrom, Okret, Yu, Goldstein, Steinbusch, Verhofstad &
Gustaffson, 1986). Presently, it is not known whether the fetal sheep
brainstem neurones which project to the PVN contain glucocorticoid
receptors. However, glucocorticoid modulation of the input to the CRH
and AVP-containing cells may be of significance in a global activation of
the fetal hypothalamo-pituitary-adrenal system near term.
In addition to the brainstem neurones discussed above, the
hippocampus may also be a major site for feedback regulation of the
hypothalamo-pituitary-adrenal axis (see Jacobson & Sapolsky, 1991, for
review). In the rat there is good evidence that the hippocampus mediates
inhibitory actions of glucocorticoids, for example, there is a marked
enhancement of portal CRH and AVP levels in animals bearing
experimental fornix transection, which destroys the projections of the
hippocampus to the hypothalamus (Sapolsky, Armanini, Sutton &
Plotsky, 1989). Furthermore, portal plasma levels of AVP and CRH are
inversley related to the occupancy of hippocampal glucocorticoid
receptors (Sapolsky, Armanini, Packan, Sutton & Plotsky, 1990).
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2.6 Aims of this thesis.
This review has discussed the regulation of the pituitary-adrenal axis
during fetal life in the sheep, and has illustrated the various issues with
information drawn from studies carried out in other animals. Based on
the information obtained from these reports, it was decided to embark
upon an investigation of the factors which might regulate the activity of
the fetal sheep pituitary-adrenal axis during fetal life. Of specific interest
were hypothalamic CRH and AVP which may control pituitary drive to
the fetal adrenal gland. These factors are therefore implicated in the
mechanisms which bring about fetal maturation in late gestation, and
may have a pivotal role in the initiation of parturition. However, it is
not possible to measure directly the hypothalamic secretion of AVP and
CRH into the fetal portal vasculature. Therefore, the aims of this thesis
were to develop a fetal sheep hypothalamic culture system (chapter 4),
and to investigate the secretion of CRH and AVP at different gestational
ages (chapter 5). Subsequently, the results of these studies were to be
compared to the levels of immunoreactive and bioactive ACTH-releasing
factors present in the intact hypothalamus (chapter 6). Latterly, the
effects of glucocorticoids (chapter 7) and opioids (chapter 8) on the
secretion of ACTH-releasing factors was to be assessed at varying
gestational ages.
3. General Materials and Methods
This chapter describes the techniques common to a number of studies in
this thesis. Other methodologies unique to specific experiments are
elaborated upon in the relevant chapters.
3.1 Animals and Husbandry
3.1.1. Sheep Management.
The animals used for the studies presented in this thesis were mature
ewes of mixed breed, obtained from the Macauley Land Use Research
Institute at Sourhope Research Farm, Roxburghshire. Animals were kept
indoors at the University of Edinburgh's Marshall Building, Roslin,
Midlothian in groups of 10 in large pens (3m x 6m). Sheep had constant
access to hay and water, and were fed a dietary supplement (500g
Moredun Nuts, Dalgety Agriculture, Bristol,) each day.
3.1.2. Timed Mating.
Mature ewes were implanted intravaginally with sponges containing 60
mg medroxyprogesterone acetate ("Veramix Sheep Sponge", Upjohn
Limited, Crawley, Sussex). After 13 days the sponges were withdrawn and
48 hours later the ewes were penned with proven rams. The ewes were
removed after a further 24 hours, and these animals were considered to
have a single date of insemination with day 1 of pregnancy taken as the
date upon which the rams were introduced.
During seasonal anoestrus, ovulation was induced by treating
animals with progesterone sponges as previously described, in
conjunction with 300 I.U. pregnant mare serum gonadotrophin (PMSG,
Intervet U.K. Ltd., Milton Road, Cambridge) administered at the time of
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sponge withdrawal. Subsequently, the ewes were mated in the same way
as before. Pregnant animals were returned to a separate pen where they
were kept until required for tissue collection at the appropriate stage of
gestation.
3.2 Materials for Cell Culture
3.2.1. Culture Media and Reagents.
Basic Culture Media. Dulbecco's Modified Eagle's Medium (with phenol
red and without 1-glutamine), Dulbecco's Phosphate Buffered Saline,
Ham's F12 Medium (with phenol red and without 1-glutamine), Earle's
Balanced Salt solution (without phenol red) and Hank's Balanced Salt
Solution (with calcium and magnesium and without calcium and
magnesium) were purchased from ICN Flow Ltd. (Rickmansworth,
Hertfordshire).
Culture Grade Biochemicals and Enzymes. Progesterone, oestradiol 17-0,
sodium selenite, transferrin, putrescine, gentamycin, insulin, triiodo¬
thyronine (T3), glucose, bovine serum albumin (BSA; Fraction V), poly-1-
lysine hydrobromide (MWt. 70,000 - 150,000), double processed tissue
culture water, HEPES (1M stock) and deoxyribonuclease Type 1 (DNAse)
were purchased from Sigma Chemical Co. Ltd., Poole, Dorset,
penicillin/streptomycin mixture ("Penstrep", 5000 I.U./ml and 5000
(ig/ml respectively) and glutamine were obtained from ICN Flow Ltd..
Dispase (cell culture grade Neutral Protease) was obtained from BCL Ltd,
London U.K..
Miscellaneous Reagents. Glacial acetic acid and sodium hydroxide were
obtained from BDH Ltd., Thornliebank, Glasgow.
3.2.2. Glassware and Plastics.
Supplies. Pasteur pipettes were obtained from John Poulten Ltd.,
Barking, Essex and glass storage bottles (Schott glass) came from BDH.
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Gamma irradiated Nunc 6-well multidishes were obtained from Gibco
Ltd., Paisley, Scotland. Aseptically prepared 7 ml bijou tubes and 30 ml
universal tubes, sterile 60 ml and 150 ml plastic containers, Corning
500ml filter sterilisation units (0.2 micron) and sterile medium storage
bottles were obtained from Mackay and Lynn Ltd., Edinburgh. Disposable,
sterile plastic pipettes, syringes and needles were obtained from Becton
Dickinson U.K. Ltd., Cowley, Oxford, and small 0.2 micron filters were
obtained from Sartorius, Epsom, Surrey.
Glassware Treatment. In order to remove surface contamination from
medium storage bottles or coverslips upon which cells were plated, such
glassware was chemically cleaned before use. Articles were steeped
overnight in 2% "Micro" detergent (International Products Ltd,
Chislehurst, Kent). Next morning, they were rinsed and immersed in
sterile water (Sigma) for several hours. Glassware was then washed in
1M hydrochloric acid (BDH), rinsed, and steeped in sterile water as before.
Subsequently, several rinses of sterile water were applied, followed by a
rinse in absolute ethanol (Hayman Ltd., Witham, Essex) and further
rinses in sterile water. Finally, articles were autoclaved (2 atmospheres
pressure for 30 minutes at 121°C) and stored until ready for use.
All glassware which was to come into contact with cell suspensions
was siliconised before use, to prevent cell adhesion. Articles were briefly
immersed in "Sigmacote" (Sigma) and then left to dry in a fume
cupboard. Subsequently, these articles were rinsed once in ethanol and
several times in sterile water before autoclave sterilisation.
Siliconised pasteur pipettes of varying diameters were required
during the tissue dispersions. Pipettes were heated gently in a bunsen
flame until the tips were red hot ("fire polished"). Varying the amount of
heating produced pipettes of differing tip diameter.
3.2.3. Stock Solutions for Dispersion and Culture Media.
The media used for cell culture were made from stock solutions (stored at
4°C) and frozen concentrates (-20°C), prepared using a class 2
microbiological safety cabinet (Medical Air Technology, Denton,
Manchester) to prevent microbial contamination. Whilst a few
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concentrated reagents could be bought from commercial suppliers, most
stock solutions were made up in the laboratory, as described in this
section.
20% BSA. 10 g BSA were added to 50 ml pure water and the BSA was
dissolved over several hours with gentle shaking. The solution was then
filter-sterilised and aliquots of 1 ml were stored frozen in autoclaved 1.5
ml eppendorf tubes (BDH).
Penstrep. 100 ml penicillin/streptomycin mixture was thawed, 5 ml
aliquots were placed in sterile bijou tubes and these were stored at -20°C.
Insulin. 20 mg of insulin were dissolved in sterile acetic acid solution
(10% v/v) to yield an insulin concentration of 10 mg/ml. This was
diluted to 5 mg/ml with sterile water and the solution was filter-sterilised
and stored at 4°C for up to 1 month.
Triiodo-Thyronine (T3). 5 mg T3 were dissolved in 0.1M sterile sodium
hydroxide solution resulting in a final T3 concentration of 0.651 mg/ml
(lxl0-3 M). This mixture was further diluted to a concentration of
lxlO-6 M and was filter-sterilised and stored in a sterile universal at 4°C
for up to 1 week.
Combined Supplement. 20 ml glutamine solution (29.2 mg/ml, 0.2 M)
and 20 ml transferrin solution (10 mg/ml) were mixed together in a
plastic container. 2 ml putrescine solution (16.11 mg/ml, 0.1M) and 20fil
sodium selenite (0.52 mg/ml, 3xlO"3M) were added to the above and the
mixture was filter sterilised. Aliquots of 10.5ml were stored frozen for up
to a month.
Oestradiol 17-ji. 3.67 ml sterile, absolute ethanol were added to 1 mg
powdered hormone (supplied in a sterile 50 ml serum vial), giving a
solution of lxlO_3M. This was diluted to a concentration of 1x10'6M, and
50pl of this solution was added to 50 ml Earle's Balanced Salt Solution
(EBSS), resulting in a final concentration of lxlO"9M. This solution was
stored in a tightly stoppered, autoclaved glass bottle at 4°C and was
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replaced approximately every 3 months.
Progesterone. 1.59 ml sterile, absolute ethanol were added to 1 mg
hormone powder in a sterile 50 ml serum vial, resulting in a
concentration of 2xl0*3M. 500pl of this solution were added to 50 ml
EBSS, giving a stock concentration of 2xlO'5M. The final solution was
stored under the same conditions as oestradiol and replaced at the same
time.
3.2.4. Preparation of Media for Tissue Dispersion.
Media were prepared one day in advance, filter-sterilised, then stored
overnight at 4°C. The following morning, they were warmed to 37°C and
the appropriate enzymes were added to the media as described below.
Collection Buffer. 2 ml of 1M HEPES, 2 ml Penstrep and 0.5 ml 20% BSA
were added to 100 ml Hank's Balanced Salt Solution (HBSS; without
calcium and magnesium).
Dispersion Medium. This buffer was made in the same way as collection
buffer, however, 2 ml 20% BSA were added per 100 ml solution, instead
of 0.5 ml, and this medium was supplemented with 20 mg Dispase and 25
mg DNAse per 100 ml before use.
DNAse Medium. Again, this solution was made up according to the
formulation for collection buffer, however, the base was HBSS plus
calcium and magnesium, and 50 mg DNAse were added per 100 ml
solution before use.
3.2.5. Preparation of Serum-Free Medium for Cell Culture.
500 ml basic medium was made, containing 250 ml Ham's F12 medium
(F12) and 250 ml Dulbecco's Modified Eagles Medium (DMEM). To this
were added 500 pi triiodo-thyronine stock solution (1x10'6M), 500 pi
insulin solution (5 mg/ml), 500 pi oestradiol 17-6 (lxlO"9M), 500 pi
progesterone stock (2xlO_5M), 500 pi gentamycin (50 mg/ml), 10 ml
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penstrep concentrate and an aliquot of combined supplement (10.5 ml).
The serum-free medium was then filter-sterilised and stored for up to a
week at 4°C, and aliquots were withdrawn and heated to 37°C before use.
Table 3.1 shows the composition of the serum-free culture medium.
3.3 Preparation of Fetal Sheep Hypothalamic Cell Cultures
3.3.1. Coating of Culture Dishes.
On the morning of the tissue dispersion, an aliquot of poly-l-lysine
solution (Sigma, MWt. 70,000-150,000 kD; 10 mg polypeptide per ml sterile
water, filter sterilised) was thawed and a 1000-fold dilution (lOpg/ml) was
prepared in sterile, culture grade water. 1 ml of this solution was placed
in each 35 mm culture dish for 30 minutes, after which it was aspirated
and the wells were washed twice with 1 ml sterile water. Subsequently, 1
ml of culture medium containing 20% fetal calf serum (ICN Flow Ltd.)
was placed in each well. Finally, the plates were returned to a humidified
incubator (Scotlab, Bellshill, Scotland) at 37°C, in an atmosphere of 95%
air : 5% CO2, until required approximately four hours later.
3.3.2. Euthanasia.
20 ml Euthesate (Pentobarbitone sodium, 200 mg/ml, Willows Francis
Vetetrinary, A.H. Robbins Co. Ltd., Horsham, West Sussex) were
administered as an intravenous bolus to pregnant ewes. After maternal
death, the fetuses were rapidly delivered via abdominal and uterine
incisions and were euthanised with intracardiac administration of 1 - 2ml
Euthesate. The fetuses were weighed and transferred to a sterile surface
for gross dissection of the brain.
3.3.3. Dissection.
The fetal brain was exposed by cutting around the skull at the level of the
supraorbital ridges using either stout scissors or bone shears, depending
on gestational age. The head was inverted and the brain was removed by
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blunt dissection.
The brain was placed ventral surface uppermost on an ice cold,
sterile glass dish and irrigated with cold, sterile Hank's Balanced Salt
Solution (HBSS, ICN Flow Ltd.). With reference to the stereotaxic atlas
prepared for the fetal sheep (Gluckman & Parsons, 1983), the rostral edge
of the mammillary bodies, the lateral hypothalamic sulci, the rostral edge
of the optic chiasm and the most dorsal extent of the third ventricle were
used as the landmarks defining the hypothalamus. Using sterile
instruments, this block was dissected out from the rest of the brain tissue
and placed in approximately 50ml sterile collection buffer on ice. All
tissue was collected within one hour of the start of dissection and was
rapidly transported to the MRC Reproductive Biology Unit in chilled
buffer for dispersion.
3.3.4. Tissue Dispersion.
The manipulations from this stage onwards were carried out in the class 2
microbiological safety cabinet to minimise the risks of airborne
contamination.
Washing. The hypothalami were removed from the collection buffer and
finely chopped in a sterile petri dish using a sterile scalpel blade. The
tissue pieces were resuspended in 20 ml fresh, warmed (37°C) collection
buffer in a universal container, which was rotated end over end to wash
the tissue. The suspension was centrifuged (30 g, 1 minute) and the
supernatant was aspirated. Fresh collection buffer (20 ml) was added and
this process was repeated 3 times.
Stage 1. The tissue pieces were suspended in 40 ml warmed dispersion
medium in a 50 ml Bellco stirrer flask (Arnold Horwell Ltd., West
Hampstead, London) which was placed on a magnetic stirrer (Arnold
Horwell Ltd.). This assembly was located in a conventional laboratory
incubator (Gallenkamp Economy Incubator; Fisons Scientific Equipment,
Loughborough, Leicestershire), and the suspension was stirred at 75 rpm
for 30 minutes at 37° C. Solid pieces of tissue were allowed to settle and
the supernatant was aspirated, placed in a sterile pot, and returned to the
*
Average hypothalamic weights were 241 +/- 50 mg, 330 +/- 35 mg, and 462
+/- 58 mg at day 70, 100 and day 130 gestation respectively (mean +/- S.E., n
= 5-6).
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incubator for short term storage (Harvest 1).
Stage 2. A little fresh dispersion medium was added to the tissue pieces
left over from Stage 1. These were triturated using two sterile, siliconised
pasteur pipettes of decreasing diameter (fire polished- approximately 1
mm and 0.5 mm). The cell suspension was then made up to roughly 40
ml with dispersion medium, and the digestion process was repeated as
described above.
The supernatant was then aspirated and stored in the incubator
(Harvest 2). Remaining pieces of hypothalami were further triturated
(pipettes of 0.5 mm and 0.2 mm) and the resultant suspension was added
to Harvest 2.
Stage 3. Harvests 1 and 2 were centrifuged for 10 minutes at 200g. The
pellets were resuspended and combined in 40 ml DNAse medium in a
sterile plastic pot. The cell suspension was then returned to the incubator
for 30 minutes with occasional end over end rotation. The cells were
then centrifuged at 200g for 10 minutes.
The cell pellet was resuspended in 5 ml collection buffer. In order
to remove debris, the suspension was then layered on top of 20 ml
collection buffer containing 4 % BSA, then centrifuged at 200g for 10
minutes.
Plating Out. The pelleted cells were resuspended in a little culture
medium containing 20% fetal calf serum. The total cell number and
viability were assessed using a haemocytometer and trypan blue
exclusion. The suspension was diluted to 2.5 x 106 cells/ml and 1 ml of
suspension was added to each culture dish. Approximately 6 to 10
million cells were obtained from a single hypothalamus, according to
gestational age, and the average viability was 96.75 +/- 0.53%, (Mean +/-
S.E.M., n= 16).
After 2 days in culture, the medium was changed to serum-free
culture medium alone and was thereafter replaced every 3 days, or more
often as appropriate.
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3.4 Experimental Procedures
Experiments carried out on cell cultures utilised incubation media based
on Earle's Balanced Salt Solution (EBSS; ICN Flow Ltd.). EBSS was
supplemented with antibiotics and protease inhibitors for use in peptide
release experiments as described below.
3.4.1. Preparation of Media and Supplements.
Basal Medium. Supplemented EBSS was made by adding 1ml fresh,
sterile, ascorbic acid solution (Sigma; 3 mg/ml in culture grade water,
filter-sterilised), 1 ml sterile bacitracin solution (Sigma; 3 mg/ml,
prepared as for ascorbic acid), 1 ml sterile HEPES (1 M stock), 800 pi
Aprotinin solution ("Trasylol", Bayer U.K. Ltd., Newbury, 10,000
K.I.U./ml), a-D glucose (Sigma), up to a final concentration of 2 mg/ml,
and 500pl sterile 20 % BSA solution to each 100ml of EBSS. The resultant
solution was filter-sterilised and stored at 4°C for up to 1 week. The final
concentrations of the various constituents of this medium are shown in
Table 3.2 and Table 3.3.
56 mM Potassium-Containing Medium. EBSS, identical to the standard
product except that it contained high potassium levels and isotonically
reduced sodium levels, was made in the laboratory (see Table 3.2). The
various components of the basic salt solution were accurately weighed,
and all components, excepting calcium chloride, were added to 400 ml
sterile, culture grade water. The calcium chloride was dissolved
separately in 100 ml sterile water and this solution was added slowly, with
vigorous mixing, to the 400 ml salt solution. Finally, the complete
solution was filter sterilised and stored at room temperature.
Supplemented, 56 mM potassium-containing medium was prepared in
exactly the same way as basal medium and stored under the same
conditions.
3.4.2. General Experimental Procedure.
Throughout this thesis, a common approach was used for peptide release
Table 3.2. Composition of EBSS and 56 mM potassium-
containing medium.
Component mg/ litre mmol/litre
EBSS 56 mM K+ EBSS 56mMK+
NaCl 6800 3820 116 65
KC1 400 4170 5.4 56
CaCl
2 2H 2 O 265 1.8
MgS04 97 o.8
NaH2P04*2H20 i58 1
NaHCO 3 2200 24
Glucose 2000 11
Table 3.3. Supplements to the experimental media.





















*K.I.U. = Kallikrein Inactivator Units.
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experiments. Briefly, cultures were removed from the incubator and
placed in the class 2 cabinet. The culture medium was aspirated and each
dish was washed with 1 ml prewarmed basal medium. This medium was
replaced and the cells were returned to the incubator for ten minutes.
Subsequently, this medium was aspirated and replaced with 700(il fresh
basal medium, and the cells were incubated for the determined
experimental period.
After the basal release period, the medium was aspirated and
collected in polystyrene sample tubes (Teklab, Sacriston, Durham) for
storage at -20°C. 700(0.1 56 mM potassium-containing medium was then
placed in each well and the cultures were returned to the incubator for a
further incubation period. At the end of this time, the medium was
collected and stored as before, and the cells were washed 3 times with 1 ml
DMEM. Finally, this was replaced with 1 ml serum-free culture medium
and the cells were returned to the incubator.
3.5 Peptide Radioimmunoassays
The following sections detail the procedures which were used to measure
the peptide concentrations in culture media or the peptide content of
tissue or culture extracts.
3.5.1. Arginine Vasopressin.
AVP was measured by a radioimmoassay procedure, originally described
by Kasting, Carr, Martin, Blume & Bergland (1983). The assay has been
somewhat modified for use in the studies presented in this thesis, and so
is fully described below. The assay uses a rabbit anti-AVP antiserum (NK-
2), which was kindly supplied by Dr. Norman J. Kasting (Department of
Medical Physiology, University of British Columbia, Vancouver, Canada).
This antiserum, raised in a New Zealand male rabbit, shows minimal
cross reactivity with a variety of neuropeptides, including oxytocin, in
RIA procedures (Oxytocin cross reactivity; <0.2%; Kasting et al., 1983).
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Assay Buffer. Assays were carried out in 0.05M phosphate buffer which
contained NaCl (100 mmol/1), EDTA (1 mmol/1), NaN3(0.1%) and BSA
(0.1%; Sigma, Fraction V, RIA Grade). Reagents were dissolved in
deionised water which was made up to 1 litre with 100ml 0.5M phosphate
buffer solution. The pH of the assay buffer was adjusted to 7.4.
Antiserum. The lyophilised antiserum was reconstituted in assay buffer,
diluted to a concentration of 1:500 and stored in aliquots of lOOpl at -20°C.
Immediately prior to use, an aliquot was added to 25 ml assay buffer,
giving a final dilution of 1:125,000.
AVP Standards. 1 mg of AVP peptide (Cambridge Research Biochemicals,
Northwich, Cheshire) was dissolved in 2 ml 0.1 M acetic acid, giving a
concentration of 500 pg/ml, and aliquots of 10 pi and 20 pi were stored at -
20°C.
Iodination. AVP may be iodinated directly at the Tyr2 position by the
Chloramine-T method, originally described by Hunter & Greenwood
(1962). Briefly, 15 pi 0.5 M phosphate buffer and 10 pi Nal25I (1 mCi,
Amersham International, Aylesbury, Buckinghamshire) were added to an
aliquot of AVP (lOpl containing 5 pg peptide). Fresh chloramine-T
solution (BDH; 50 pg chloramine-T in lOpl 0.05M phosphate buffer) was
added to start the reaction. The mixture was vortexed, and the reaction
was terminated after 10 seconds by adding 600 pi 0.05M phosphate buffer
containing 0.5 % BSA.
Trace Purification. A C-18 Sep-Pak cartridge (Millipore, Hertfordshire,
U.K.) was attached to a 5 ml syringe and was wetted with 2 ml 1%
Trifluoroacetic acid in water (1%TFA; Aldrich, Poole, Dorset), followed by
5 ml of a mixture of 4 parts methanol with 1 part 1% TFA. The column
was washed with 3 ml 1% TFA and coated with polypep (Sigma; 1 ml of
1% TFA containing 0.1 mg polypep). The iodinated preparation was
pipetted on to the column and allowed to wash in to the bed under
gravity.
Unincorporated 125I was washed off the column by adding 0.7 ml
1% TFA and gently pushing the solvent through the cartridge with the
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syringe plunger. The iodinated peptide was eluted with an ascending,
step gradient of methanol in 1% TFA, with between 10% and 80%
methanol, in 700|il aliquots. A Mini-Assay gamma counter (Type 6-20,
Mini Instruments, Burnham on Crouch, Essex) was used to count each
fraction as it was eluted from the column. The fraction which showed
the highest binding activity to the NK-2 antiserum was used as the trace
for conventional assays and was stored at -20°C for up to 1 month (see
Figure 3.1).
Assay Procedure. On day 1, lOOpl aliquots of standards, samples and
quality control media (Low and High QCs) were incubated with 200|il
assay buffer and lOOpl NK-2 antiserum (added at 1:125,000) in 3 ml
polystyrene tubes (Sarstedt, Beaumont Leys, Leicester). There were always
two or more standard curves, one at the beginning and one at the end,
which were prepared from a freshly thawed standard aliquot of AVP
(500|ig/ml), giving a range of dilutions from 500pg/ml to 0.5 pg/ml. The
samples were assayed in duplicate, whereas the standards were assayed in
triplicate, as were the QCs. Included with the standard curves were tubes
containing either 400|xl buffer (NSB) or 300(il buffer plus lOOpl antiserum
(Bo). These were to be used to determine the non-specific binding of
trace to the assay tubes (NSB) and the maximal binding of trace in the
absence of AVP (Bo). Assays were vortexed and then incubated for 24
hours at 4°C.
On day 2, 100(il of dilute trace (-15,000 cpm in lOOpl) was added to
all assay tubes. A further set of tubes, containing only trace, were
included at this stage to determine the total amount of activity added to
each assay tube (Total counts; TC). Assays were vortexed and then
incubated at 4°C for a further 24 hours.
Separation of Bound and Free 125I-AVP. 200|il DAR (Donkey Anti-Rabbit
IGG Magnetic Particles; gift of Dr. Rodney Kelly, MRC Reproductive
Biology Unit), diluted 1:16 in 0.05M phosphate buffer containing 0.015%
Triton X-100 (BDH), was added to each assay tube (except TC). The tubes
were placed in magnetic separation racks (Amerlex-M assay racks,
Amersham), vortexed, and incubated at room temperature for 30
minutes. Racks were then placed on specially designed magnets
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Figure 3.1. Purification of 125I-AVP Trace;
Elution Profile of Radioactivity and
Antiserum Binding Activity.
The dashed line shows the fraction with the highest
binding activity. A binding assay was carried out for
each new trace, and only the fraction with the highest
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(Amerlex magnetic separator, Amersham) and incubated for a further 15
minutes to precipitate the immunocomplex. Subsequently, the rack and
magnet assembly was inverted to pour off the supernatant.
300(0.1 wash buffer (0.075 M phosphate-buffered saline, containing
0.075 M NaCl, 0.1% NaN3 and 0.015% Triton X-100) was added to each
tube (except TC). The tubes were vortexed, and the immunocomplex
magnetically precipitated as previously described. Finally, the tubes were
inverted, the supernatant was poured off and the tubes were allowed to
stand upside down to drain for 30 minutes. The precipitate was then
counted for 60 seconds on a gamma counter (1261 Multigamma, LKB,
Wallac OY, Turku, Finland).
Data Processing. During counting, data were collected onto a floppy disk
by an online recorder ("Datagrabber"; Mutek, Box, Wiltshire).
Subsequently, these data formed the input for an assay calculation
program (AssayZap; Biosoft, Cambridge) written for the Apple Macintosh
computer. This program initially plots a simple standard curve to the
data. Subsequently, it reiteratively adjusts the curve to fit best the
experimental data and the theoretical shape of the assay curve. The assay
results were generated directly by AssayZap, along with historical data
about the assay, e.g. % tracer binding and QC values.
Assay Sensitivity and Variation. The limit of sensitivity of the assay,
defined as 2 standard deviations from the zero point, was 1.75 pg/ml and
the intraassay coefficient of variation was 16.0%. The interassay
coefficients of variation for the low (8.46 pg/ml) and high (51.1 pg/ml)
QCs were both 21.8%. It was noticed that different trace preparations gave
somewhat different assay sensitivities, and this may account for what is
felt to be a rather high limit of sensitivity overall. To minimise variation
from such sources, all samples within a study were assayed using one
batch of trace. A representative AVP standard curve is shown in Figure
3.2.
3.5.2. Corticotrophin-Releasing Hormone Immunoradiometric Assay.
Ovine Corticotrophin Releasing Hormone (oCRH) was measured by
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Figure 3.2. A Representative AVP Standard
Curve.
Non-specific binding was subtracted from the counts
for each tube, and the results were expressed as a
percentage of the values obtained in the absence of
cold AVP (Bo). Binding values were then plotted
against the quantity of cold AVP added.
AVP (pg/ml)
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immunoradiometric assay (IRMA) either alone or in conjunction with
oCRH RIA (see 3.5.3). In contrast to RIA, an IRMA depends on the
specific binding of two antibodies from different species to one molecule
of the analyte (see Figure 3.3). One antibody (sheep anti-C terminal CRH)
is radiolabeled; when it binds to the CRH, it effectively radiolabels the
analyte. The second antibody (guinea pig anti-N terminal; "link") binds
to another epitope on the same molecule, and the whole complex is
precipitated with another antibody, directed against the link. In this way,
precipitated radioactivity is proportional to the amount of intact
hormone present, as it is the CRH molecule which joins the precipitating
antibody to the radiolabel. The strength of the IRMA lies in its ability to
detect only full size hormone, rather than fragments which may cross-
react in an RIA.
The methodology reported here is an adaptation of the assay first
described by Linton & Lowry (1986). Dr. Peter Saphier (University of
Reading, U.K.) very kindly prepared all the reagents used in these assays,
which were carried out at the MRC Reproductive Biology Unit in
Edinburgh.
200pl R1 reagent (0.05 M phosphate buffer containing 2% normal
sheep serum, 0.5% BSA, guinea pig anti N-CRH at 1:5000 and 125I-sheep
anti C-CRH; ~100,000 cpm in 200|il) were added to 200(il of samples
(duplicates), standards and QCs (triplicates). Standards were prepared in
sample buffer in the same way as for the RIA, to give a range of
10,000pg/ml down to lOpg/ml. Included in the standard curve was a set
of tubes containing 200pl sample buffer and 200pl Rl; these were used to
determine the background counts with no added hormone (3ml
polystyrene tubes; as for RIA). The assay tubes were then vortexed and
incubated at room temperature for 18 hours.
On day 2, lOOpl of diluted, solid phase second antibody (Rabbit
Anti-Guinea Pig, "Estapor"; 1:5 in 0.05M phosphate buffer) were added to
each tube and the tubes were incubated for 30 minutes on the bench. The
suspension was diluted with 2 ml wash buffer (0.05M phosphate buffer
containing 150 mmol/1 NaCl and 0.01% Triton X-100) per tube, and the
tubes were centrifuged for 10 minutes at 3000 rpm (2110g). Subsequently,
the assay tubes were placed in magnetic separation racks and the
supernatant was decanted. Finally, the wash buffer, centrifugation and
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Figure 3.3. Principles of the
oCRH Immunoradiometric Assay.
The radiolabelled sheep antibody binds to the C-
terminal end of the CRH molecule. A guinea pig
antibody binds to the N-terminus, and the complex is
immunoprecipitated using an anti-guinea pig
antibody. Thus, precipitated counts are proportional
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decanting steps were repeated, and the tubes were left inverted to drain,
before counting the precipitates as previously described.
The limit of sensitivity of the IRMA was 34 pg/ tube, the intraassay
coefficient of variation was 14.5%, and the interassay coefficients of
variation for the low (123 pg/ml) and high (479 pg/ml) QCs were 18.5%
and 16.9% respectively. Figure 3.4 shows a standard curve for the CRH
IRMA.
3.5.3. oCRH Radioimmunoassay.
In some experiments presented in this thesis, oCRH was measured by
conventional RIA with magnetic separation. The assay reported here is a
modified version of that first described by Brooks et al. (1989) and is
described below. Both CRH (1-41) standard peptide and [Tyr°] CRH (1-41),
for iodination, were purchased from Cambridge Research Biochemicals.
100(0.1 rabbit anti-CRH antiserum (CRF-2G; 1:100,000) and 100gl
assay buffer (0.05M phosphate buffer containing 0.1 mol/1 NaCl, 25
mmol/1 EDTA, 0.1% NaN3, 0.1% Triton X-100 and 0.1% BSA,pH 7.4) were
added to 200|il of samples, standards or QCs in 3 ml polystyrene tubes.
Standard curves, containing NSB and Bo tubes, were prepared by diluting
a freshly thawed aliquot of CRH (10|ig/ml) in assay buffer to give a range
from 10,000 pg/ml to 20 pg/ml (see Figure 3.5). Samples were assayed in
duplicate, whereas standards and QCs were assayed in triplicate. All tubes
were vortexed and incubated for 24 hours at 4°C.
The next day, 100(0.1 dilute 125I-[Tyr°] CRH trace (Brooks et al. 1989),
containing -15,000 cpm was added to each tube, including TC tubes.
Subsequently, all tubes were vortexed and incubated overnight at 4°C. On
day 3, antibody-bound tracer was magnetically precipitated and the assay
results were calculated as previously described.
The lower limit of sensitivity of the assay was 14pg/tube, the
intraassay coefficient of variation was 16.2%, and the interassay
coefficients of variation for the low (241 pg/ml) and high (948 pg/ml) QCs
were 16.5% and 15.5% respectively. Figure 3.5 shows a CRH RIA standard
curve.
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Figure 3.4. A Representative oCRH IRMA
Standard Curve. Counts measured in tubes
containing no hormone were subtracted from all
tubes, and the logs of the resultant figures were
plotted against the quantities of added hormone.
10 100 1000 10000
CRH (pg/ml)
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Figure 3.5. A Representative oCRH RIA
Standard Curve. Non-specific binding was
subtracted from the the counts for each tube, and the
results were expressed as a percentage of the values
obtained in the absence of cold CRH (Bo). Binding
values were plotted against the quantity of cold CRH
added.
CRH (pg/ml)
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3.6. Sephadex Chromatography
Several experiments presented in this thesis required the characterisation
of immunoreactive species present in tissue extracts or culture
supernatant. In order to determine the approximate molecular weight of
these molecules, Sepahdex chromatography was carried out followed by
CRH or AVP RIA.
Sephadex G50 Fine (Pharmacia, Uppsala, Sweden) was swollen
overnight in 0.1M HC1. The slurry was then packed into a glass column
(50cm x 1cm internal dimensions; Amicon Ltd., Stonehouse,
Glocestershire) under gravity at 4°C. The column was perfused for 24
hours (0.1M HC1, 3.5 ml/hour, Watson Marlowe Pump, Type 202U;
Falmouth, Cornwall) and binding to non-specific sites in the gel matrix
was prevented by priming the column with 1ml 20% BSA solution.
Standard 1ml aliquots containing 0.1% BSA and either AVP
(500pg/ml), oCRH(l-41) (10,000pg/ml) were added to the column in
duplicate. These were eluted with 0.1M HCL at a flow rate of 3.5ml/hour,
and fractions were collected every 20 minutes in polystyrene tubes
(10x75mm; Sarstedt) with a fraction collector (Gilson Microcol TDC 80;
Scotlab, Bellshill, Scotland). Fractions were neutralised with 10M NaOH
and the oCRH or AVP concentration was measured by RIA. Figure 3.6
shows the elution position of synthetic oCRH and AVP. Blue dextran
(2mg/ml ; Pharmacia) exclusion was used to determine the void volume
of the column.
3.7 Data Analysis
The effects of experimental manipulations were assessed in the first
instance by Analysis of Variance (ANOVA), using a programme designed
for the Macintosh computer called CLR ANOVA (Clear Lake Research,
Houston, Texas, U.S.A.). The strategy of an analysis was dictated by the
number of between- and within-subject variables, taking into account
whether the data represented repeated measures on the same subjects or
independent samples. For pairwise comparisons subsequent to ANOVA,
data were compared using Duncan's multiple range test.
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Figure 3.6. Sephadex G50 Chromatography.
0.1M HC1 was used to elute AVP and CRH, which
were then measured by RIA. Blue dextran was used
























4. Development of the
Fetal Sheep Hypothalamic Cell Culture System.
4.1 Introduction
The chronically instrumented fetal sheep model of Bassett & Thorburn
(1969) has made possible the dynamic assessment of the fetal pituitary-
adrenal axis in utero. However, this approach relies on the quantitation
of systemic hormones such as ACTH and Cortisol in the peripheral
circulation, and so the developing hypothalamic control of the fetal
pituitary-adrenal axis remains poorly understood.
There are several studies which have examined the maturation of
the fetal sheep hypothalamus by indirect techniques. For example, the
fetal hypothalamic contents of CRH and AVP have been investigated at
different developmental ages (Brieu et al. 1989), and this research shows
that the hypothalamic concentration of these ACTH-releasing factors is
substantially increased with advancing gestation. In parallel with such
changes in peptide content, immunocytochemistry has revealed the
progressive maturation of CRH- and AVP-containing cells in the
paraventricular nucleus of the fetal hypothalamus (Levidiotis et al. 1987).
These studies give some insights to fetal hypothalamic activity during
development, however, they are unable to show how control of the
various releasing factors evolves with advancing gestational age.
Recently, Brooks et al. (1989) investigated developmental changes
in the regulation of CRH release from fetal sheep hypothalamic tissue in
vitro . These researchers were able to demonstrate that a glucocorticoid
agonist, dexamethasone, inhibited CRH release from tissue removed at
day 140 of gestation. However, they showed that there was no inhibitory
effect of the agonist on CRH release from day 100 hypothalami. These
results were in agreement with those of Clarke & Gillies (1988), who
showed that CRH and AVP secretion from fetal rat hypothalamic
neurones removed late in gestation were inhibited by corticosteroids.
However, the latter authors utilised a cell culture system to maintain
hypothalamic neurones over long periods in vitro. This technique made
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possible more sophisticated investigations of hypothalamic neuronal
function.
Hypothalamic cell culture has undergone a transformation with
the introduction of serum-free culture media (Bottenstein & Sato, 1979,
Faivre-Bauman, Rosenbaum, Puymirat, Grouselle & Tixier-Vidal, 1981,
Puymirat, Barret, Picart, Vigny, Loudes, Faivre-Bauman & Tixier-Vidal,
1983). Release of AVP and CRH from fetal rat hypothalamic cultures is
enhanced in serum-free medium when compared to serum-
supplemented medium (Clarke & Gillies, 1988). Furthermore, peptide
secretion in these cultures is stimulated by potassium-induced
depolarisation in a calcium-dependent fashion. These recent
developments have suggested that a cell culture system would be a most
elegant means by which to investigate hypothalamic function in the fetal
sheep.
In order to develop a system for the culture of fetal sheep
hypothalamic cells, it was first necessary to assess the optimal culture
conditions for maintaining these cells. Variations in plating density are
known directly to modulate expression of neurotransmitters and proteins
in cultured cells (Lucas, Edgar & Thoenen, 1979; Zurn & Mudry, 1986) and
culture substrates which are reported to be optimal for certain cell types
may be less so for the same cell type in different species. For example,
Faivre-Bauman, Puymirat, Loudes, & Tixier-Vidal (1984) carried out a
thorough investigation to determine the appropriate substrate for
maintenance of mouse hypothalamic neurones in vitro . These authors
reported that gelatin plus poly-l-lysine coating was far superior to gelatin
or poly-l-lysine alone, whereas excellent results have been acheived in
fetal rat hypothalamic cultures with a poly-l-lysine substrate (Clarke,
Lowry & Gillies, 1987).
In order to assess the optimum conditions for maintaining fetal
sheep hypothalamic cultures in vitro, cells were plated at densities
between 1.5 x 105 and 3 x 105 cells/cm2 on gelatin or poly-l-lysine
substrates or on a combination of both. The accumulated AVP in the
supernatant was measured as an indicator of cell function. A second
culture was then maintained under the optimised conditions as suggested
by the first experiment. These cells were then subject to experimental
stimulations to assess functional responses after 2 weeks in vitro.
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4.2 Experimental Procedures
4.2.1. Optimisation of Culture Conditions.
Cell Culture. Fetal sheep hypothalamic tissue was obtained from 7
fetuses at a gestational age of 50 days (Term = 145 days). The tissue was
dispersed for cell culture as previously described.
Experimental Conditions. To establish the effect of cell plating density on
subsequent AVP output, four dilutions of the final cell suspension were
prepared, giving rise to cell densities of 1.5, 2, 2.5 and 3 x 105 cells/cm2
when plated. The effect of culture substrate was assessed by plating cells
on sterile glass coverslips (Chance Propper Size 3, 13 mm round; R.A.
Lamb, London), previously coated with gelatin, poly-l-lysine, or a
combination of both substrates, according to modifications of published
methods (Faivre-Baumanef al. 1984), described in more detail below.
Each combination of substrate and cell density was assessed in duplicate
or triplicate wells.
Briefly, coverslips were immersed in a solution of gelatin (Sigma)
in culture grade water (0.25 mg/ml) for 30 minutes. They were
subsequently rinsed in sterile water, placed on edge in 4-well culture
dishes (Nunc 4-well multidish, Gibco) and allowed to dry in the culture
hood before use. Coverslips were coated with poly-l-lysine (Sigma) by
incubating overnight in coating solution (100 pg/ml in sterile water), and
then rinsing and drying as described previously. Where both treatments
were applied, coverslips were first coated with gelatin and then with poly-
l-lysine.
Coverslips were then incubated with 200 pi culture medium
containing 20% fetal calf serum for 3 hours. Finally, this medium was
aspirated, and the cells were plated out on the coverslips in a volume of
200 pi.
Culture Maintenance. Cells were maintained in serum-containing
medium for 48 hours after plating. Subsequently, the cells were
transferred to serum-free medium alone. This medium was changed
every 3 or 4 days, at which times the culture supernatants were collected
and stored at -20°C, for later measurement of AVP by RIA. Cultures were
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frequently assessed under phase-contrast microscopy and a photographic
record of the appearances of different cultures was maintained
throughout this time.
Statistics. The AVP concentration in the culture supernatants was
expressed as pg/dish. To compare AVP output from the various culture
conditions, ANOVA was carried out with plating density and substrate as
between-group variables and time in vitro as the within-group variable.
This was followed by Duncan's multiple range test for pairwise
comparisons, in order to assess which substrates or densities had
enhanced AVP output in the culture medium. Data were log
transformed prior to analysis to eliminate heterogeneity of variance.
4.2.2. Assessment of Experimentally-Induced AVP Release.
A hypothalamic tissue culture was prepared from fetal sheep at 100 days
of gestation as previously described. Cells were plated in 35 mm wells on
a substrate coated with poly-l-lysine, at a density of 2.5 x 105 cells/cm2
(equal to 2.5 x 106 cells/dish), as detailed in Chapter 3.
On the 15th day in vitro, cells were incubated with control medium and
with 56 mM potassium-containing medium for 3 hours each. On day 19,
this protocol was repeated, except that cells received control medium
containing 100 pM N-Methyl D-Aspartate (NMDA; Cambridge Research
Biochemicals) instead of high potassium medium. Subsequently, the
content of AVP in these samples was measured by RIA.
Statistical comparison of the response to potassium or NMDA with basal
release was carried out in each case by one way ANOVA, where treatment
was the within-group variable, followed by Duncan's multiple range test.
Chapter 4 Hypothalamic Culture System 67
4.3 Results
4.3.1. Optimisation of Culture Conditions.
Observations. The cultures were first observed 7 hours after plating, at
which time all cells were firmly adhered to the coverslips. Within 24
hours (day 2 in vitro ), the hypothalamic cells had extended projections
and formed a dense network throughout the culture dishes. On the 4th
day in vitro cells grown on poly-l-lysine had spread over the substrate,
showing some localised clumping. However, those grown on gelatin
showed a greater degree of clumping, forming a net-like structure
throughout the dish. These changes, which became more exaggerated
with time, are shown in Figure 4.1.
Cell cultures were maintained up to 28 days in vitro. Cultures
plated on poly-l-lysine remained attached to the coverslips throughout
the culture period, however, cells plated on either gelatin or gelatin plus
poly-l-lysine peeled away from their substrates between day 22 and 25.
For this reason, AVP output data are shown only until day 22 of culture.
AVP Output. Figure 4.2 shows the AVP output from hypothalamic cells
maintained under the various culture conditions. Analysis of variance
revealed that there were highly significant effects of plating density (p <
0.001) and culture substrate (p< 0.001) on the quantity of AVP
accumulated in culture supernatant. Individual comparisons on each day
in vitro showed that medium removed from cells grown on gelatin had
a significantly greater AVP content at all time points in culture, when
compared to the combination of gelatin and poly-l-lysine (p < 0.01, except
day 19, p < 0.05). Poly-l-lysine alone had enhancing effects similar to
gelatin when compared to the combination substrate, although these
were not as marked (significant enhancement on days 6 and 9, p < 0.01,
and day 16, p < 0.05). Gelatin coating enhanced AVP accumulation in
comparison to poly-l-lysine only on day 6 of culture (p < 0.01), thereafter,
there were no differences between these groups.
AVP accumulation in culture media was very much elevated at
high plating densities. At all time points, supernatant from high density
cultures (2.5 and 3 x 105 cells/cm2) contained significantly more AVP than
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Figure 4.1. Appearance of cell cultures at
different times after plating. A. Cells plated on
poly-l-lysine. B. Cells plated on gelatin. C. Cells
plated on gelatin plus poly-l-lysine. Representative
photographs are shown of cultures on day 2, 4, 10
and 20 in vitro. Cells plated on gelatin show a
marked clumping when compared to other
substrates, which is exaggerated with time in vitro .
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Figure 4.2. The effects of plating density and
culture substrate on AVP accumulation in
hypothalamic culture supernatant. A. Cells
plated on poly-l-lysine. B. Cells plated on gelatin. C.
Cells plated on gelatin plus poly-l-lysine. Each graph
shows the AVP contents of the media, collected from
cultures of different densities. AVP accumulation is
shown as pg/dish. Each data point represents the
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did the lower density cultures (p < 0.05), whereas there were few
differences between the two high density groups (output from 3 x 105
cells/cm2 greater than 2.5 x 105 cells/cm2 at days 6 and 9 only, p < 0.01).
4.3.2. Assessment of Experimentally-Induced AVP Release.
Figure 4.3 shows that AVP release from hypothalamic cultures was
significantly elevated by both 56 mM potassium and 100 |i.M NMDA
treatment (p < 0.01). This suggests that the AVP-secreting cells were
capable of a secretory response to membrane depolarisation induced
either by 56 mM potassium or receptor activation via the
NMDA/glutamate receptor.
4.4 Discussion
The studies reported in this chapter examined the effects of different
plating densities and growth substrates on the function of hypothalamic
cell cultures, which was assessed by measuring accumulated AVP in the
culture supernatant. Medium removed from cells plated at higher
densities contained more AVP than supernatant aspirated from lower
density cultures. Furthermore, AVP accumulation was accentuated in
cultures plated on either gelatin or poly-l-lysine, in contrast to lower AVP
levels observed in medium from cells grown on a combination of the two
substrates. In fact, there was a tendency for cells plated on gelatin to show
a greater AVP output than cells plated on poly-l-lysine, however, it was
later found that gelatin coating was associated with failure of cell-
substrate adhesion. In a second experiment to assess AVP secretion in
response to different secretagogues, AVP output was significantly
elevated in response to 56 mM potassium and to lOOpM NMDA.
There was a dramatic difference in AVP levels between the
cultures plated at 1.5 x 105 cells/cm2 and 3 x 105 cells/cm2 (see Figure 4.2),
more so than could be explained by the two-fold difference in cell
numbers. It may be that at the highest densities, AVP synthesis and
secretion per neurone is enhanced. Adler & Black (1985, 1986) have
demonstrated that a 30-fold increase in substance P content of rat
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Figure 4.3. The effects of 56 mM potassium
and 100 pM NMDA on AVP secretion by
hypothalamic cell cultures. A. Secretory
response to 56 mM potassium. B. NMDA response
(100 pM). Each result is the mean of 6 wells, +/-
S.E.M., **p < 0.01, significantly different from basal
values.
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sympathetic neuronal cultures occurs when density is increased 4-fold.
Similar density-dependent effects have been reported in cultured chick
sympathetic neurones (Zurn & Mudry, 1986), bovine adrenal chromaffin
cells (Acheson & Thoenen, 1983) and the PC 12 phaeochromocytoma cell
line (Lucas et al. 1979) for catecholamine synthesis, tyrosine hydroxylase
activity and Choline Acetyl Transferase (ChAT) activity respectively.
Alternatively, it may be that AVP accumulation is adversely affected in
the lowest density cultures. Early work has shown that low plating
density is associated with poor cell growth in vitro (Sanford, Earle &
Likely, 1948) and it has become widely accepted that cells plated below a
minimum density fail to thrive (Ham & McKeehan, 1979).
The effect of culture substrate on AVP levels could be explained in
several ways. The most interesting may be that specific substrates induce
greater expression of neuronal AVP synthesis, and hence secretion.
Culture substrate has previously been examined as a factor regulating the
expression of Glutamic Acid Decarboxylase (GAD) and ChAT activities in
cultured chick neurones (Mangoura, Sakellaridis & Vernadakis, 1990).
Whilst collagen selectively enhanced GAD activity, poly-l-lysine
stimulated ChAT. Furthermore, increased GAD activity was associated
with greater numbers of GAD-immunopositive cells, suggesting that
substrate might exert a profound effect on cell function. Cell-substrate
interactions have been found by other workers greatly to enhance or
retard the differentiation of CNS cells in culture (Agresti, Aloisi, & Levi,
1991). These findings relate indirectly to the present study, however, in
the absence of comparable data, the data suggest that peptidergic function
of cultured AVP neurones may well be determined to some degree by
substrate. Another explanation may be that the poor adhesive qualities of
the gelatin plus poly-l-lysine-coated coverslips led to a progressive loss of
cells, and so reduced AVP accumulation. However, cells plated on gelatin
also detached from the substrate, and yet the data suggest that AVP levels
in these cultures were greater than those observed in other cultures. The
interesting possibility remains that the clumping of cells observed in
cultures plated on gelatin effected a local increase in cell-cell contact, and
so improved AVP secretion from these cells via a density-dependent
mechanism.
Cells maintained on gelatin or gelatin plus poly-l-lysine but not
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poly-l-lysine alone peeled away from the coverslips between day 22 and 25
of culture. It was observed that cells plated on a gelatin-based substrate
tended to form tight clusters of cells connected by "cables" of neurites
(Figure 4.2). As time in vitro progressed, these cables became detached
from the substrate, and ultimately, all cultured tissues became detached
from the substrate as the cells peeled away. Other authors have reported
"stringiness" and peeling in serum-free cultures (Mangoura et al. 1990).
On the same note, Faivre-Baumanet al. (1984) mention "cables" in
association with gelatin-coated substrates. Substrate requirements may
well vary between different species and this may account for the relative
successes of different substrates with different preparations. In the work
described here, poly-l-lysine was found to be the optimum substrate for
fetal sheep cells.
56 mM potassium-induced neuropeptide release is widely used as a
demonstration of culture viability (Clarke et al. 1987; Sarkar & Sakaguchi,
1990) and N-Methyl D-Aspartate (NMDA) has been shown to stimulate
peptide release from cultured neurones via glutamate receptors (Tapia-
Arancibia & Astier, 1988). In the present study, AVP release over a 3 hour
period was elevated 6-fold and 10-fold in the presence of 100(iM NMDA
and 56mM potassium-containing medium respectively. Although each
of the experiments reported in this chapter was carried out only once,
these results provide good evidence that the cell culture system
developed here is capable of maintaining functional neurosecretory cells
over prolonged periods in vitro.
A major advantage of serum-free cell culture is the degree of
control which is possible over the cellular environment. The medium
used in the present study is based on that first described by Bottenstein &
Sato (N2 medium; 1979), supplemented with Triiodo-thyronine
(Puymirat et al. 1983) and Oestradiol-173 (Faivre-Bauman et al. 1981). No
attempt was made to alter the reported composition, as the development
of a specific medium for fetal sheep neurones would have been outside
the scope of these studies. However, a description of some of the
important components of the chosen medium is given here.
Transferrin, the major iron transport protein in the blood (Fletcher
& Huehns, 1968), is present at high levels in this medium. Many cell
types have a most stringent requirement for this additive, and fail to
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proliferate or die in its absence (Bottenstein & Sato, 1979; Faivre-Bauman
et al. 1981, Bottenstein, 1984). Similarly, triiodo-thyronine markedly
enhances neurite extension and is obligatory for peptide secretion in
hypothalamic cell cultures (Puymirat et al. 1983, Clarke & Gillies, 1988).
Another important supplement is selenium, which was discovered to be
the active factor in trace contaminants of early media (McKeehan & Ham,
1979). Again, previous workers have shown that selenium-deficient
media do not support cell growth (Bottenstein & Sato, 1979, Bottenstein,
1984).
Insulin is present at high levels in this medium. It is localised in
cultured neurones by immunocytochemistry (Schechter, Holtzclaw,
Sadiq, Kahn & Devaskar, 1988), suggesting a paracrine role within the
CNS. It may also be acting as a neurotrophic agent in culture, as the high
concentrations present in vitro may result in cross-reactivity at IGF-1
receptors (Adamo, Raizada & LeRoith, 1989). Other additives include
oestradiol-17(3, which enhances the neurone: glial cell ratio (Faivre-
Bauman et al. 1981); putrescine, found in greatly elevated quantities in
fetal brain tissue and associated with rapid cellular growth (Seiler &
Lamberty, 1975), and progesterone, which is trophic to neuroblastoma
cells (Bottenstein & Sato, 1979) and is routinely added to neuronal culture
media (Maurer, 1986).
In summary, a range of culture conditions have been assessed in
order to develop a serum-free culture system for fetal sheep hypothalamic
cells. Using available tissue, it was determined that AVP release was
facilitated by plating cells at high densities, and that a poly-l-lysine
substrate was superior in maintaining the integrity of cell cultures.
Furthermore, cells plated under these conditions displayed a dramatic
secretory response to membrane- or receptor-mediated depolarising
stimuli after 2 weeks in vitro, suggesting that this culture system is
perfectly suitable for subsequent investigations of fetal neuroendocrine
function in vitro.
5. Ontogeny of AVP and CRH Secretion
from Fetal Sheep Hypothalamic Cells.
The previous chapter decribed the development and optimisation of a
serum-free culture system for the maintenance of fetal sheep
hypothalamic cells. These cultured cells were shown to secrete the
hypothalamic peptide AVP, and furthermore, could respond to
depolarising stimuli with increased AVP secretion some 2 weeks after
plating out. Previously, studies of the developing hypothalamic input to
the pituitary corticotrophs in the fetal sheep were dependent on
evaluation of ACTH levels, and were therefore based on indirect
measurements. By contrast, the present chapter seeks to quantify directly
the secretion of ACTH-releasing factors from the developing fetal sheep
hypothalamus in vitro .
5.1 Introduction
Evidence has now accumulated to suggest that in fetal sheep, increasing
hypothalamic drive to the pituitary is responsible for the preparturient
activation of the fetal pituitary-adrenal axis. Around day 110-120 of
gestation in the sheep fetus, plasma ACTH and Cortisol concentrations
begin to increase (Term= day 145; Norman et al. 1985) and undergo
further sharp elevations in the last few days of pregnancy (Rose et al.
1978). Administration of CRH or AVP stimulates fetal plasma ACTH
levels (Wintour et al. 1984; Norman & Challis, 1987a,b), and repeated
infusion of boluses containing CRH+AVP to the fetus results in elevated
basal plasma ACTH levels and significant adrenal corticosteroid secretion
(Brooks & White, 1990).
In the intact fetal hypothalamus, CRH and AVP content is greatly
increased with advancing gestational age (Brieu et al. 1989; Brooks et al.
1989). In addition, pituitary cell bioassays reveal that the ACTH-releasing
activity of fetal hypothalamic extracts is augmented in parallel with CRH
and AVP content (Brieu et al. 1989). Recently, Antolovich and colleagues
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obtained good evidence to suggest that the fetal hypothalamus provides a
crucial stimulatory input to the fetal pituitary-adrenal axis in late
gestation. These workers showed that surgical disconnection of the fetal
hypothalamus from the pituitary prevents the normal increase in fetal
plasma ACTH and Cortisol in late gestation, and hence abolishes
parturition at the normal time (Antolovich et al. 1990; 1991).
The objective of the present chapter was therefore to investigate
the gestational changes in secretion of ACTH-releasing factors from the
fetal sheep hypothalamus. Hypothalamic cultures were prepared from
tissues obtained at day 70, day 100 and day 130 of gestation. Basal and
potassium-stimulated release of CRH and AVP were measured on several
occasions from each culture, in order to assess more fully the secretory
capacity at the different gestational ages. In addition, the facilitatory
effects of repeated potassium stimulation on AVP and CRH output were
determined in all cultures, as was the time and calcium dependency of
AVP and CRH release. Finally, cultures were extracted for measurement
of AVP and CRH content at each gestational age, and quantitative
immunocytochemistry was carried out to examine numerical differences
in cell types between different cultures.
5.2 Experimental Procedures
A total of 37 hypothalami were removed from fetal sheep at day 70 (5+4
hypothalami) day 100 (8+7 hypothalami) and day 130 (4+5 hypothalami)
of gestation. Hypothalamic cell cultures were prepared as described
previously, and the experiments described below were carried out in
duplicate cultures at each gestational age, the results from which were
combined for statistical analysis. In the experimental procedures
described below, the statitistical analyses are described for AVP alone.
CRH release data were assessed using the same procedures. To eliminate
heterogeneity of variance, data were log-transformed where appropriate.
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5.2.1. AVP and CRH release from the developing hypothalamus in vitro .
The objectives of this experiment were to assess whether potassium
stimulation enhanced AVP and CRH output from the hypothalamic
cultures, to assess the effects of gestational age on the basal and 56 mM
potassium-stimulated secretion of AVP and CRH, and to examine the
facilitatory effects of repeated potassium stimulation on AVP and CRH
secretion.
Culture dishes were incubated with basal release medium for 3
hours and then with 56 mM potassium-containing medium for a further
3 hours, as detailed in section 3.5.2. These experimental treatments were
repeated every 3 or 4 days, from day 7 to day 27 in vitro (Group 1 cells).
To assess whether such incubations had a facilitatory effect on subsequent
peptide release, AVP and CRH output from these cells was compared
with output from a second group of wells, experimented upon from day
17 until day 27 in vitro (Group 2 cells). After each incubation, samples
were stores at -20°C until measurement of AVP and CRH contents by RIA
and IRMA respectively.
Statistics. To assess whether potassium stimulation enhanced AVP
release from the hypothalamic cultures, ANOVA was carried out on data
obtained from group 1 cells at each gestational age individually with day
in vitro (day 7, 10, 14, 17, 21, 24 and 27) and incubation (basal or
stimulated) as the within-groups variables. Duncan's multiple range test
was then employed for post-hoc comparisons, to determine whether
potassium stimulated AVP release on each day in vitro. A similar
analysis was applied to results from group 2 cells at each gestational age.
To examine the changes in basal peptide secretion with advancing
gestational age, ANOVA was carried out on basal AVP release data from
from group 1 cells. Gestational age (day 70, 100 or 130) was the between-
groups variable, and day in vitro (day 7,10,14, 17, 21, 24 and 27) was the
within-groups variable. The ANOVA was followed by Duncan's
multiple range test to assess the overall differences in basal AVP secretion
between hypothalamic cultures prepared at different gestational ages. An
identically structured analysis was employed to compare potassium-
stimulated AVP release at the different gestational ages.
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In order to investigate the facilitatory effects of potassium
stimulation on basal AVP secretion in the hypothalamic cultures,
ANOVA was carried out to determine if there was an overall difference
in basal AVP secretion between group 1 and group 2 cells at each
gestational age. Cell group (1 or 2) was the between-groups variable and
day in vitro (day 17, 21, 24 and 27) was the within-groups variable.
Duncan's test was used to examine specific differences in basal AVP
release between group 1 and 2 cells. Similar approaches were then used to
investigate stimulated AVP release at each gestational age.
5.2.2. Time and Calcium dependency of AVP and CRH Release.
Time Dependency. In order to assess whether secretion of AVP or CRH
was time-dependent, all wells were assigned to one of four groups at
random on day 30 in vitro. These groups were incubated with basal
release medium for either 30, 60, 120 or 240 minutes. Subsequently, wells
were re-randomised, allocated to one of four new treatment groups, and
incubated with 56 mM potassium-containing medium for a further 30, 60,
120 or 240 minutes. Media were collected and stored at -20°C until AVP
and CRH were measured by RIA and IRMA respectively.
To examine the effects of increasing the duration of the
experimental incubations, basal and stimulated AVP release data from
the different time groups by were compared by ANOVA, with time (30,
60, 120 and 240 minutes) and incubation (basal or stimulated) as the
between-groups variables, followed by Duncan's test to examine the
differences between the group means.
Calcium Dependency. On day 33 in vitro, the calcium dependency of
peptide release was examined. Dishes were incubated with basal release
medium for 3 hours and then assigned to one of two groups at random.
Group A was washed 3 times with 1 ml basal medium, then 700pl 56 mM
potassium-containing medium was added to each dish for a further 3
hours. Group B was treated in the same way, except that washing and 56
mM potassium-containing media were calcium-free. Again, media were
stored at -20°C for subsequent measurement of AVP and CRH by RIA and
IRMA respectively.
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An individual ANOVA, followed by Duncan's test, was then
carried out at each gestational age to compare basal with potasssium-
stimulated AVP release in group A and Group B cells.
5.2.3. AVP and CRH Content of Cell Cultures.
To assess whether cultures from different gestational ages contained
similar quantities of AVP or CRH, cultured cells were resuspended by
trypsinisation (section 5.2.4) on day 36 in vitro, and aliquots of the
suspension were stored at -20°C for subsequent measurement of AVP and
CRH content by RIA and IRMA respectively.
To determine the effects of gestational age on AVP content of the
cultured cells, ANOVA was used with gestational age (day 70, 100 and 130)
as the between-groups variable. Duncan's test was employed post-
ANOVA to examine specific differences in content between the age
groups.
5.2.4. Cell Numbers after 36 days in vitro.
The possibility existed that gestational differences in peptide secretion
might reflect better survival of cells from a particular developmental age.
To investigate cell survival after 36 days in vitro, cultures were
trypsinised and the cells were counted by the following method.
All dishes were washed twice (2 x 1 ml Dulbecco's Phosphate-
Buffered Saline without calcium and magnesium - DPBS; (ICN Flow
Ltd.) and 500|il of the same medium, containing 0.02% EDTA (ICN Flow
Ltd.) and 0.5 mg/ml trypsin (Sigma), were added to each well. 300pl
excess medium was aspirated, and the dishes were incubated for 10
minutes at 37°C. 800pl DPBS, containing 150 pg/ml soybean trypsin
inhibitor (Sigma) and supplemented with the same quantities of ascorbic
acid, bacitracin, BSA and aprotinin as basal release medium (Section
3.4.1), were added to each well. The cells were triturated and 100pl of
suspension was removed from each well for cell counting with a
haemocytometer. The rest was used to determine the AVP and CRH
contents of cultured cells (Section 5.2.3) and for immunocytochemistry
(sections 5.2.5 - 5.2.7).
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To examine differences between cell numbers at different
gestational ages, ANOVA was carried out with gestational age as the
between-group variable. Duncan's test was used to examine differences
between individual means.
5.2.5. Immunocytochemistry; Antibody Characterisation.
Matutration of the fetal hypothalamus in vitro may be associated with an
increasing number of the peptidergic neurones which synthesise CRH
and AVP. To investigate the gestational differences in the numbers of
hypothalamic neurones in vitro, and in the numbers of cells
synthesising CRH or AVP, it was proposed to carry out
immunocytochemical procedures to specifically stain cultured cells
containing either Neurone-specific enolase (NSE), CRH or AVP.
Antisera. All antisera were raised in rabbits, either in the laboratory
(oCRH antiserum; CRF-2G; see Brooks et al. 1989, AVP antiserum;
AVP#26, gift of Miss Barbara Graham, MRC Reproductive Biology Unit)
or by a commercial supplier (NSE; Cambridge Research Biochemicals).
Immunostaining of NSE in fixed specimens was abolished when anti-
NSE (Batch 01841) was preincubated with 10 nmol/ml NSE protein
(Cambridge Research Biochemicals Data Sheet). The specificity of this
antibody was therefore not investigated further, however, CRF-2G nor
AVP#26 had previously been validated in immunocytochemical (ICC)
procedures.
To show that immunostaining is due to the presence of a specific
antigen, and not to non-specific interaction of the antibody with tissue
proteins, it is neccessary to demonstrate that removal of antigen-specific
antibodies abolishes the immunostaining. Therefore, specific antipeptide
antibodies were removed by incubating CRF-2G and AVP#26 with
magnetic particles coupled either to oCRH or AVP respectively, or with
magnetic particles alone as a control. The supernatants were then used to
carry out ICC procedures. The preparation of the magnetic particles and
the preabsorbed antibodies were carried out as detailed below.
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Preparation of Conjugates. 2 ml magnetic particles (bearing hexane-NH2
groups; gift of Dr. Rodney Kelly, MRC Reproductive Biology Unit) were
were washed in 50 ml 0.5M NaCl and then magnetically precipitated on
an Amerlex-M separator (Amersham). The supernatant was decanted
and the process was repeated 3 times. Finally the particles were washed in
50 ml deionised water (dFUO), pH 4.5, at 4°C, precipitated, and
resuspended in 8 ml of the same medium. 200 |ig AVP or CRH was
added in 200|il dH20, alternatively, control conjugate was prepared by
adding 200|il water alone at this stage. N-ethyl-N'-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC; Sigma) was
added dropwise (2 ml, 75 mg/ml in dH20, pH 4.5, at 4°C) and the mixture
was placed on a rotary mixer at 4°C for 18 hours.
The next day, the suspension was washed and pecipitated
alternately in 50 ml acetate buffer (18% 0.1M Sodium Acetate, 82% ml
0.1M Acetic Acid, in 0.5M NaCl, pH 4) and 50ml bicarbonate buffer (0.1 M
NaHC03 in 0.5M NaCl, pH 8.3) four times each. The conjugate was
finally washed in dH20 and resuspended in 5 ml 0.9% saline (containing
lOmM phosphate buffer and 1% NaN3) and stored at 4°C.
Preabsorbtion of Antisera. Control, AVP and CRH-conjugated magnetic
particles were precipitated and resuspended in 1 ml of lOmM phosphate-
buffered saline (PBS). To preabsorb the CRF-2G antiserum, CRF-2G (1:250)
in 1 ml preabsorption buffer (40% Normal Swine Serum (NSS) and 4%
BSA in PBS), was added to the CRH-conjugated magnetic particles.
AVP#26 at 1:125 in 1 ml preabsorption buffer was added to the AVP-
conjugate. Control preabsorptions were carried out in parallel by adding
either CRF-2G or AVP#26 in preabsorption buffer to 1 ml of the control
conjugate. The mixtures were then turned end over end for 18 hours at
4°C. The next day, the mixture was magnetically separated. The
supernatants were divided into aliquots of lOOpl and stored at -20°C.
Binding Characteristics of Antisera. Serial dilutions of the peptide or
control-preabsorbed antisera were prepared in triplicate in either AVP or
CRH RIA buffers. 100|il of diluted antiserum was added to 300|il assay
buffer and lOOpl 125I CRH or AVP trace (Bo tubes). NSB and TC tubes,
containing respectively 400(il buffer plus 100pl trace or lOOpl trace alone
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were prepared in parallel. All tubes were incubated overnight at 4°C. The
next day, antisera were precipitated by conventional magnetic separation
(Section 3.5.1.) and the precipitates were counted. The trace binding for
each tube was calculated as (Bo-NSB)/TC.
Figure 5.1 overleaf shows the AVP tracer binding to AVP#26
antibody previously incubated with AVP- or control conjugate, and CRH
trace binding to CRF-2G preabsorbed with CRH- or control magnetic
particles. The results of this validation clearly show that substantial trace
binding activity was present in antisera incubated with control
conjugates, whereas no trace binding was observed in peptide-preabsorbed
antisera. Therefore, the peptide-specific antibodies were absent from the
peptide-preabsorbed antisera, but present in the control antisera.
5.2.6. Validation of Immunocytochemical Procedures.
Fixation Procedure. Cells were resuspended by trypsinisation on day 36
in vitro (section 5.2.4). 4 x 5|il aliquots of suspension from each well
were placed on glass microscope slides (C.A. Hendley, Essex). These
smears were dried and were fixed by immersion for 10 minutes in
Bouin's fluid. Slides were then washed once in water and 3 times in 70%
ethanol. Finally, slides were dried and stored at -20°C.
Immunocytochemical Validation. To investigate the specificity of the
antisera in immunocytochemical procedures, and to determine the
optimum antibody dilution for strong specific staining, ICC was carried
out in fetal sheep hypothalamic cells with peptide- and control-
preabsobed CRF-2G and AVP#26 at different dilutions, according to the
method described below. A similar validation was carried out for the
NSE antibody, using non-immune rabbit serum as a parallel control.
Slides containing cell smears were incubated in a bath containing
0.1% Triton X-100 in PBS for 2 minutes. They were then rinsed and
incubated in PBS alone for 10 minutes. Subsequently, a little blocking
buffer (PBS containing 20% NSS and 2% BSA) was applied to each cell
smear, and the slides were left to incubate in a humidified chamber at
room temperature for 1 hour. The excess blocking buffer was removed,
and primary antiserum diluted in blocking solution was added to the cell
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Figure 5.1. Binding Characteristics of
Preabsorbed Antisera. A. Various dilutions of
CRF-2G, previously incubated with magnetic particles
coupled to CRH or magnetic particles alone were
incubated with CRH tracer and the trace binding was
determined. B. Serial dilutions of AVP#26
preabsorbed with control- or AVP-conjugated
magnetic particles were incubated with AVP tracer to
determine the residual AVP-binding capacity of the
preabsorbed antiserum. Neither antibody which had
been preabsorbed with the appropriate peptide-
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smears. Parallel controls were included which received blocking soluiton
alone, or blocking solution containing non-immune rabbit serum. These
slides were then incubated in the humidified chamber at 4°C for 21 hours.
Next day, the slides were washed in PBS for 10 minutes and the
second antibody, Biotinylated Swine Anti-Rabbit (SARB; DAKO, High
Wycombe, Bucks), was applied to the smears at a dilution of 1:500 in
blocking buffer. After 1 hour, unbound antibody was washed off in the
same way as for the primary antiserum. Slides were then incubated for 30
minutes with Avidin-Biotin Complex (DAKO) inTris HC1 buffer, pH 7.6.
After a further 10 minute wash in PBS, chromagen solution
(diaminobenzidine tetrahydrochloride; Sigma, 0.5 mg/ml in 0.05M Tris
HC1 buffer, pH 7.6, containing 0.02% H2O2) was added for 5 minutes. The
reaction was than terminated with copious washing in tap water. Slides
were than counterstained with Haematoxylin, dehydrated in ascending
alcohols and mounted in Histomount (National Diagnostics, New Jersey,
USA). The slides were then photographed, and the results from these
studies are shown in Figure 5.2.
The results show that intense staining was observed with NSE
antibody at a dilution of 1:500, whereas non-immune rabbit serum did
not cause staining at this dilution, suggesting that the NSE staining was
specific. Optimal specific staining with low background was observed
with anti-NSE concentration of 1:1000, and so this concentration was used
in further studies. In contrast, the staining with either CRF-2G or
AVP#26 seemed to be weak and was not different between control- or
peptide preabsorbed antisera. These observations suggested that the
staining was not specific, and so it was decided not to utilise these
antibodies further in immunostaining procedures.
5.2.7. Quantitative NSE Immunocytochemistry.
To determine if the numbers of neurones in culture, as defined by NSE
immunocytochemistry, varied with gestational age, cells from 6
randomly chosen dishes at each gestational age were processed in
quadruplicate for NSE ICC. Approximately 1000 stained and unstained
cells were counted in total over several fields in the replicates from each
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Figure 5.2. Immunocytochemical staining
with anti-NSE, CRF-2G and AVP#26.
Immunostaining was assessed with anti-NSE at
various dilutions. Anti-NSE showed strong staining
at 1:500, whereas non-immune rabbit serum (NRS)
showed no staining at this concentration. Control
slides which had received no primary antibody, or no
primary anitbody and no secondary antibody did not
stain. Optimal NSE immunostaining was observed
at a dilution of 1:1000. CRF-2G ICC was carried out
at several dilutions using control- and CRH-
preabsorbed antibody. No difference in
immunostaining was observed between control or
CRH-preabsorbed antibody. AVP#26 ICC was carried
out in the same fashion as for CRF-2G. Again, no
difference in immunostaining was observed between
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well and the number of stained cells as a percentage of the total was
estimated. ANOVA followed by Duncan's test was used to compare the
percentages of stained cells at each gestational age.
ft
5.3 Results
5.3.1. AVP and CRH release from the developing hypothalamus in vitro.
Figures 5.3 to 5.5 show the basal and 56 mM potassium-stimulated release
of AVP and CRH from cultured hypothalamic cells plated at days 70,100
and 130 of gestation. Figures 5.3 and 5.4 show that potassium-induced
depolarisation significantly (p < 0.01) enhanced AVP release from day 70
and day 100 hypothalamic cultures on each experimental occasion.
However, Figure 5.5 shows that AVP release in day 130 cells was
enhanced by 56 mM potassium only on day 7 (p < 0.01) and day 21 (p <
0.05)in vitro .
Figure 5.3 shows that CRH release in day 70 cultures was
significantly stimulated by 56 mM potassium (p < 0.01) at days 7 and 21 in
vitro . Overall analysis revealed that CRH release by day 100 cells was not
significantly enhanced in response to this treatment (ANOVA; p = 0.7), as
shown in Figure 5.4. Analysis of variance indicated that there was a
significant effect of 56 mM potassium on CRH release from day 130
#
cultures (ANOVA; p< 0.001). Surprisingly, further analysis revealed that
there was a significant inhibitory effect of elevated potassium on day 17 (p
< 0.01) and day 27 (p < 0.01) in vitro, as shown in Figure 5.5.
Figures 5.3 to 5.5 demonstrate that advancing gestational age had a
significant effect on AVP and CRH secretion. Overall analysis showed
that basal and potassium-stimulated AVP secretion from day 70 cells was
significantly greater than basal and stimulated release from day 100 cells
(p < 0.01) , which in turn were greater than basal and potassium-induced
release from day 130 cells (p < 0.01). A similar analysis showed that there
was no difference in basal CRH release from day 70, day 100 and day 130
cells (ANOVA; p = 0.3). However, potassium-stimulated CRH release
from day 70 cells was greater than from day 100 cultures (p < 0.05), which
in turn exceeded that from day 130 cells (p < 0.05).
I
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Figure 5.3. AVP and CRH secretion in fetal
sheep hypothalamic cultures from 70 days of
gestation. AVP and CRH secretion was measured
in Group 1 cultures between day 7 and day 27 (A and
C respectively) and in Group 2 cultures between day
17 and day 27 in vitro (B and D respectively). Data
shown are means of 10 or more wells, +/- S.E.M. ** p
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Figure 5.4. AVP and CRH secretion in fetal
sheep hypothalamic cultures from 100 days of
gestation. AVP and CRH secretion was measured
in Group 1 cultures between day 7 and day 27 (A and
C respectively) and in Group 2 cultures between day
17 and day 27 in vitro (B and D respectively). Data
shown are means of 19 wells, +/- S.E.M. ** p < 0.01;
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I
Figure 5.5. AVP and CRH secretion in fetal
sheep hypothalamic cultures from 130 days of
gestation. AVP and CRH secretion was measured
in Group 1 cultures between day 7 and day 27 (A and
C respectively) and in Group 2 cultures between day
17 and day 27 in vitro (B and D respectively). Data
shown are means of 16 or more wells, +/- S.E.M. * p
< 0.05, **p< 0.01; significant difference between basal
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The design of the present study allowed a comparison between day
17 and 27 in vitro of AVP and CRH secretion by cells which either had
(Group 1) or had not (Group 2) received previous experimental
treatments, as shown also in figures 5.3 to 5.5. Overall analysis revealed
that there were no significant differences in basal AVP secretion between
the group 1 and group 2 cells in day 70, day 100 or day 130 cultures, neither
was potassium-stimulated AVP secretion significantly different between
the two groups at any gestational age. Similarly, there were no differences
in basal or stimulated CRH secretion between the two groups at any
gestational age.
*
5.3.2. Time and Calcium dependency of AVP and CRH Release.
4
4
The time course of AVP and CRH release was studied on day 30 in vitro,
and on day 33, the calcium dependency of peptide scretion was assessed.
Figures 5.6, 5.7 and 5.8 show the time dependency and calcium
dependency of AVP and CRH release from cultures of day 70,100 and 130
hypothalamic cells respectively.
The quantity of AVP released from day 70 and day 100 cells was
dependent on the duration of the incubation. With each increase in
incubation length between 30 and 240 minutes in day 70 cultures, there
was a significant increase in both basal (p < 0.01) and potassium-
stimulated (p < 0.01) AVP release. In day 100 cells, basal and potassium-
stimulated release of AVP was significantly increased between 60 and 120
minutes (p < 0.01), and between 120 and 240 minutes (p < 0.01). By
contrast, there were no significant differences between the AVP contents
I
of samples collected from day 130 cells after 30, 60, 120 or 240 minutes
basal incubation. However, potassium stimulation for 240 minutes
caused a significant elevation of AVP levels when compared to
potassium stimulation for 30 minutes (p < 0.05).
Overall analysis showed that there was no significant effect of
incubation length oh basal or potassium-stimulated CRH output from
day 70, day 100 or day 130 hypothalamic cultures.
4
Figures 5.6-5.8 show that AVP secretion was calcium-dependent in
cells from day 70 and day 100 of gestation. 56 mM potassium-containing
f •
medium significantly stimulated AVP output in these cells (p < 0.01)
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Figure 5.6. Time and calcium dependency of
AVP and CRH secretion by hypothalamic
cultures from 70 days of gestation. A. Basal and
*
potassium-stimulated AVP and B CRH secretion
were measured in incubations of increasing duration,
to show time dependency of peptide release. Data
shown are means of 5-7 wells, +/- S.E.M. Data within
either basal or potassium-stimulated groups were
compared amongst their own groups. Data without
common superscripts are significantly different (p <
0.01). C. AVP and D CRH secretion were determined
under basal and potassium-stimulated conditions,
and the effects of omitting calcium from the elevated
potassium medium were examined. Data shown are
means of 13 wells, +/- S.E.M. Data without common
superscripts are significantly different (Upper case; p








Figure 5.7. Time and calcium dependency of
AVP and CRH secretion by hypothalamic
cultures from 100 days of' gestation. A. Basal
and potassium-stimulated AVP and B CRH secretion
were measured in incubations of increasing duration,
to show time dependency of peptide release. Data
shown are means of 9-10 wells, +/- S.E.M. Data
within either basal or potassium-stimulated groups
were compared amongst their own groups. Data
without common superscripts are significantly
different (p < 0.01). C. AVP and D CRH secretion
were determined under basal and potassium-
stimulated conditions, and the effects of omitting
calcium from the elevated potassium medium were
examined. Data shown are means of 18-19 wells, +/-
S.E.M. Data without common superscripts are
significantly different (Upper case; p < 0.01; lower
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%
Figure 5.8. Time and calcium dependency of
AVP and CRH secretion by hypothalamic
cultures from 130 days of gestation. A. Basal
and potassium-stimulated AVP and B CRH secretion
were measured in incubations of increasing duration,
to show time dependency of peptide release. Data
shown are means of 8 wells, +/- S.E.M. Data within
either basal or potassium-stimulated groups were
••
compared amongst their own groups. Data without
common superscripts are significantly different (p <
0.01). C. AVP and D CRH secretion were determined
O
under basal and potassium-stimulated conditions,
and the effects of omitting calcium from the elevated
potassium medium were examined. Data shown are
means of 14-15 wells, +/- S.E.M. Data without
common superscripts are significantly different
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whereas calcium-free 56 mM potassium-containing medium either had
no effect (day 70 cells) or was significantly inhibitory to AVP release (day
100 cells, p < 0.01) when compared to basal AVP secretion. Potassium-
stimulated AVP secretion from day 130 cells was not significantly
different from basal release, either in the presence or absence of calcium.
As depicted in figures 5.5-5.8, CRH release was not significantly
stimulated in the presence of elevated potassium at any gestational age.
However, in day 70 (p < 0.05) and day 100 (p < 0.01) cells, calcium-free 56
mM potassium-containing medium significantly inhibited CRH release .
«
5.3.3. Culture Contents of AVP and CRH.
At day 36 in vitro, the contents of CRH and AVP were measured in each
well. Figure 5.9 shows that advancing gestational age was associated with
significant reductions in the contents of AVP and CRH. AVP and CRH
levels in day 100 cells were significantly less (p < 0.01) than the
corresponding levels in day 70 cells. In day 130 cultures the AVP content
had fallen significantly compared to day 100 cells (p < 0.01), however,
there was no signficant difference between the CRH contents at these
gestational ages.
9
5.3.4. Cell Counting and Immunocytochemistry.
On day 36in vitro,, resuspended cells were counted with a haemo-
cytometer. Figure 5.10 shows that there was no significant difference in
the number of cells between day 70 and day 100 cultures. However, a
significant increase was observed between day 100 and day 130 cells (p <
0.01). Figure 5.10 also shows that there was a significant decline in the
proportion of alls which were immunopositive for NSE with advancing
gestational age. This technique demonstrated that whilst 65 +/- 0.5 %
(mean +/- S.E.M.) of cells were labelled by this antibody in day 70 cultures,
this proportion fell significantly (p < 0.01) to 51 +/- 1.4% in day 100 cells
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Figure 5.9. AVP and CRH content of
hypothalamic cultures after 36 days in vitro .
Cultures were extracted on day 36 and A the AVP and
B the CRH contents of the cell cultures were
determined. Data shown are means of 20-28 wells,
+/- S.E.M. Data without common superscripts are
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Figure 5.10. Total cell numbers present in
cultures on day 36 in vitro and the
proportion immunopositive for NSE. A. The
number of cells per dish was determined in cultures
at each gestational age. Data shown are means of 20-
28 wells, +/- S.E.M. B. The propotion of cells which
were immunopositive for NSE was assessed in
representative wells in day 70, 100 and day 130
cultures. Data shown are means of 6 wells, +/- S.E.M.
Data without common superscripts are significantly
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5.4 Discussion
The objective of this study was to examine the secretion of AVP and CRH
from cultured fetal sheep hypothalamic cells removed at day 70, day 100
C
and day 130 of gestation. AVP release from day 70 and day 100 cells was
consistently stimulated by potassium-induced depolarisation, and these
A
effects were shown to be time and calcium-dependent. In contrast,
potassium rarely increased AVP secretion by day 130 cells, and AVP
release from these cells was not convincingly shown to be time or
calcium dependent. CRH release from day 70 cultures was sporadically
enhanced by potassium stimulation, whereas no significant effect of
w
potassium was seen in day 100 cells, although potassium treatment was
inhibitory to CRH release from day 130 cultures on some occasions.
However, none of the effects of potassium on CRH release were shown to
be calcium and time dependent at any gestational age. An important
finding made here was that in general, the secretion of AVP and CRH
declined with advancing gestational age. Although this could be
A
explained by a maturation-dependent reduction in the adaptability of the
cells to the culture conditions, the large numbers of cells present in vitro
after 36 days culture, and the considerable percentage of neurones found
at this time in all cultures, suggested that reduction in peptide release was
due to factors other than poor viability.
Considerable evidence has accumulated to suggest that
hypothalamic drive to ACTH release is increased in fetal animals in late
gestation. In the rat, fetal plasma ACTH levels are diminished by
administration of CRH antibody to the fetus at day 19 of gestation (Term =
day 22), but not in fetuses at day 17 (Boudouresque et al. 1988). ACTH-
releasing bioactivities of fetal sheep hypothalamic extracts are much
increased with advancing gestational age (Brieu et al. 1989), and the
massive elevation in plasma ACTH levels which occurs in the last few
days of gestation is abolished in fetuses in which the pituitary is
disconnected from the hypothalamus (Antolovich et al. 1991). In
contrast to these observations, the present study showed that overall,
AVP and CRH secretion from day 100 cells was reduced when compared
to day 70 cultures, and was further diminished in day 130 cells. In view of
A
the observations made by previous authors, these data suggest that AVP
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and CRH secretion from the cell cultures may not reflect the
developmental pattern of hypothalamic secretion in vivo.
It was not possible to make a direct comparison of the results from
the present study with data obtained in the intact animal, as there have
been no studies to examine hypothalamic secretion of AVP and CRH into
the portal blood of the sheep fetus. Nevertheless, Brooks and colleagues
(1989) described CRH release from fetal sheep hypothalamic pieces
maintained over the short term in vitro. These authors showed that
CRH release from tissues removed at day 140 was significantly greater
than CRH secretion from hypothalami collected at day 100 of gestation.
These results suggested that that advancing gestation was associated with
an increase in hypothalamic release of ACTH-releasing factors, in contrast
to the present study, which showed that CRH and AVP release from day
130 cells was reduced when compared to output at day 100.
It was possible to explain the reduction in AVP and CRH output
from the hypothalamic cultures in terms of the amounts of peptides
contained by the cultured cells. The present study showed that the AVP
and CRH contents of the cell cultures were decreased with advancing
gestational age, in parallel with the reduction in secretion of these
peptides. By contrast, a recent study has demonstrated that the contents of
AVP and CRH in the intact fetal sheep hypothalamus were markedly
increased with advancing gestational age (Brieu et al. 1989). Therefore,
these results suggest that there may be factors present in vivo but not in
vitro, which act to enhance the synthesis and storage of AVP and CRH
with advancing gestational age. The present studies were not directed to
reveal which endogenous substances might act to enhance peptide
secretion from hypothalamic cells. However, cultured cells were
removed from the normal presynaptic input which acts on hypothalamic
neurones in vivo. Therefore, synthesis and storage of large quantities of
AVP and CRH, as observed in intact hypothalami, may well be dependent
on trophic stimulation from these presynaptic cells.
The possibility exists that decreasing output of AVP and CRH with
advancing gestational age was due to a progressive reduction in culture
viability. In order to test the hypothesis that gestational differences in
peptide output arose through variations in culture viability, the total
number of cells present in the culture dishes and the proportions of NSE-
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immunopositive cells were quantified after 36 days in vitro. The results
showed that regardless of gestational age, the number of cells remaining
in culture on day 36 was remarkably similar to the number originally
ft
plated in each dish (2.5 x 106 cells). On the other hand, a smaller
proportion of cells were NSE-immunopositive in cultures prepared from
hypothalami collected later in gestation. These data suggested that the
gestational reduction in peptide output was attributable to the presence of
reduced numbers of neurones in vitro, although it was notable that the
small decline in the percentage of NSE-positive cells did not parallel the
dramatic reduction in peptide output. However, the possibility remains
*
that the numbers of CRH and AVP cells were selectively attenuated in .
cultures prepared later in gestation.
ft
Quantifying the numbers of AVP and CRH cells in vitro was one
of the objectives of the present investigation, to which end immuno-
cytochemical techniques were developed to detect AVP- and CRH-
containing cells. Unfortunately, the final validation procedures for these
techniques showed that the immunostaining was not specific to CRH or
AVP cells, as the staining persisted when specific AVP and CRH
antibodies were removed. It was therefore not possible to carry out the
quantification of cultured AVP and CRH cells as planned. However,
future studies, utilising techniques similar to those described here, could
develop affinity-purified antibodies for use in immunostaining
procedures. These antisera would be less likely to show the non-specific
staining observed in the present studies.
Recent investigations have shown that potassium-induced
depolarisation stimulates AVP and CRH secretion from fetal rat
hypothalamic cells in vitro (Clarke, 1988). These studies showed that the
e
response to potassium was augmented as the culture aged, and that aside
from its direct stimulatory action on AVP and CRH release, potassium
treatment acted in a trophic manner to effect an overall enhancement of
AVP and CRH release. The present study was designed to investigate
basal and potassium-stimulated release of AVP and CRH from fetal sheep '
hypothalamic cells over several weeks in vitro. In contrast to the results
obtained in fetal rat hypothalamic cultures, there was no progressive
increase in AVP or CRH secretion observed over these weeks in vitro at
any gestational age. Rather, peptide secretion tended to be greatest on the
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first experimental day, and then to plateau thereafter. To determine
whether potassium stimulation could act in the trophic manner described
in fetal rat hypothalamic cultures, the present studies also compared AVP
and CRH secretion between cultured cells previously left untreated or
potassium-stimulated 3 times. A rigourous statistical evaluation showed
that there were no significant differences in basal or potassium-induced
release of AVP or CRH between the 2 groups at any gestational age, which
again contrasts with the enhancing effects of potassium reported in rat
cells (Clarke, 1988).
Taken together, the data described above suggest that the responses
of cultured fetal sheep and rat hypothalamic cells to repeated potassium
stimulations are dissimilar in some respects. This may relate to
differential effects of potassium stimulation on AVP and CRH gene
transcription in the two species. Recently, it has become evident that
potassium-induced depolarisation elevates intracellular calcium levels,
resulting in phosphorylation of cAMP response element-binding protein
(CREB; Sheng, McFadden & Greenberg, 1990). CREB may then activate
the transcription of c-fos , one of a class of immediate early response genes
which are thought to play a major role in the regulation of gene
transcription in neuronal cells (Sheng & Greenberg, 1990). In addition,
CREB may act directly to regulate neuropeptide gene transcription, as
CREB binding sites have been located on the regulatory regions of the
genes coding for somatostatin (Montminy & Bilezkijian, 1987) and
preproenkephalin (Comb, Birnberg, Seasholtz, Herbert & Goodman,
1986). Therefore, the trophic effect of potassium stimulation observed in
fetal rat hypothalamic cultures may be due to increases in AVP and CRH
gene transcription. By contrast, the absence of this effect in the present
studies suggests that potassium stimulation may not act in the same way
in sheep cells. Future studies could investigate the regulation of
transcription factors, including c-/os and CREB, in the fetal sheep
hypothalamus. In this way, it may be possible to understand the
mechanisms underlying the massive increases in hypothalamic AVP and
CRH content observed in the fetal sheep hypothalamus before parturition
(Brieu et al. 1989).
In conclusion, the studies described in this chapter investigated the
secretion of AVP and CRH from fetal sheep hypothalamic cells cultured
4
4
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at different gestational ages. The principal findings were that in cultures
prepared at day 70 and day 100 of gestation, the secretion of AVP was
stimulated by potassium-induced depolarisation in a time- and calcium-
dependent fashion. By contrast, neither AVP release from day 130 cells
nor CRH release from any of the cultures showed consistent responses to
potassium stimulation. Overall, the results showed that secretion of AVP
and CRH from fetal hypothalamic cells was reduced with advancing
gestational age. In view of the apparent viability of the cultures in terms
of the numbers of cells remaining after 36 days in vitro and the
considerable percentage of neurones present, the data suggested that
hypothalamic cells may be dependent on extrahypothalamic input to
maintain the high levels of peptide content observed in vivo.
6. Corticotrophin-Releasing Factors in the
hypothalamus of the developing fetal sheep.
In the previous chapter, the fetal sheep hypothalamic culture system
optimised in chapter 4 was used to investigate the development of AVP
and CRH secretion by the fetal sheep hypothalamus in vitro. The results
of these studies clearly suggested that in vitro hypothalamic secretion of
the ACTH-releasing factors AVP and CRH is much diminished with
advancing gestational age in the sheep fetus. These data contrast with
evidence obtained by other workers, which supports the hypothesis that
hypothalamic drive to fetal pituitary ACTH secretion is increased with
advancing gestational age. However, few reports have directly
investigated ACTH-releasing factors in the fetal sheep hypothalamus, and
none have examined the various molecular species which may be
biologically active in this regard. Therefore, the current understanding of
ACTH-releasing factors in the fetal sheep hypothalamus is not sufficient
to relate the results of the previous chapter to hypothalamic function in
vivo. Using a number of different approaches, such as
radioimmunoassay, gel chromatography and pituitary cell bioassay, this
chapter sought to catalogue more fully the ontogeny of ACTH-releasing
factors in the fetal sheep hypothalamus.
6.1 Introduction
Prior to the advent of hypothalamic tissue culture, direct methods to
study the developing hypothalamic drive to corticotropes in the fetus
were not available, and so a number of authors assessed hypothalamic
contents of ACTH-releasing factors as an index of the functional maturity
of fetal hypophysiotropic neurones. In the fetal sheep, immunoreactive
CRH and AVP have been detected by RIA in hypothalamic extracts as
early as day 63-88 of gestation (Brieu et al. 1989). The hypothalamic
concentration of CRH and AVP increased progressively from day 63-88 to
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ACTH-releasing bioactivity of the hypothalamic extracts. However, the
AVP and CRH content fell by 80% and 50% respectively between day 138
and day 143, whereas ACTH-releasing activity fell only slightly during
this time frame. To account for the discrepancy between reductions in
hypothalamic CRH and AVP and bioactivity, these data suggest the
presence of hypothalamic factors, other than CRH and AVP, which
possess substantial ACTH-releasing activity in the late gestation
hypothalamus. Alternatively, the hypothalamic contents of ACTH-
0
releasing factors as measured by RIA may not accurately reflect bioactive
CRH and AVP, as RIA does not differentiate between biologically inactive
precursors or mature peptides bearing the same antigenic determinants.
Recently, data have been obtained in the fetal human
hypothalamus to suggest that CRH immunoreactivity is accounted for by
two forms of CRH. In addition to a small bioactive CRH which co-elutes
with CRH(1~41) on Sephadex chromatography, there is present a large
CRH of molecular weight 8-10kD which shows no ACTH-releasing
activity (Ackland et al. 1986). Between 12-16 weeks of gestation, the high
molecular weight species accounts for approximately 50% of CRH
immunoreactivity. This proportion is reduced in more mature fetuses
and is absent in fetal hypothalami removed after week 20 of gestation.
Therefore, hypothalamic maturation in the fetal sheep may also be
associated with substantial remodelling of CRH and AVP peptides.
However, at the present time, no studies have been carried out to
examine the developing immunoreactivity and bioactivity of individual
hypothalamic releasing factors in the fetal sheep.
The aim of this chapter was therefore to examine the ontogeny of
ACTH-releasing factors in the fetal sheep hypothalamus. AVP and CRH
were extracted from hypothalamic tissues removed at day 70,100 and 130
4
of gestation, and the hypothalamic contents of these peptides were
determined by specific AVP RIA and CRH IRMA. In order to investigate
the ontogeny of molecular weight species of AVP and CRH, the
hypothalamic extracts were subjected to Sephadex chromatography.
Fractions were collected and lyophilised, and the AVP and CRH
immunoreactivity were determined in these fractions. In addition, the
ontogeny of bioactive ACTH-releasing factors was examined by
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reconstituting aliquots of these fractions in culture medium, and adding
these to an adult sheep'pituitarycell bioassay.
6.2 Experimental Procedures
I
Fetal sheep hypothalami were dissected as previously described for
hypothalamic cultures. They were snap frozen on dry ice and stored at
-70°C. A total of 16 hypothalami were collected from fetuses at day 70 (5),
day 100 (6) and day 130 (5) of gestation to carry out the work described
here.
6.2.1. Immunoreactive AVP and CRH in the Fetal Sheep Hypothalamus.
»
Extraction. Hypothalamic extracts were prepared according to published
methods (Brooks et al. 1989). Tissue was weighed and added to 1 ml
boiling acid mixture (0.1 M HC1,1 M Acetic acid, 50:50). The hypothalami
were boiled for 5 minutes, cooled on ice, and then homogenised in a glass
. 'homogeniser (Uniform Homogeniser; Jencons Scientific, Leighton
Buzzard, Bedfordshire). The homogeniser was washed out with 1 ml acid
mix, which was added to the tissue homogenate. The homogenate was
then vortexed, and 50pl of the suspension was removed for
measurement of protein content. The tissue extracts were centrifuged for
30 minutes at 10,000g (Beckman J2-21 Centrifuge; Beckman Instrument
Inc., Palo Alto, California), and the supernatant was divided into a
number of aliquots which were freeze-dried and stored at -70°C.
Protein Assay. Protein concentrations in the tissue homogenates were
M
determined using a commercial kit (Biorad, California, US.A.). Tissue
proteins were dissolved by adding 950pl 0.1M NaOH to 50pl of tissue
homogenate and then by boiling for 30 minutes. A protein standard
curve was prepared in distilled water using BSA (Sigma) at
concentrations from 25pg/ml to 1.56pg/ml in doubling dilutions. 200pl
chromagen was then added to 800pl sample or standard in duplicate, the
tubes were vortexed and incubated for 30 minutes at room temperature,
and the absorbance of the solutions was measured at 595 nm (Uvikon 880
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Spectrophotometer, Zurich, Switzerland). Finally, the protein
concentrations in the samples were calculated with reference to the
absorbance readings for the standard curve.
Hypothalamic Peptide Content. Aliquots of tissue extracts were
reconstituted in 1ml of the appropriate assay buffers for CRH IRMA and
AVP RIA. To ensure that peptide concentrations were measured on the
most sensitive parts of the assay curves, a range of dilutions were assayed
for each peptide. Content was expressed as ng peptide/hypothalamus, ng
peptide/g tissue and ng peptide/mg protein. CRH content of the
hypothalamic extracts was also determined by RIA and the results from
the two CRH assays were compared.
To assess whether immunoreactive AVP and CRH present in the
fetal hypothalamus diluted in parallel with standard peptides in assay
procedures, the CRH and AVP concentrations present in the diluted




Data Analysis. AVP or CRH levels in hypothalami of different
gestational ages were compared by ANOVA followed by Duncan's
multiple range test. To determine whether the CRH IRMA and the CRH
RIA measured similar quantities of hypothalamic CRH, CRH
concentrations obtained by IRMA and RIA were compared by ANOVA
9
and Duncan's test.
6.2.2. Gel Chromatography of Fetal Corticotrophin-Releasing Factors.
Tissue extracts were subject to Sephadex G50 chromatography in duplicate
at each gestational age. AVP and CRH immunoreactivity and ACTH-
releasing bioactivity in the resultant fractions were assayed by RIA and in
a pituitary cell bioassay respectively.
Sephadex Chromatography. Tissue extracts from 2 or 3 hypothalami at
each gestational age were reconstituted in a total volume of 1ml 0.1M
HC1. The solution was centrifuged for 2 minutes at 10,000g and the
9
supernatant was added to the Sephadex column. The column was
V
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perfused with 0.1M HC1 at 3.5 ml/hour and fractions were collected in
polystyrene tubes every 20 minutes as previously described. Fractions
were divided into aliquots of 200pl and 1ml for immunoreactivity and
bioactivity measurements respectively, freeze-dried and then stored at
-20°C.
Assay Procedures. The AVP and CRH contents of fractions were
determined at several dilutions by R1A. Results were expressed as ng
peptide/fraction. ACTH-releasing activity was determined using an adult
sheep pituitary cell bioassay (Section 6.2.3).
To measure ACTH-releasing activity in the chromatography
samples, lyophilised fractions were reconstituted in 250|il incubation
medium and added to culture wells for 3 hours. Subsequently, ACTH
output from the wells was measured by RIA (Section 6.2.4). Results were
expressed as ng ACTH/dish. To eliminate interassay variation, all
samples were assayed in one culture at the same time and all ACTH
measurements were made in a single RIA. To show that the bioassay
could respond to synthetic ACTH-releasing factors, dose-response curves
of AVP and oCRH(l-41) were included in triplicate at ranges of 10"11 to 10"
*
7 M, with parallel control wells receiving medium alone. ANOVA, with
peptide (AVP or CRH) and dose (10-11 to 10"7 M) as the between groups-
variables, followed by Duncan's test, was used to determine the
minimum effective dose of AVP or CRH which stimulated ACTH
release, and which of AVP or CRH was overall more potent in this
regard.
6.2.3. Pituitary Cell Bioassay.
1
The ACTH-releasing activity in chromatographic fractions was
determined using a sheep pituitary cell bioassay, prepared as described in
the literature (Tsonis, McNeilly, Baird, 1986).
to
[Cu IturePreparation. Heads from adult ewes were obtained from a local
4
abbatoir within 1-2 hours of slaughter. Anterior pituitaries were washed
in sterile Dulbecco's Phosphate Buffered Saline (DPBS) containing 7.5
mM glucose. Pituitaries. were finely chopped and washed 6 times in
9
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DPBS (supplemented with 7.5 mM glucose, 0.1% BSA). The tissue pieces
were gently stirred in a spinner flask containing DPBS with 0.1% BSA and
0.5% Trypsin (Sigma) for 30 minutes at 37°C. The remaining pieces were
washed four times with culture medium (DMEM containing 10% lamb
serum, (ICN Flow Ltd.), 2.5% fetal calf serum, 2 mM glutamine, penicillin
and streptomycin; 50 I.U./ml and 50 pg/ml respectively). The pieces were
stirred in this medium for a further 30 minutes at 37°C then washed 4
times and stirred for 15 minutes in DPBS without calcium or magnesium
. (DPBS"; ICN Flow), containing 0.1% BSA and 2 mM EDTA. Tissue was
washed a further 4 times in DPBS" alone and the pieces were
mechanically dispersed using siliconised glass pipettes of decreasing
diameter (5mm to 2mm). The supernatant was aspirated and the cells
4
were precipitated by centrifugation at 200g for 10 minutes. Cells were
resuspended in culture medium and this procedure was repeated.
Finally, viability was estimated using trypan blue exclusion. The
suspension was diluted to 2 x 106 live cells/ml and lOOpl suspension was
added to each well (Nunc Multidish 24, Gibco), followed by 400 ill culture
medium. Cultures were maintained in an incubator as described
previously for neuronal cells.
Three days after plating, the culture medium was replaced with
medium containing cortisol-free sera, to enhance the response to ACTH-
m
releasing factors. Endogenous steroids were removed from sera by
incubating the mixture of lamb serum and fetal calf serum (80:20) with
Norit A charcoal (lOmg/ml; Sigma) for 60 minutes at 4°C. Subsequently,
the mixture was centrifuged at 3000g for 30 minutes and the supernatant
was aspirated and filter sterilised.
Bioassay Procedure. On day 8 in vitro, cells were washed twice with 500iil
DMEM supplemented with bacitracin (30iig/ml) and glutamine (2mM).
Chromatography fractions were reconstituted in 250iil supplemented
DMEM, and these were warmed and added to the cells for a further 3
%
hours. Afterwards, the culture supernatants were aspirated and stored at
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6.2.4. ACTH Radioimmunoassay.
ACTH was measured by conventional RIA with magnetic separation.
ACTH(l-39) peptide for standards and iodination was obtained from
Cambridge Research Biochemicals, and the rabbit anti-ACTH antiserum
9
were supplied by Dr. A. F. Parlow, National Hormone and Pituitary
Program, National Institues of Health, Bethesda, Maryland, USA.
IOOjjiI rabbit anti-ACTH antibody (AFP 6328031; 1:19,000) in assay
buffer (distilled water containing 8mM Na2HPC>4,12.5 mM EDTA, 30mM
NaN3, 0.1% Triton X-100 and 23pg/ml aprotinin (Sigma), pH 7.4) were
added to lOOpl samples in duplicate or standards in triplicate in 3 ml
polystyrene tubes. Standard curves containing TC, NSB and Bo tubes and
A
ranging between 5000pg/ml and 20pg/ml were prepared by serial
dilutions of a freshly thawed aliquot of ACTH. All tubes were vortexed
and incubated for 24 hours at 4°C.
lOOjil 125I-ACIH trace, iodinated by the chloramine-T method and
purified by Sephadex G50 chromatography, was added to all tubes the next
day. After a further 24 hours at 4°C, magnetic separation was carried out




6.3.1. Immunoreactive AVP and CRH in the Fetal Hypothalamus.
Immunoreactive AVP and CRH in fetal hypothalamic tissue diluted in
parallel to the standard curves at all gestational ages studied, as shown in
Figure 6.1. Figure 6.2 shows the hypothalamic contents of AVP and CRH,
expressed as ng peptide/hypothalamus, ng peptide/g tissue and ng
peptide/mg protein. These figures show that the hypothalamic contents
of AVP and CRH increased significantly between day 70 and day 100
(p <0.01), and between day 100 and day 130 (p <0.01) of gestation.
Similarly, hypothalamic concentrations of these peptides, expressed as
ng/g tissue, were significantly increased between day 70 and day 100
(p <0.05), and day 100 and day 130 (p <0.01). However, when peptides
were expressed as ng/mg protein, the rise from day 70 to day 100 was not
1
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Figure 6.1. Parallel dilution of hypothalamic
extracts in assay. Hypothalamic extracts were
diluted and A immunoreactive AVP and B CRH
were measured by RIA and IRMA respectively. Data
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Figure 6.2. AVP and CRH Content of the fetal
hypothalamus with advancing gestational
Peptide contents were expressed as A,
ng/hypothalamus, B, ng/g tissue and C, ng/mg
protein. Levels of AVP or CRH at different
gestational ages were compared separately, and
superscripts describe statistical differences within
either AVP or CRH data groups. Data points without
common superscripts are significantly different
(Upper case; p <0.01, lower case; p <0.05). Means of 5
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significant for either CRH or AVP, whereas the increase from day 100 to
day 130 remained highly significant in each case (p <0.01).
Measurement of CRH molecules other than CRH (1-41) after gel
filtration required the use of an RIA rather than the IRMA, which could
only detect intact CRH (1-41). To compare the RIA and the IRMA,
hypothalamic contents of CRH were measured in both assays and the
results were plotted against each other. Figure 6.3 shows the very close
agreement between the assays. An overall ANOVA revealed that there
was no effect of assay methodology on the results obtained for
hypothalamic levels of CRH (ANOVA; p = 0.2608).
I »
6.3.2. Gel Chromatography of Corticotrophin-Releasing Factors.
Figures 6.4 to 6.6 show that after gel chromatography, two
immunoreactive peaks were detected in hypothalamic extracts at each
gestational age. The first peak cross-reacted in the CRH RIA and eluted in
fractions 20-24 (Void Volume = fraction 14), whereas the second peak
eluted in fractions 33-38 and corresponded to immunoreactive AVP. At
each gestational age, these immunoreactive peaks co-eluted with
synthetic oCRH(l-41) and AVP respectively. As suggested by the
increasing hypothalamic contents of CRH and AVP, successively greater
quantities of these peptides were evident in the fractions with advancing
gestational age.
A pituitary cell bioassay was employed to determine the bioactivity
of fetal hypothalamic corticotrophin-releasing factors. The responses of
the bioassay in terms of ACTH release to standard doses of AVP or CRH
are shown in Figure 6.7. The minimum concentration at which AVP (p
<0.01) or CRH (p <0.05) caused a significant increase in ACTH release
when compared to control wells was Overall analysis of variance
followed by Duncan's test showed that AVP was significantly more
potent than CRH in stimulating ACTH release from the pituitary cells
(p <0.01).
At each gestational age, peaks of AVP and CRH immunoreactivity
after Sephadex chromatography were associated with elevated ACTH
output from the cells, as shown in Figures 6.4 to 6.6. Substantial
bioactivity was also present in the void volume and in fractions 29-30 at
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Figure 6.3. CRH Content of the Fetal
Hypothalamus; comparison of CRH RIA and
CRH 1RMA. CRH in hypothalamic extracts was
• »
measured by CRH RIA and CRH IRMA. The results
from the assays were compared, and an overall
ANOVA showed that the results were not
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Figure 6.4. Chromatography of
Corticotrophin-Releasing Factors in the Fetal
t
Hypothalamus at day 70 of Gestation. AVP and
CRH immunoreactivity were determined in fractions
after chromatography of (A) 3 pooled and (C) 2 pooled
hypothalami from 70 days of gestation. The elution
positions of synthetic AVP and CRH are shown by
the filled bars. Blue Dextran (M.Wt. =2 x 106) eluted
at Vo.
ACTH-releasing activity was then determined in
the fractions from pools A and C (B and D
respectively). In the bioassay, the emtpy bars
represent the bioactivity of the various fractions.
Black bars correspond to fractions containing CRH
immunoreactivity or AVP immunoreactivity.
Where bioactivity exceeded the maximum shown on
the graph, figures denote the peak levels detected.
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Figure 6.5. Chromatography of
Corticotrophin-Releasing Factors in the Fetal
Hypothalamus at day 100 of Gestation. AVP
and CRH immunoreactivity were determined in
fractions after chromatography of (A) 3 pooled and
(C) 3 pooled hypothalami from 100 days of gestation.
The elution positions of synthetic AVP and CRH are
shown by the filled bars. Blue Dextran (M.Wt. =2 x
106) eluted at Vo.
ACTH-releasing activity was then determined in
the fractions from pools A and C (B and D
respectively). In the bioassay, the emtpy bars
represent the bioactivity of the various fractions.
Black bars correspond to fractions containing CRH
immunoreactivity or AVP immunoreactivity.
Where bioactivity exceeded the maximum shown on
the graph, figures denote the peak levels detected.
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Figure 6.6. Chromatography of
Corticotrophin-Releasing Factors in the Fetal
Hypothalamus at day 130 of Gestation. AVP
and CRH immunoreactivity were determined in
fractions after chromatography of (A) 3 pooled and (C)
2 pooled hypothalami from 130 days of gestation. The
elution positions of synthetic AVP and CRH are
shown by the filled bars. Blue Dextran (M.Wt. =2 x
106) eluted at Vo.
ACTH-releasing activity was then determined in
the fractions from pools A and C (B and D
respectively). In the bioassay, the emtpy bars
represent the bioactivity of the various fractions.
Black bars correspond to fractions containing CRH
immunoreactivity or AVP immunoreactivity.
Where bioactivity exceeded the maximum shown on
%
the graph, figures denote the peak levels detected.
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Figure 6.7. Responses of Sheep Pituitary Cell
Bioassay to AVP or CRH. Standard AVP (A) or
CRH (B) were diluted in incubation medium
immediately before use. Data represent means from
triplicate wells, and are shown +/- S.E.M. Data
without common superscripts are significantly
different (p <0.01). Analysis of varicance showed that
overall, AVP was significantly more potent than
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each gestational age. Neither of these peaks was associated with
significant CRH or AVP immunoreactivity.
«<
6.4 Discussion.
The objective of the present study was to examine ACTH-releasing factors
in intact fetal sheep hypothalami removed at different gestational ages.
The major finding was that a progressive rise in the hypothalamic
contents of immunoreactive AVP and CRH occurred with fetal
maturation, and that this rise was especially striking between day 100 and
day 130 of gestation. Gel permeation chromatography revealed that fetal
hypothalamic CRH and AVP were present as single immunoreactive
species, co-eluting with either synthetic oCRH or AVP, at all gestational
ages studied. Bioactivity assessed in a pituitary cell culture system
revealed marked ACTH-releasing activity in the fractions corresponding
to immunoreactive CRH and AVP. In addition, significant bioactivity
was present in other fractions which were devoid of CRH or AVP
immunoreactivity.
The present work found a small increase in hypothalamic CRH
I
and AVP concentrations between day 70 and day 100 of gestation, and a
conspicuously large increase between day 100 and day 130. These data are
%
in broad agreement with previous studies (Brieu et al. 1989), although
the gestational increases in those studies were not as striking as those
observed here. For example, the present work showed increases of
approximately 6-fold and 20-fold respectively in the hypothalamic
concentrations of immunoreactive AVP and CRH between day 70 and
day 130 of gestation. The previous report suggested that hypothalamic
CRH and AVP concentrations increased by a factor of 2 during this stage
of development (Brieu et al. 1989). However, those authors collected
hypothalami from the earliest gestational age over an interval of 25 days
(day 63-88). The increases in hypothalamic peptide content between day
70 and day 100, as reported in the present study,' suggest that marked
changes in hypothalamic CRH and AVP may occur between day 63 and
day 88. Therefore, the striking increases in CRH and AVP as described
here may have been obscured in the previous investigation.
4
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It is unlikely that the findings reported here arose through
variation in tissue weight at different gestational ages. When corrected
for the changes in tissue weight, the gestational increases in AVP and
CRH concentration remained significant. Expressed as ng peptide/mg
protein, only the rise in AVP and CRH between day 100 and day 130 was
significant. These results indicate that early hypothalamic development
is associated with a concomitant increase in peptide and protein
expression, suggestive of hypothalamic growth. Whereas, the marked
rise in AVP and CRH between day 100 and day 130 of gestation may be
related to the increasing function of the hypothalamo-pituitary-adrenal
axis over this time (see Norman et al. 1985).
CRH concentrations, expressed either as ng/g tissue or ng/mg
protein, were consistently lower than AVP levels in the work reported
here, although the CRH/AVP ratio rose from 0.17 at day 70 of gestation to
0.6 at day 130. This was likely due to the especially noticeable increase in
hypothalamic CRH concentration between day 100 and day 130 of
gestation. It is not clear why there was such an increase in hypothalamic
CRH during this time. The present study utilised two independent assay
methods to determine CRH levels in the fetal hypothalamic extracts. The
IRMA, which detects only CRH molecules bearing both N and C-terminal
epitopes, and the RIA, which could detect smaller immunoreactive
fragments, produced results which were not significantly different.
Therefore, it is unlikely that the present findings arose spuriously, as a
result of methodological inadequacies.
Interestingly, a selective rise in CRH, compared to AVP, was
reported at the slightly later gestational age of day 138 by Brieu and
colleagues (Brieu et al. 1989). CRH is known to be less effective than
AVP in stimulating ACTH release from pituitary cells isolated from
young fetuses, whereas the converse is true in pituitary cells collected late
in gestation (Brieu & Durand, 1987). The present study supports the
hypothesis that AVP may be a more important ACTH-releasing factor in
early gestation, and further suggests that either CRH alone or synergy
between CRH and AVP may gain importance later in development. This
is in contrast to findings in the adult sheep in which AVP is gaining
acceptance as the major ACTH-releasing factor (see Shen, Clarke, Canny,
Funder & Smith, 1990). In agreement with the results of other workers
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(Familiari et al. 1989), the data presented here showed that AVP was
more potent than CRH in releasing ACTH from the adult sheep pituitary
cell bioassay.
Chapter 5 of this thesis quantified secretion of CRH and AVP from
fetal sheep hypothalamic cells in vitro. Secretion of CRH and AVP by
cultured cells removed at day 70, 100 or 130 of gestation was diminished
with advancing gestational age, and this was associated with a reduction
in the contents of AVP and CRH in the hypothalamic cultures. These
data contrast with the results of the present study, which has shown that
immunoreactive hypothalamic CRH and AVP are present in increasing
quantities with fetal maturation. Taking these results together, the
present study has shown that hypothalamic synthesis and/or storage of
CRH and AVP is most probably dependent on factors which are present
%
in vivo but not in vitro. These factors may take the form of
neurotransmitter inputs to the PVN neurones, or they may be specific
neurotrophic molecules or endocrine growth factors which act on the
CRH and AVP cells. The previous chapter indicated that whilst the
hypothalamic CRH and AVP cells in vitro show differences in function
with advancing gestational age, suggestive of hypothalamic maturation,
the cultured cells do not closely mimic neurones in vivo in terms of
peptide content, as reported here. Therefore, it is perhaps more
appropriate to study the qualitative responses of these cultured cells,
rather than to ascribe significance to the quantities of peptides secreted.
The present study utilised Sephadex chromatography to examine
the multiplicity of molecular species in the fetal sheep hypothalamus
which were immunoreactive in CRH and AVP RIA procedures.
.Importantly, only one immunoreactive peak was detected in the CRH
assay and one in the AVP assay at all gestational ages studied, each of
which co-eluted with the appropriate synthetic peptide. The CRH and
AVP precursors contain several paired basic amino acids at which
cleavage occurs during post-translational modification (Furutani et al.
1983; Land et al. 1982), therefore, several extended molecular forms of
CRH and AVP can exist, depending on the degree to which post-
translational cleavage occurs. The present study provides good evidence
that as early as midgestation (day 70), fetal sheep hypothalamic neurones
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correctly process the CRH and AVP precursors, giving rise to CRH(1-41)
and AVP(l-9).
By contrast to the above, immunoreactive CRH in the human fetal
hypothalamus at an equivalent developmental age (prior to week 20;
Term = 39 weeks) elutes as two peaks on Sephadex chromatography, one
corresponding to a molecular weight of 8-1OkD and another which co-
elutes with oCRH(l-41) (Ackland et al. 1986). The large molecular form
may represent an intermediate between prepro-CRH and CRH(1-41).
Cleavage of the precursor at amino acids 123-124 (CRH(1-41) present at
amino acids 154 to 194; Shibahara et al. 1983) would give rise to a CRH(1-
41)-containing polypeptide of 71 amino acids, with a molecular weight of
around 9kD. A similar cleavage site exists at amino acids 116-117 in the
ovine CRH precursor (Furutani et al. 1983). However, the absence of
large CRH molecules as reported here suggests that immunoreactive
prepro-CRH molecules are present in very low abundance in the fetal
sheep hypothalamus. Alternatively, the antibody used in the present
work may not cross react with this form of CRH. To examine prepro-
CRH in the hypothalamus of the fetal sheep, a recent study used
Sephadex chromatography followed by RIA with multiple anti-CRH
antibodies to screen CRH molecules in hypothalami removed as early as
day 48 of gestation. These workers convincingly demonstrated that CRH-
like immunoreactivity co-eluted with CRH(1-41) at all gestational ages
investigated (Watabe et al. 1991). Therefore, in contrast to the human,
these data suggest that the fetal sheep hypothalamus may not store
appreciable amounts of prepro-CRH.
The work reported here showed that the peaks of CRH and AVP
imunoreactivity after Sephadex chromatography were associated with
peaks of ACIH-releasing activity, as determined by pituitary cell bioassay.
This was most obvious in extracts prepared from hypothalami removed
at day 70 of gestation. Prior to these studies, it was not clear whether CRH
and AVP synthesised by the developing hypothalamus contained
biological activity. Both CRH and AVP depend on C-terminal amidation
9
for biological activity (Sossin, Fisher & Scheller, 1989), and there are no
studies which have assessed the activity of peptidyl-glycine a-amidating
9
monooxygenase, the enzyme which catalyses a-amidation (Eipper &
Mains, 1988), in the fetal sheep hypothalamus during development.
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Therefore, the present work strongly suggests that as early as day 70 of
gestation, the fetal sheep hypothalamus correctly cleaves and amidates
the CRH and AVP precursors to give rise to the bioactive peptides.
It is also possible that the ACTH-releasing activity observed in
hypothalamic extracts may be attributable to molecular species other than
CRH or AVP. Oxytocin (Antoni, Holmes & Jones, 1983), angiotensin II
(Ganong & Marakami, 1987) and galanin (Hoo, Maiter, Martin & Koenig,
1990) have been implicated as ACTH-releasing factors, and these
substances may co-elute with CRH or AVP on Sephadex chromatography.
The present work does not distinguish between these various ACTH-
releasing factors, and confirmatory studies, such as HPLC purification
followed by antibody quenching experiments (Gillies & Lowry, 1982), will
have to be carried out to identify further the contributions of these
substances.
»
The work reported here shows that substantial ACTH-releasing
activity elutes in fractions containing little or no detectable AVP or CRH
at each gestational age. For example, bioactivity was present in the
column void volume and in fractions 29 and 30 in each case, and these
activities tended to increase with advancing gestation. Brieu and
colleagues (1989) observed a gestational age-dependent increase in the
bioactivity of hypothalamic extracts, which they suggested was due to the
rising levels of AVP and CRH. However, their study showed similar
ACTH-releasing activity in hypothalami from day 138 and day 143,
despite a large reduction in hypothalamic AVP and CRH content over
this time. These authors were unable to explain this observation,
however, the present study clearly shows that both high molecular
weight (void volume) and low molecular weight (fractions 29 and 30)
species may contribute significantly to ACTH-releasing bioactivity of
hypothalamic extracts.
A high molecular weight ACTH-releasing factor has previously
been reported in extracts from adult bovine hypothalami (Yasuda,
McClung & Greer, 1978). Interestingly, low molecular weight ACTH-
releasing factor (corresponding to CRH) was generated from the high
molecular weight molecule on storage (Yasuda et al. 1978). The void
volume species in the present report could be a CRH precursor, which is
cleaved by proteolytic enzymes present in the bioassay to yield CRH(1-41).
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Whilst a protease inhibitor was included, it is not clear whether all such
enzymes would have been inactivated in the bioassay. It would be
interesting to re-examine CRH immunoreactivity - in the fractions after
incubation with pituitary cells.
The identity of the low molecular weight ACTH-releasing factor in
the present study is unknown. Fractions 29 and 30 were relatively acidic,
but were neutralised before incubation with pituitary cells. It is therefore
likely that this represents an intrinsic ACTH-releasing activity in this
fraction rather than a non-specific stimulus such as hydrogen ions. It
remains an exciting prospect that a fetus-specific CRF exists, neither CRH
feedback
preparturient phase.
In conclusion, this chapter has examined the ontogeny of ACTH-
releasing factors in the fetal sheep hypothalamus. Hypothalamic AVP
and CRH corresponded to mature, biologically active peptides, as
demonstrated by Sephadex chromatography, RIA and pituitary cell
bioassay, as early as day 70 of gestation. It is concluded that in terms of
peptide synthesis and storage, the fetal hypothalamus displays functional
competence by midgestation. Moreover, the present chapter found that
fetal maturation was associated with progressive increases in AVP and
CRH, which is consistent with the functional maturation and activation
of the hyopthalamo-pituitary-adrenal axis in fetal life.
I
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- 7. Cortisol Negative Feedback at the level of the
fetal Hypothalamus in vitro.
To examine the ontogeny of AVP and CRH in the fetal sheep
hypothalamus, the previous 2 chapters have investigated AVP and CRH
release from cultured hypothalamic cells in vitro and the levels of these
peptides in the intact hypothalamus at several gestational ages. These
studies have revealed a progressive reduction in AVP and CRH secretion
in vitro with advancing gestational age, and furthermore, that AVP
secretion was calcium- and time-dependent in day 70 and day 100
cultures, whereas CRH secretion did not conform to these criteria at any
gestational age. In contrast to these observations, the fetal hypothalamus
in vivo was found to contain very large amounts of immunoreactive
and bioactive AVP and CRH peptides as early as day 70 of gestation, the
0
levels of which increased with advancing gestational age.
Whilst these chapters have revealed aspects of the functionality of
*
fetal hypothalamic cells at different stages in development, they have not
assessed physiological aspects of AVP and CRH regulation, such as the
responses to adrenal steroids or neuropeptides. The remit of the
remaining experimental chapters in this thesis is to examine these issues.
Furthermore, as reliable measurement of CRH in vitro has been shown
to be problematic, and certainly not possible at different gestational ages, it
was decided to pursue these studies quantifying AVP alone.
7.1 Introduction
The fetal sheep hypothalamus contains high levels of immunoreactive
and bioactive AVP and CRH from day 70 of gestation onwards (Brieu et
al. 1989; see Chapter 6, this thesis) and either of these peptides alone or in
combination stimulates ACTH release by fetal sheep pituitary cells from
0
day 63 of gestation onwards (Durand et al. 1986; Brieu & Durand, 1987).
However, fetal ACTH levels remain low until rather later in gestation
(Rose, Meis & Morris, 1981; Norman et al., 1985), suggesting that, early in
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development, the fetal hypothalamo-corticotrope system is under
inhibitory control, possibly through the negative feedback actions of
adrenal glucocorticoids. These data also suggest the hypothesis that a
reduction in the effectiveness of glucocorticoid negative feedback may
underlie increases in ACTEi levels in the fetal sheep in late gestation.
The effects of glucocorticoids on fetal sheep pituitary ACTH release
at different times in gestation have recently been investigated, and
available data indicate that Cortisol or dexamethasone inhibits the release
of ACTH from the fetal pituitary over a wide range of gestational ages,
both in vivo (Norman & Challis, 1987b) and in vitro (Brieu et al 1986).
However, the development of negative feedback regulation of ACTH-
releasing factors in the fetal sheep hypothalamus is less well studied. The
available evidence suggests that feedback may well regulate synthesis and
secretion of ACTH-releasimg factors at certain times in development. For
example, implants of dexamethasone to the fetal PVN at day 108-111 of
gestation abolish the elevation in fetal ACTH after fetal hypotension or
hypoxaemia at day 120 (McDonald et al. 1990), whereas fetal adrenal¬
ectomy at day 118-121 increases PVN CRH mRNA levels within a few
days (Myers et al. 1991). In contrast to investigations of fetal pituitary
ACTH secretion, these studies have not attempted a quantitative
description of glucocorticoid feedback at the fetal hypothalamus.
Therefore, the question of whether negative feedback becomes more or
less effective with advancing gestation remains unanswered.
Recently, evidence has been provided that the secretion of ACTH-
releasing factors from the fetal sheep hypothalamus is more sensitive to
glucocorticoid inhibition in late gestation (Brooks et al. 1989). These
authors showed that basal CRH secretion from perifused fetal sheep
hypothalami removed at day 140 of gestation was inhibited by
glucocorticoids, whereas this treatment had no effect on basal CRH release
from tissues obtained at day 100. These data may contrast with receptor
binding studies which show that glucocorticoid receptors in the sheep
hypothalamus are present at lower concentrations in late gestation fetuses
(Yang et al. 1990). However, both studies provide very good evidence
that the efficacy of glucocorticoid negative feedback at the fetal
hypothalamus may vary during fetal development.
4
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To investigate the hypothesis that the efficacy of glucocorticoid
negative feedback at the fetal hypothalamus undergoes change during
development, the present study assessed the secretion of AVP from
cultured fetal sheep hypothalamic cells removed at day 70 and day 100 of
gestation, in the presence and absence of a glucocorticoid. Cultures were
divided into two groups and maintained in serum-free medium, or in
serum-free medium containing Cortisol and AVP release was measured
under basal conditions and in response to incubation with 56 mM
potassium-containing medium. At the end of the experiment, cultures
were extracted to determine the effects of Cortisol on AVP content.
Finally, the secreted AVP was characterised by gel chromatography and
RIA to assess identity with synthetic AVP.
7.2 Experimental Procedures
Hypothalami were removed from fetal sheep at day 70 and day 100 of
gestation, and 2 cultures were prepared at each gestational age as
"
previously described. 2 groups of 5 fetuses and 2 groups of 3 fetuses were
used for day 70 and day 100 hypothalamic cultures respectively, and the
results from duplicate cultures were combined for analysis. Where
appropriate, data were logarithmically transformed to eliminate
heterogeneity of variance.
%
Experimental Design. The wells in each culture were divided into 2
groups at the time of plating. 48 hours later, serum-free medium was
added to all cells, however 1 group received medium containing 150nM
Cortisol (Sigma; 50 pM stock in 0.1% ethanol). Subsequently, Cortisol was
routinely added to all culture medium and experimental media which
*
were prepared for this group of cells, whilst the other group remained
cortisol-free. .
Between day 7 and day 18 after plating, all cultures were incubated
every 3 or 4 days with basal medium for 3 hours and then with 56 mM
potassium-containing medium for a further 3 hours. Incubations were
carried out as previously described, in die presence or absence of 150nM
Cortisol, as appropriate to the experimental group. All media were stored
\
* *
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at -20°C prior to measurement of AVP by RIA. To assist detection of low
levels of AVP, basal samples from each well were frozen as 2 aliquots of
300pl. These were freeze-dried and reconstituted in a smaller volume at
•»
the time of assay. On day 21, cultures were photographed, and wells in
each group were washed 3 times with basal release medium and extracted
in 1ml of this solution.
The samples from this study were assayed for AVP by RIA as
described previously, except that the lyophylised basal release samples
were reconstituted in 100 ill deionised water immediately prior to assay.
All results were expressed as pg/dish. The AVP contents in cell extracts
♦
from different cultures within the same gestational age group showed
marked variation. To reduce this variation, the AVP contents of cells
from each well in a culture were expressed as a percentage of the average
AVP content of all the wells in that particular culture. The percentage
values for the two cultures from each gestational age were then combined
for statistical analysis.
ft
Statistics. The multiple between- and within-grpups variables in the
present study precluded a simple statistical analysis to determine the
effects of Cortisol on basal and potassium-stimulated release of AVP.
Therefore, a preliminary ANOVA was carried out to determine the
overall effects of and interactions between Cortisol and potassium
stimulation, gestational age and age in culture, on AVP release.
To determine whether potassium stimulation enhanced AVP
secretion from the cortisol-free wells in day 70 cultures, basal AVP release
was compared to stimulated release by ANOVA, followed by Duncan's
multiple range test, with day in culture (day 8, 11, 15 and 18) and
incubation (basal or stimulated) as the within-groups variables. Identical
analyses were then carried out for the cortisol-supplemented day 70
cultures, and for both groups of day 100 cells.
Similarly, ANOVA, followed by Duncan's multiple range test, was
carried out to determine the effects of Cortisol on basal AVP release, with
gestational age (day 70 and day 100) and Cortisol (present or absent) as the
between-groups variables an day in culture (day 8, 11, 15 and 18) as the
within-groups variable. Similar analyses were utilised to determine the
effects of Cortisol on potassium-stimulated AVP release. Finally, the
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effects of Cortisol on the AVP contents of the cultured cells was assessed by
one-way ANOVA, followed by Duncan's multiple range test, with
gestational age (day 70 and day 100) and Cortisol (present or absent) as die
between-groups variables.
Characterisation of Secreted AVP. In order to assess parallelism of
secreted AVP with the AVP standard curve in RIA procedures, doubling
dilutions of culture supernatant (excess, cortisol-free 56 mM potassium-
containing medium) were prepared in duplicate in AVP assay buffer.
After conventional AVP RIA procedures were carried out, the degree of
tracer binding in these tubes was expressed as a percentage of the Bo
levels, and these results were plotted alongside the corresponding values
for a standard curve.
Size fractionation of AVP immunoreactivity was carried out by
Sephadex chromatography, essentially as previously described. However,
some modifications were required in view of the much reduced peptide
levels. A pool of excess, cortisol-free 56 mM potassium-containing media
(~3ml) was collected from each culture. This was freeze-dried, and
reconstituted in 1ml assay buffer. Each was added to a Sephadex G50
column, 30 x 1cm, and eluted with 0.01M HC1, containing 0.9% NaCl, at a
rate of 3.5 ml/hour. Fractions were collected every 12 minutes (0.7 ml)
and were immediately assayed for AVP. Results were expressed as
pg/fraction.
7.3 Results
Figure 7.1 shows phase contrast micrographs of cultured cells at day 21 in
vitro, immediately before culture extraction. The viability of the cultures
was subjectively assessed in terms of the cell density and the phase
characteristics (bright or dark cells) of the hypothalamic cells. This
procedure suggested that neither gestational, age nor the presence of
glucocorticoids adversely affected the viability of these cultures.
Chapter 7
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Figure 7.1. Day 70 and day 100 fetal sheep
hypothalamic cells cultured in the presence
or absence of 150 nM Cortisol. The phase-
contrast photomicrographs show day 70 cells in A the
absence or B the presence of 150 nM Cortisol.
Similarly, C and D show day 100 cells in the absence
and presence of Cortisol (150nM) respectively.
Subjective assessment, in terms of cell density and
phase contrast appearance of the cells, suggested
there was no detrimental effect of corticosteroid
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A preliminary analysis of variance suggested that both elevated
potassium stimulation (ANOVA; p <0.001) and Cortisol (ANOVA; p
<0.001) had profound effects on the secretion of AVP from fetal sheep
hypothalamic cultures. Further statistical analyses established that in day
70 and day 100 hypothalamic cells cultures, either in the presence or
absence of Cortisol, incubation with elevated potassium-containing
medium significantly stimulated AVP output on each experimental day
in vitro (p <0.01), as shown in Figure 7.2. However, Cortisol significantly
and profoundly inhibited basal (p <0.01) and potassium-stimulated (p
<0.01) AVP output from cells removed at day 70 gestation. In contrast
Cortisol had no significant effect on either basal or potassium-stimulated
AVP secretion from day 100 cultures.
A marked variation characterised the AVP contents of wells in
• •
different cultures, even within the same gestational age grouping. To
eliminate such variation, the AVP contents of wells in each culture were
expressed as a percentage of the average content for that particular
culture. These normalised data revealed that 150nM Cortisol significantly
•«
reduced the AVP content of fetal sheep hypothalamic cells cultured at
*
day 70 of gestation (p <0.05), whereas it had no effect on the AVP content
of cells removed at day 100 of gestation, as shown in Figure 7.3.
The immunoreactive AVP present in the supernatant of fetal
sheep hypothalamic cultures, prepared either at day 70 or at day 100 of
gestation, reproducibly showed parallelism with the synthetic peptide in
RIA procedures, as shown in Figure 7.4. This figure also shows that AVP
I
in the supernatant from cultures of day 70 or day 100 hypothalamic cells
consistently co-eluted with standard AVP on Sephadex chromatography.
7.4. Discussion.
The aims of the present study were to investigate the ability of Cortisol to
inhibit AVP secretion from cultures of fetal sheep hypothalamic cells,
ft
and to assess the gestational age-dependent changes in hypothalamic
sensitivity to this steroid by investigating the effects of Cortisol in cells
from day 70 and day 100 of gestation.
The results showed that basal and potassium-stimulated AVP
Chapter 7
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Figure 7.2. The effects of 150 nM Cortisol on
AVP secretion from cultured day 70 and day
100 fetal sheep hypothalamic cells. A and B
show AVP secretion from day 70 cells cultured in the
absence or presence of 150 nM Cortisol repectively,
A
and C and D show the corresponding AVP released
from day 100 cells. Data shown are means of 12 or 13
wells (+/- S.E.M.) combined from 2 separate cultures
at each gestational age. Cortisol significantly
inhibited basal (p < 0.01) and potassium-stimulated (p
< 0.01) AVP secretion from day 70 cells, but was
without effect on either basal or stimulated AVP
secretion in day 100 cultures. At each time point in
vitro, 56 mM potassium treatment significantly





























Chapter 7 Cortisol Negative Feedback 131
Figure 7.3. The effects of 150 nM Cortisol on
AVP content of cultured day 70 and day 100
fetal sheep hypothalamic cells. Data shown are
means (+/- S.E.M.) of 6 or 7 wells combined from 2
different cultures at each gestational age. AVP
*
ft
content in each well of a culture was expressed as a
percentage of the average AVP content for that
— culture, and the data from 2 cultures at the same
gestational age were combined for analysis. Cortisol
significantly reduced AVP content in day 70 cells (*p .
< 0.05), but had no significant effect in day 100
cultures.
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Figure 7.4. Characterisation of AVP secreted
by day 70 and day 100 fetal sheep
hypothalamic cultures. A. Parallelism of the
♦
secreted peptide with the standard curve in an AVP
RIA. In all cases, hypothalamic culture supernatant
diluted in parallel with the standard peptide.
B. Immunoreactive profile of culture supernatant
subjected to Sephadex G50 chromatography and AVP
RIA. Supernatant from cultures showed one peak of
immunoreactive AVP which co-eluted with the
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secretion by hypothalamic cultures were inhibited by Cortisol in cultures
from day 70 of gestation, but not in cultures from day 100. This effect in
day 70 cells was characterised by a 25% fall in AVP content of the cells and
a 50% reduction in AVP output. Whilst the effect of Cortisol differed at
the two gestational ages, the nature of AVP secreted from the cells was
identical, both in terms of its parallelism with synthetic AVP in the RIA
and its molecular size as assessed by Sephadex chromatography.
AVP is present as a 20-fold molar excess when compared to CRH in
the hypothalamus of the ovine fetus at midgestation (Term = 145 days;
see Chapter 6). Well before this developmental age, neuronal tracts
containing AVP project from the hypothalamus to the external lamina of
the median eminence (Levidiotis et al. 1987). In the present study, AVP
secretion from cultured fetal sheep hypothalamic cells was significantly
inhibited in the presence of Cortisol, which is consistent with the
hypothesis that hypothalamic AVP is a site of negative feedback
regulation of the pituitary-adrenal axis in the ovine fetus.
To investigate this hypothesis, the effects of glucocorticoid
administration to the hypothalamic PVN have recently been examined in
the chronically catheterised fetal sheep (McDonald et al. 1990). Fetuses
responded to hypotension or hypoxaemia with a significant elevations in
circulating ACTH levels. However, dexamethasone crystals placed
bilaterally beside the fetal PVN completely abolished these responses,
without affecting basal ACTH release. Furthermore, AVP immuno-
staining in the fetal median eminence was dramatically reduced after
dexamethasone treatment, consistent with a reduction in synthesis and
secretion of this peptide. The data presented here confirm and extend
these observations, and firmly support the hypothesis that glucocorticoids
during development negatively regulate the fetal hypothalamo-pituitary-
adrenal axis at a hypothalamic level.
Currently, it is believed that expression of glucocorticoid receptors
is a prerequisite for the action of glucocorticoids in a particular cell (see
Gustaffson et al. 1987, for review). The present study revealed a profound
inhibitory effect of Cortisol on AVP release from day 70 cells whereas
there was no inhibition of AVP secretion from day 100 cultures.
Paradoxically, Yang and colleagues (1990) have shown that the
concentration of glucocorticoid receptors in the fetal sheep hypothalamus
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is much lower at days 60-70, when compared to day 100. However, these
workers did not determine the distribution of glucocorticoid receptors
within this tissue, and it may be that glucocorticoid receptor expression by
cells outwith the PVN contributed significantly to hypothalamic
corticosteroid binding in this study. On the other hand, glucocorticoid
receptor expression in the hypothalamus of the rat is most dense within
the medial parvocellular PVN (Gustaffson et al. 1987), the area containing
the AVP and CRH cells which regulate ACTH release (Antoni, 1986).
The observation in the present study that glucocorticoids had
minimal effects in tissues removed at day 100 of gestation is difficult to
4
reconcile with the glucocorticoid receptor binding' studies, as described
above. However, substantial remodelling of hypothalamic glucocorticoid
receptors may occur during development, such that the PVN at day 100 of
gestation may not contain glucocorticoid receptors. Further histological
studies co-localising the glucocorticoid receptor and AVP mRNA
throughout develoment would be required to clarify these issues. .
In order to determine whether glucocoticoid treatment had effects
on both basal and stimulated AVP release, the present report measured
'AVP secretion under basal and 56 mM potassium-stimulated conditions
in cells receiving chronic exposure to either cortisol-supplemented
culture medium or to control medium. The results clearly showed that
ft
cortisol-mediatedinhibitionaffected both basal and potassium-stimulated
release of AVP from the hypothalamic cultures, and was associated with a
substantial reduction in the AVP content of the cells. However, acute
administration of the potent glucocorticoid agonist dexamethasone is
known to inhibit basal but not potassium stimulated CRH release.
(Brooks et al. 1989). These data suggest that the acute and chronic
inhibitory effects of glucocorticoids on the secretion of ACTH-releasing
factors may operate through different mechanisms.
The rapid onset of dexamethasone-induced inhibition of CRH
release (within 30 minutes) suggested that the mechanism does not
involve a reduction in CRH synthesis at the cell body and reduced CRH
transport to nerve terminals. Rather, the reversal of the effects of
glucocorticoids by potassium-induced depolarisation suggests that acute
dexamethasone treatment directly inhibited CRH release from the axon
terminals. By contrast, the reduction in basal and potassium-stimulated
Chapter 7 Cortisol Negative Feedback 135
release of AVP in concert with a reduction in AVP content, as reported in
the present work, is consistent with a cortisol-induced reduction in AVP
synthesis.
In a recent study, Schilling, Schmale, Oeding & Pilgrim (1991)
examined glucocorticoid effects on mRNA transcription. Using cultured
fetal rat hypothalamic cells, these workers showed that AVP mRNA but
not oxytocin mRNA expression was much increased when RU 486, a
glucocorticoid antagonist, was added to the serum-containing culture
medium. In parallel, Clarke & Gillies (1988) have shown that
corticosterone inhibits AVP and CRH secretion but not somatostatin in
serum-free cultures of fetal rat hypothalamic cells. These data are very
supportive of a highly specific, inhibitory effect of glucocorticoids on AVP
synthesis which subsequently leads to reduced AVP secretion. Further in
vitro studies, utilising northern blotting techniques to visualise AVP
mRNA (see Schilling et al, 1991), and [35S] methionine-labelling of
• •
nascent proteins (see Gainer, Same, & Brownstein, 1977), may reveal
9
more precisely the nature of glucocorticoid effects on the synthesis and
secretion of hypothalamic AVP.
The AVP content of the fetal sheep hypothalamus increases
between days 70, 100 and day 130 of gestation, moreover, the peptide
elutes as a single immunoreactive and bioactive peak on Sephadex
chromatography, corresponding to synthetic AVP, at each gestational age
(Chapter 6, this thesis). In the present study, it was not possible to assess
the bioactivity of AVP collected from cultured hypothalamic cells.
However, gel filtration of supernatant from day 70 and day 100 cultures
revealed that secreted AVP co-eluted with the synthetic peptide at each
gestational age. It is therefore likely that the complex biochemistry
required to fully process the high molecular weight AVP precursor to the
mature peptide is present in the fetal hypothalamus in vitro. Therefore,
the reduction in AVP secretion observed with advancing gestational age,
as seen in this chapter and in Chapter 5, is unlikely to be associated with a
loss of differentiated function in these cultured cells.
The present report does not reveal whether the fetal hypothalamus
is under the inhibitory influence of glucocorticoids in vivo. Plasma
Cortisol levels early in fetal sheep development are very low compared to
late gestation (Rose et al. 1978), which possibly reflects the finding that
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prior to day 120 of pregnancy, fetal Cortisol is largely of maternal origin
(Hennessy, Coghlan, Hardy, Scoggins & Wintour, 1982). Until the onset
of labour, a further 90% of this Cortisol is bound to corticosteroid binding
globulin (Ballard, Kitterman, Bland, Clyman, Gluckman, Platzker, Kaplan
& Grumbach, 1982). Therefore, free bioactive Cortisol levels in the fetal
sheep are likely to be extremely low until late in fetal development.
On the other hand, lung, liver, and gut maturation occurs well
before parturition in this species, and is dependent on Cortisol from the
fetal adrenal (Liggins, 1976; Silver, 1990). Moreover, the ratio of adult to
fetal corticotropes in the fetal pituitary gland is increased by Cortisol
% m
(Antolovich et al. 1989), and the increase in vivo is apparent from day 87
of gestation (Mulvogue et al. 1986). These data suggest that biologically
active Cortisol is present in the fetal circulation from mid-gestation at
least, and this could be implicated in the negative feedback regulation of
the fetal pituitary-adrenal axis. These data also present the intriguing
hypothesis that maternal Cortisol inhibits the activity of the fetal
hypothalamo-pituitary-adrenal axis in early development. This may
have some physiological importance, as the fetal adrenal before day 50 of
gestation is extremely sensitive to ACTH (Wintour et al. 1975), and so
premature hypothalamic drive to pituitary ACTH release could have
disasterous consequences for the very immature fetus.
The data presented in this study are subject to a number of
alternative interpretations to those suggested in the body of this
discussion. It is shown here that Cortisol inhibited AVP output from cells
removed at 70 days of gestation, and yet the steroid had no effect on cells
from later in development. These differential effects of Cortisol cannot be
explained by a reduction in the potency of die stock solution over time in
storage, as cultures from day 100 of gestation were experimented upon
first, and these cultures showed no effect of Cortisol on AVP secretion.
These observations would tend to rule out suggestions that variability in
the Cortisol stock solution lead to the discrepancies between day 70 and
day 100 cells.
It is also possible to explain the effect of Cortisol on AVP output
from day 70 cells in terms of a toxic effect on the cultures. If this were so,
the same responses would be expected in day 100 cells. Clearly, this was
not the case. Furthermore, the viability of the cultures was demonstrated
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by treatment with 56mM potassium-containing medium, and throughout
the culture period, depolarisation continued to stimulate AVP release
from cells in the presence or absence of Cortisol. On the other hand, these
ft
studies do not rule out a cortisol-mediated selective toxicity on neuronal
cells. However, the concentration of Cortisol used in these studies is less
than the plasma level observed at term in the fetal sheep (Basset &
Thorbum, 1969), suggesting that the dose was physiological, rather than
toxic.
ft
In conlcusion, this chapter has demonstrated that Cortisol may act
at a hypothalamic level as a negative feedback regulator of the developing
fetal pituitary-adrenal axis. Interestingly, the inhibitory effects of Cortisol
on hypothalamic cells were highly dependent on the gestational age of
the tissue from which the hypothalamic cultures were prepared. Both
basal and potassium-stimulated AVP secretion by day 70 cells was
inhibited by Cortisol, which suggested that AVP synthesis was inhibited in
these cells, whereas this treatment was without effect in cultures prepared
from day 100 hypothalami. The present study also determined by RIA
and gel chromatography that mature AVP peptide is secreted by cultured
cells removed either at day 70 or day 100 of gestation, which suggest the
cells retain differentiated function and biochemical maturity in vitro.
ft
The data presented in this chapter support the hypothesis that changes in
hypothalamic glucocortcoid sensitivity may underlie activation of the
pituitary-adrenal axis which is observed in the developing fetal sheep.
8. Opioid regulation of AVP secretion in the
developing fetal sheep hypothalamus in vitro.
In the previous chapter, the effects of Cortisol on basal and 56 mM
potassium-stimulated AVF secretion from cultured fetal sheep
hypothalamic neurones were investigated. The principal findings were
that Cortisol treatment in vitro significantly inhibited AVP release and
reduced AVP content of cultured hypothalami removed at day 70 of
gestation, whereas these effects were absent in hypothalamic cells
cultured at day 100 of gestation. These data suggest that changes in the
Cortisol sensitivity of the fetal hypothalamus may underlie the pre-
parturient activation of the pituitary-adrenal axis. On the other hand, a
reduction of inhibitory neural input may account for the increase in fetal
hypothalamo-pituitary-adrenal activity. What is. more likely is that
several factors interact to regulate the pituitary-adrenal axis at central and
peripheral sites. The objective of this chapter was therefore to investigate
the effects of one of these putative factors, the opioids, on AVP secretion
I
from the fetal sheep hypothalamus. To examine the interactions between
neuropeptides, steroids and development, the hypothalamic responses to





The fetal sheep hypothalamus releases CRH and AVP (Brooks et al. 1989;
Chapter 5), which act to stimulate ACTH release from the fetal sheep
pituitary gland (see Brooks & White, 1990). ACTH release from the fetal
pituitary may also be stimulated by administration of opioids (Brooks &
i
Challis, 1988), an effect which is probably mediated via hypothalamic
CRH and AVP, as the fetal pituitary gland does not contain opioid
receptors (Yang & Challis, 1991). A hypothalamic site of action for the
ACTH-releasing activities of the opioids is supported by studies in adult
animals, which show that opioids greatly elevate secretion of bioactive
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ACTH-releasing factors from adult hypothalami in vitro (Buckingham,
1982).
The studies reviewed above suggest that the fetal sheep pituitary-
adrenal axis is under stimulatory opioid control at the level of the
hypothalamus. However, they do not demonstrate whether endogenous
opioid peptides are involved in the physiological regulation of the fetal
pituitary-adrenal axis. Brooks & Challis (1988) found that intravenous
administration of a bolus of naloxone to the fetal sheep had no effect on
fetal plasma ACTH concentration, suggesting that endogenous opioids
were not tonically active. However, these authors demonstrated in a
recent study that naloxone infusion to the fetal sheep near term
profoundly inhibits fetal plasma ACTH levels (Brooks & Challis, 1991),
strongly suggesting that endogenous opioids are stimulatory to the fetal
pituitary-adrenal axis.
In the fetal sheep hypothalamus, opioid receptor binding increases
with advancing gestational age (Yang & Challis, 1991), in parallel with
maturation of the fetal ACTH response to exogenous opioid treatment
(Brooks & Challis, 1988). It is notable that these maturational changes
occur at the time when fetal plasma Cortisol levels begin to rise towards
* term (Norman et al. 1985). These data suggest that there is a progressive
maturation of the hypothalamic opioid system in the fetal sheep.
Further, fetal plasma Cortisol concentration may increase as a result of
hypothalamic maturation, or act to enhance hypothalamic development.
Indeed, Cortisol may be stimulatory to the endogenous opioids, and so
form a positive feedback loop which maintains the rise of fetal plasma
ACTH and Cortisol towards term.
In order to investigate the actions of opioids on the fetal
hypothalamus and the effects of Cortisol on the developing opioid
responses, fetal sheep hypothalamic cells were removed at day 70 and day
100 of gestation and cultured in the presence and absence of Cortisol. Cells
. were subjected to incubations with the highly specific k-agonist [D-Pro10]
Dynorphin (1-11), the opioid antagonist naloxone, or both treatments
together. It was not possible to characterise the dose-dependent effects of
selective mu- (p.), delta- (d) and kappa- (k) receptor agonists in fetal sheep
cultures, as there were insufficient numbers of fetal sheep available.
Therefore, the effects of different doses of these drugs were fully
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Cultures of fetal rat hypothalamic cells were prepared using adaptations
of the methods described in Chapter 3. For the experiments reported
here, cultures were prepared on 6 different occasions, using a cumulative.
total of 412 fetal rat hypothalami removed at day 18 of gestation (Term =
22 days). The experiments on fetal sheep hypothalamic cells reported
here were carried out on the cultures described in the previous chapter.
Preparation of Fetal Rat Hypothalamic Cell Cultures. Vaginal cytology
was used to detect oestrus in Female Wistar rats. These animals were
placed with proven males the next day (Dioestrus) and removed at the
time of next oestrus (72 hours later). Females were then kept isolated
until required on day 18 of pregnancy. Animals were then asphyxiated
with 100% CO2 and the cervical vertebrae were dislocated. The fetuses
were dissected out, decapitated and the brains were removed.
Hypothalami were dissected away from the base of the brain and placed in
ice cold, sterile collection buffer.
Fetal rat hypothalamic cell cultures were prepared in the same
fashion as fetal sheep hypothalamic cell cultures (Chapter 3), except that
only half the volumes of enzyme-containing media were used and the
cells were plated out in culture medium containing 10% fetal calf serum.
For the studies reported in this chapter, the average viability at plating
was 96.2 +/- 0.35 % (mean +/- S.E.M., n = 6)
As with the fetal sheep cell preparations, cultures were placed in
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8.2.1. The Effects of Selective Opioid Agonists on AVP Secretion from
Fetal Rat Hypothalamic Cells.
Overall Experimental Design. Four independent fetal rat hypothalamic
cell cultures were used to carry out the two opioid experiments described
in the present section. Each experiment was performed in all cultures,
and the mean results from each culture were combined for analysis (n = 4
cultures). Cultures were routinely incubated with basal and 56 mM
potassium-containing medium every 3 or 4 days, starting at 8 days in
vitro, to enhance AVP output from the cells (Clarke & Gillies, 1988). The
experiments were then carried out on either day 17, day 21, day 24, day 28
or day 31 in vitro, and to randomise the effects of advancing time in
vitro, the three replicate experiments in the other cultures were
performed on different days across this time span. To avoid any carry¬
over effects of previous treatments, wells were randomised into new
treatment groups at the start of each experiment. Finally, each sample
from a particular experiment was assayed at the same time to avoid
interassay variation.
General Protocol. Cultures were incubated with basal medium for 2
hours (Bl) and then immediately afterwards with 56 mM potassium-
containing medium for a further 2 hours (SI). After a recovery period,
this procedure was repeated (B2 and S2) in the presence or absence of the
various opioids. AVP output from each well during B2 and S2 was
expressed relative to output during Bl and SI (B2/B1 and S2/S1), and the
values of these ratios were compared for wells receiving control or
ft
opioid-containing media during B2 and S2. Therefore, opioid-mediated
stimulation or inhibition would reveal itself as an increase or decrease in
ft
these ratios respectively.
In order to validate the experimental approach described here, it
was necessary to establish the optimum interval between the control
incubations such that the B2/B1 and S2/S1 ratios were approximately
equal to 1. Using fetal rat hypothalamic cultures which were entirely
different from those used for the opioid experiments, 6 groups of 3-4
wells were incubated with basal and 56 mM potassium medium for 2
hours each as described above (Bl and SI) on day 24 in vitro. After
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intervals of either 1,2,4, 8/12 or 20 hours, cells were incubated again with
basal and 56 mM potassium-containing medium (B2 and S2). Media were
stored at -20°C until they were assayed for AVP by RIA, and the B2/B1
and S2/S1 ratios were then calculated for each groups of wells. The
results from these wells were combined with those from a duplicate
experiment carried out in a separate culture. Data were expressed as the
means of the ratios (B2/B1 and S2/S1) calculated for each time group, +/-
S.E.M. (n = 6-8 wells).
To determine the intervals after which the B2/B1 and S2/S1 ratios
equalled 1, one-way ANOVA, followed by Duncan's Multiple Range Test,
was used to compare the means of B2 and B1 at each time point (also S2
and SI). The ratio was taken to be unity when the two means were not
significantly different.
Differential Regulation of AVP Secretion by Selective Opioid Agonists.
This experiment was designed to examine the AVP secretory responses of
cultured fetal rat hypothalamic cells to various selective opioid receptor
agonists. On day 17 in vitro, cells were incubated with basal and 56 mM
potassium-containing medium for 2 hours each as previously described.
20 hours later, cultures were randomised into 10 treatment groups and
incubated with basal and elevated potassium-containing media, in the
presence of medium alone (control) or either the p./3-agonist
P-Endorphin (1-31) (P~End; Cambridge Research Biochemicals Ltd,
Northwich, Cheshire), the d-agonist [D-Ala2, D-Leu5] Enkephalin
(DADLE; Cambridge Research Biochemicals) or the K-agonist [D-Pro10]-
Dynorphin A (1-11) (Dyn 1-11; Bachem, Saffron Walden, Essex) at
concentrations of 10"12M, 10"9M, or 10"6 M. All drug solutions were
prepared immediately before use from concentrated stock solutions
(lmg/ml in sterile water) stored at -20°C. The modified dynorphin
analogue [D-Pro10]-Dynorphin A (1-11) was chosen as a K-agonist in the
present studies as dynorphin(l-17), the endogenous K-ligand, (Chavkin et
al. 1982) showed a surprising cross-reactivity in the AVP RIA, whereas
Dyn (1-11) did not show this cross-reactivity.
The AVP contents of the media were determined by RIA, and the
B2/B1 and S2/S1 ratios were calculated for each well as previously
described. This experiment was carried out in duplicate or triplicate wells
s
Chapter 8 Opioid Regulation of AVP Secretion 143
and the mean B2/B1 and S2/S1 ratios for each treatment group were
calculated. This experiment was repeated in a further 3 cultures at 3
different times between day 17 and day 31 in vitro, as described above,
and the means from each culture were averaged and expressed +/- S.E.M.
(n = 4 cultures).
To assess whether there were significant responses to the opioids
when compared to controls, B2/B1 and S2/S1 data were analysed
separately by one-way ANOVA. The between-groups variable was
treatment (control, (5-End, DADLE and Dyn (1-11) at 10"12M, 10"9M and
10~6 M). Individual means were then compared to each other using
Duncan's multiple range test.
Naloxone Antagonism of the Effects of the Opioid Agonists. This
experiment was designed to investigate whether the opioid agonists were
acting through naloxone-sensitive opioid receptors. Cultures were
incubated with basal and 56 mM potassium-containing media on day 21
in vitro as previously described. Wells were allocated to 8 treatment
groups and 20 hours later, the cells were incubated sequentially with basal
and elevated potassium-containing media in the absence of opioid
(control), or in the presence of (i-End, DADLE or Dyn 1-11 at 10"6 M. Four
other groups of cells received the same treatments in the presence of
naloxone (Sigma) at a concentration of 10"5 M. As before, this experiment
was carried out in duplicate or triplicate wells and repeated in 3 other
cultures of different ages in vitro. The B2/B1 and S2/S1 ratios were
calculated for each treatment group within each culture, and the overall
means were averaged and expressed +/- S.E.M. (n = 4 cultures).
ANOVA was carried out on the B2/B1 and S2/S1 data separately,
with Drug (Control, P-End, DADLE or Dyn 1-11) and naloxone (present or
absent) as the between-groups variables. Duncan's multiple range test
was used to reveal whether concomitant naloxone administration had
abolished the opioid responses, and whether naloxone alone had
significant effects when compared to controls.
»
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8.2.2. Opioid and Steroid Regulation of AVP Secretion by Fetal Sheep
Hypothalamic Cells.
The three experiments described below were carried out in duplicate
cultures prepared from fetal sheep hypothalami removed at 70 days and
100 days of gestation. Each culture was divided two days after plating, and
half the wells were maintained in serum-free medium and the other half
were cultured in serum-free medium plus Cortisol (150 nM), as described
in Chapter 7. Cells were incubated with basal and 56 mM potassium-
containing medium for 3 hours each on day 7 in vitro, and the
experiments were carried out on days 10,14 or 17 in vitro. As described in
the previous chapter, basal incubation samples were collected as 2
aliquots of 300pl. These were freeze-dried and reconstituted in lOOpl
distilled water for measurement of AVP by RIA.
Within a particular culture, each experiment was carried out in
triplicate or quadruplicate wells in the cortisol-free and cortisol-
supplemented groups in parallel. As for the fetal rat hypothalamic
cultures, duplicate experiments performed in separate cultures were
carried out on different experimental days to randomise the effects of age
in vitro. All samples from an experiment were assayed at the same time,
and the results from the two cultures were combined for analysis.
ft
The Effects of Dynorphin A (1-11) on AVP Secretion. Experiments in the
fetal rat hypothalamic cultures indicated that Dyn (1-11) was the most
potent inhibitor of AVP secretion. Therefore, this drug was chosen as
suitable for investigations of opioid action in fetal sheep hypothalamic
cells. In order to assess the developmental effects of Dyn (1-11) on AVP
ft
secretion, in the presence and absence of Cortisol, cultures were incubated
for 3 hours in basal medium and then for a further 3 hours in 56 mM
potassium-containing medium on day 10 in vitro. 20 hours later, the
ft
cells were incubated sequentially with basal and elevated potassium
medium each containing Dyn (1-11) at 10-6M for 3 hours each. This
experiment was carried out in parallel in the wells cultured in cortisol-
containing medium, in which case all media contained Cortisol (150 nM)
ft
in addition to the experimental treatments. This experiment was
repeated in duplicate day 70 and day 100 fetal hypothalamic cultures, and
ft
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samples were stored at -20°C for later assay. The AVP contents of the
samples were determined by RIA, the B2/B1 and S2/S1 ratios were
calculated for individual wells and the means of these ratios were
expressed +/- S.E.M., (n = 6-7 wells).
One-way ANOVA and Duncan's test were then employed to
examine B2/B1 and S2/S1 ratios individually and to assess significant
differences between the various groups and their respective controls.
Cortisol (present or absent), gestational age (day 70 or day 100) and
dynorphin (present or absent) were the betweeri-groups variables.
%
i
Naloxone Antagonism of the Effects of Dynorphin A (1-11). To
determine whether Dyn (1-11) affected AVP secretion via naloxone-
sensitive opioid receptors, the experiment described above was repeated
on day 14 in vitro, except that naloxone (10"5M) was added to the media
containing Dyn (1-11). The results preparation and statistical analysis
t
were carried out as described for the experiment with Dyn (1-11) alone,
and the pairwise comparisons were made to assess whether naloxone had
abolished the effect of Dyn (1-11) under the various conditions.
The Effects of Naloxone on AVP Secretion. In order to interpret the data
obtained during the experiments described above, it was necessary to
assess the effects of naloxone treatment alone on AVP secretion from the
cell cultures. Therefore, the protocol described above (The Effects of
Dynorphin (1-11) on AVP Secretion) was carried out on day 17 in vitro,
except that Naloxone (10"5M) took the place of Dyn (1-11). The statistical
analysis was as described for the Dyn (1-11) experiment, and die data were
examined to reveal whether there was a significant effect of naloxone
alone in the different cultures.
8.3 Results
Figure 8.1 shows the recovery of basal and potassium-stimulated AVP
secretion from fetal rat hypothalamic cells after previous incubations
with basal and 56 mM potassium-containing media. Basal AVP secretion
during B2 was significantly less than secretion measured in B1 at all time
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Figure 8.1. Recovery of basal and stimulated
AVP output after previous basal and
potassium-stimulated Incubations in fetal rat
hypothalamic cells. Cells were incubated with
basal (B) and 56 mM potassium-containing media (S)
on 2 ocassions (Bl, SI and B2, S2), separated by
varying intervals. A. Basal AVP output during B2
was expressed as a ratio of Bl (B2/B1) and B.
potassium-stimulated AVP output during S2 was
expressed as a ratio of SI (S2/S1). AVP secretion in B2
was compared with output in Bl at each time point,
and a similar analysis was carried out for S2 and SI.
Data shown are means of 6-8 wells, +/- S.E.M. ** p
<0.01, Output in second incubation significantly
different from corresponding output in first (i.e. Ratio
*1).
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points except 20 hours (B2/B1 not equal to 1; p <0.01), whereas potassium-
stimulated AVP release had recovered to SI levels by 12 hours (S2/S1 not
equal to 1 at 1, 2,4 and 8 hour intervals only; p <0.01).
Figures 8.2 A and B show the effects of p-End, DADLE or Dyn (1-11)
at doses from 1(H2M to 10"6 M on AVP secretion from cultured fetal rat
hypothalamic cells, under basal and potassium stimulated conditions
respectively. None of the drugs had any significant effects on AVP
release at 10"12M or 10"9M. However, compared with the control ratio, P-
End (p < 0.05), DADLE (p < 0.05) and Dyn (1-11) (p < 0.01) significantly
inhibited basal AVP release at a dose of 10~6 M. Overall analysis of
variance revealed that there was no significant effect of any opioid
treatment in the presence of elevated potassium (ANOVA; p = 0.8910).
To determine if the effects of the opioids were naloxone-reversible,
fetal rat hypothalamic cells were incubated either with basal medium, P-
End, DADLE or Dyn (1-11) at 10-6 M in the presence or absence of
naloxone at 10~5 M. Figure 8.2 C and D show that P-End (p < 0.05),
DADLE (p < 0.05) and Dyn (1-11) (p < 0.01) significantly inhibited basal
AVP release at a dose of 10"6 M, whereas naloxone alone at 10-5 M had no
ft
significant effect. However, in each case, concurrent naloxone
administration abolished the opioid-mediated inhibition of basal AVP To
I
determine if the effects of the opioids were naloxone-reversible, fetal rat
hypothalamic cells were incubated either with basal medium, P-End,
DADLE or Dyn (1-11) at 10"6 M in the presence or absence of naloxone,
had no significant effects when added in the presence of 56 mM
potassium-containing medium (ANOVA; p = 0.7464).
Figure 8.3 shows the effects of Dyn (1-11) on AVP release from fetal
sheep hypothalamic cell cultures from day 70 and day 100 of gestation, in
the presence or absence of Cortisol. Dyn (1-11) significantly inhibited basal
AVP secretion (p < 0.05) in day 70 hypothalamic cultures, however, these
cultures did not show an inhibitory response to the opioid when
maintained in cortisol-containing media. In day 100 cultures, basal AVP
release was not significantly inhibited by Dyn (1-11), either in cells
cultured in cortisol-supplemented or cortisol-free medium. In both day
70 and day 100 cells, overall analysis of variance showed that Dyn (1-11)
had no effect on 56 mM potassium-stimulated AVP release, either in the
presence or absence of glucocorticoid (ANOVA; p = 0.4142).
Chapter 8 Opioid Regulation of AVP Secretion 148 *
Figure 8.2. The effects of Selective Opioid
Agonists on AVP secretion from fetal rat
hypothalamic cell cultures. Cells were treated
with various doses of the opioids as shown overleaf
under basal (A) and potassium-stimulated (B)
t
conditions. Cells were treated with control medium
or opioids at 10-6M, in the presence and absence of
naloxone (10-5M), in basal (C) and potassium-
stimulated (D) incubations. Basal and stimulated
ratios (B2/B1 and S2/S1) were compared to
corresponding control values. Data shown are means
of 4 cultures, +/- S.E.M. * p <0.05, **p <0.01,
Significantly different from controls.






















Chapter 8 Opioid Regulation of AVP Secretion 149
Figure 8.3. The Effects of [D-Pro1°]Dynorphin
(1-11) on AVP secretion from fetal sheep
hypothalamic cells, in the presence and
absence of Cortisol. Cells maintained in the
presence or absence of Cortisol from day 70 or day 100
of gestation were incubated with Dyn (1-11) at 10-6M
or control media under basal (B2/B1) and potassium-
stimulated (S2/S1) conditions. Data shown are
means of 6-7 wells from 2 cultures, +/- S.E.M. Data
were compared with the corresponding control
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ft
In contrast to the effects of Dyn (1-11), naloxone had no inhibitory or
stimulatory effects on AVP secretion from fetal sheep hypothalamic
cultures, as shown in Figure 8.4. Either in the presence or absence of
Cortisol, overall analysis of variance revealed that basal AVP release was
not affected by naloxone in day 70 or day 100 cells (ANOVA; p = 0.6100).
A similar analysis showed that AVP secretion during potassium
stimulation remained unchanged in the presence of naloxone,
irrespective of glucocorticoid status, at either gestational age (ANOVA;
p =0.2793).
Figure 8.5 shows the effects of Dyn (1-11) plus naloxone on the
secretion of AVP from fetal sheep hypothalamic cultures. There were no
significant effects of this combined treatment on either basal or
potassium-stimulated AVP release from day 100 cells, in the presence or
absence of Cortisol. However, this treatment schedule resulted in a
significant inhibition (p < 0.05) of basal AVP release from day 70 cultures
in the absence of Cortisol. Overall analysis of variance revealed that there
were no significant effects of Dyn (1-11) plus naloxone on AVP release in
any of the experimantal groups during the 56 mM potassium incubations
(ANOVA;p =0.2591);
8.4 Discussion.
The study reported in this chapter investigated the opioid regulation of
AVP secretion from fetal sheep hypothalamic cells in vitro, and was
further structured to assess the effects of gestational age and Cortisol on
the opioid responses. During preliminary investigations with fetal rat
hypothalamic cells, experiments showed that basal AVP secretion was
significantly inhibited by die p/d-agonist (i-End, the d-agonist DADLE and
the K-agonist Dyn (1-11), and that these effects were naloxone-reversible.
In fetal sheep hypothalamic cultures, Dyn (1-11) inhibited basal AVP
release from day 70 cells, but not in day 70 cells maintained in cortisol-
containing medium. In day 100 fetal sheep cells, Dyn (1-11) had no effect
on AVP secretion, either in cortisol-free or cortisol-treated cells. Further
experiments showed that the Dyn (l-ll)-mediated inhibition of AVP








Figure 8.4. The Effects of Naloxone, plus or
minus Cortisol, on AVP Secretion from fetal
sheep hypothalamic cell cultures. Cells
4
maintained in the presence or absence of Cortisol
from day 70 or day 100 of gestation were incubated
with Dyn (1-11) at 10-6M or control media under basal
(B2/B1) and potassium-stimulated (S2/S1)
conditions. Data shown are means of 6-7 wells horn
2 cultures, +/- S.E.M. Data were compared with the
corresponding control groups in each case. There was
no significant difference between the naloxone-
treated and control groups (ANOVA, B2/B1 p =
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Figure 8.5. The Effects of [D-Pro1°]Dynorphin
(1-11) and Naloxone on AVP Secretion from
fetal sheep hypothalamic cell cultures in the
presence and absence of Cortisol. Cells
maintained in the presence or absence of Cortisol
from day 70 or day 100 of gestation were incubated
with Dyn (1-11) at 10-6M or control media under basal
(B2/B1) and potassium-stimulated (S2/S1) conditions.
Data shown are means of 6-7 wells from 2 cultures,
+/- S.E.M. Data were compared with the
corresponding control groups in each case. * p <0.05,
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opioid-induced suppression of basal AVP release observed in fetal sheep
and rat hypothalamic cultures, opioid effects on AVP secretion were not
observed in the presence of 56 mM potassium-containing medium in cell
cultures from either species.
Intravenous opioid administration to fetal sheep stimulates ACTH
secretion from the fetal sheep pituitary gland (Bousquet et al. 1984; Brooks
& Challis, 1988). This opioid effect is most likely mediated indirectly, by
stimulation of hypothalamic CRH and AVP secretion, as the fetal sheep
pituitary contains no opioid receptors (Yang & Challis, 1991). By contrast,
the work reported here showed that a specific K-receptor agonist, Dyn (1-
11) (Gairin, Gouarderes, Mazarguil, Alvinerie & Cros, 1984), was
inhibitory to basal AVP secretion from fetal sheep hypothalamic cells.
This was mirrorred by the effects of Dyn (1-11), P-End and DADLE on
basal AVP secretion from fetal rat hypothalamic cells. The present study
therefore contrasts with recent reports suggesting a stimulatory effect of
opioids on the hypothalamic drive to fetal sheep pituitary ACTH
secretion. However, previous authors employed either the ^.-selective
Met-enkephalin analogue FK33,824 (Brooks & Challis, 1988) or the d-
agonist Leu-enkephalin (Bousquet et al. 1984), rather than the x-agonist
Dyn (1-11) used the present report. Therefore, separate opioid pathways
may exist to mediate opioid-induced stimulation and inhibition of the
hypothalamic input to the fetal sheep corticotropes.
Studies carried out in other species have examined more closely
the various opioid mechanisms which regulate secretion of
hypothalamic ACTH-releasing factors (see chapter 2). In a recent report,
Cover & Buckingham (1989) determined that administration of
naltrexone, a p-opioid antagonist, attenuated the ACTH response to
9
surgical stress in adult rats, whereas MR2266, a k-opioid antagonist,
elevated basal ACTH secretion and enhanced the ACTH response to
surgical stress. These data suggest that endogenous p-opioids acutely
stimulate and endogenous k-opioids tonically inhibit the hypothalamo-
pituitary-adrenal axis, which is in agreement with the findings of Brooks
& Challis (1988) and the present report.
9
The literature also contains reports which contrast with the present
results, showing for example that administration of x-opioids stimulates
the hypothalamo-pituitary-adrenal axis (Pfeiffer et al. 1985). Such
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contradictions may arise in part from the use of different animal
preparations and assay methodologies, amd may also stem from
differential opioid regulation of CRH and AVP. However, in studies
which have specifically addressed hypothalamic AVP secretion, opioids
have been shown to inhibit AVP release from medial basal hypothalamic
fragments in vitro (Knepel & Reimann, 1982) and to reduce hypophyseal
portal plasma concentrations of AVP in vivo (Koenig et al . 1986).
Therefore, the results of the present study are consistent with K-opioid
• I
inhibition of the fetal hypothalamo-pituitary-adrenal axis in early
development.
It is worthy of consideration that the present results reflect the
inhibitory effects of opioids on the secretion of AVP by magnocelluar
hypothalamic neurones at least in day 70 cultures. K-opioids in vivo
have a characteristic diuretic action (see Von Voightlander et al. 1983),
which is strongly suggestive of an inhibitory opioid effect on posterior
pituitary AVP secretion. Studies which have investigated systemic levels
of AVP have clearly shown that K-opioid administration inhibits plasma
concentrations of AVP (Leander, Zerbe & Hart, 1985; Oiso, Iwasaki,
Kondo, Takatsuki & Tomita, 1988). Interestingly, there is a considerable
projection of AVP-containing fibres in the developing fetal sheep
hypothalamus which arise in the supraoptic nucleus and pass to the
external layer of the median eminence (Levidiotis et al. 1987). Therefore,
the normal segregation between AVP cells projecting to the posterior
pituitary or to the median eminence may be less well defined in the fetal
sheep hypothalamus.
In contrast to the inhibitory effects of Dyn (1-11) on basal AVP
release in day 70 cells, the opioid had no effect on basal AVP release in
day 100 cultures. These data suggest a gestational-age dependent decrease
in hypothalamic sensitivity to opioid peptides, which could be mediated
by reduced expression, or functional uncoupling, of opioid receptors.
Dunlap, Christ & Rose (1986) carried out quantitative opioid receptor
binding studies in the fetal sheep brain between day 77 and day 127 of
gestation to determine how opioid receptors were regulated during
development. These authors showed a marked increase in opioid
binding with advancing gestational age, in agreement with the results of
a more recent study of the fetal sheep hypothalamus (Yang & Challis,
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1991). It is therefore not clear why cell cultures from day 70 of gestation
showed a greater opioid response than day 100 cells in the present
investigation. However, it may be that the ligands chosen in the binding
studies did not detect changes in the k-receptor to which Dyn (1-11)
preferentially binds, as neither dihydromorphine, DADLE (see Dunlap et
al ., 1986) nor naloxone (see Yang & Challis, 1991) are K-selective opioid
ligands (Patterson et al. 1983). Data from other species indicates that k-
receptors are present in the brain in early development and that specific
K-ligand binding in the CNS increases towards term (Ruis, Barg, Bern,
Coscia & Loh, 1991; Magnan & Tiberi, 1989), suggesting that the K-opioid
system assumes greater significance in late gestation. By inference, the
present report suggests that the number of inhibitory, fetal sheep
hypothalamic K-receptors is decreased with advancing gestational age.
Such a reduction in hypothalamic k-receptors would permit increased
activity of the AVP neurones in the fetal hypothalamus, which could
increasingly stimulate ACTH release from the fetal pituitary gland.
However, the present results do not permit the conclusion that such a
mechanism is operative in the fetal sheep in vivo. It would be necessary
*
to carry out quantitative binding studies in fetal hypothalamic tissue,
utilising specific k-selective ligands, such as [3H]U-69593 (see Kitchen,
Kelly & Viveros, 1990), to examine this hypothesis in a subsequent
investigation.
A surprising finding in the present report was that the inhibitory
effects of Dyn (1-11) on basal AVP secretion in fetal sheep hypothalamic
#
cultures were not naloxone-reversible. This result may be explained if
the concentration of naloxone employed here (10 pM) was too low, as
10 pM naloxone only partially reversed the inhibitory effects of a specific
k-agonist in a previous study (Tsagarakis et al. 1990). However, the
concentration of naloxone used here abolished Dyn (l-ll)-mediated
suppression of AVP release in fetal rat hypothalamic cultures, as
described in this chapter. Therefore, the experiments on fetal sheep
hypothalamic cells were carried out using this concentration of naloxone.
If it is presumed that Dyn (1-11) acts through k-receptors in the
sheep hypothalamic cultures, the naloxone-insensitivity of the effects of
Dyn (1-11) may be explained by differing k-receptor affinities in the two
species, such that Dyn (1-11) is less easily displaced by naloxone from the
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sheep K-site. Competitive binding studies could be performed in the rat
and sheep hypothalamus using the tritiated K-ligand [3H]U-69593, Dyn (1-
11) and naloxone in order to reveal such a species difference.
Alternatively, Dyn (1-11) may be toxic, or may not be a specific opioid
ligand. However, the data obtained in the fetal rat hypothalamic cultures,
which showed naloxone-reversibility of Dyn (1-11), would tend to refute
these interpretations. In order to confirm these suggestions, day 70 fetal
sheep hypothalamic cultures could be treated with Dyn (1-11) and
increasing concentrations of naloxone or more K-selective opioid
antagonists, such as MR 2266 (Patterson et al. 1983). If neither naloxone
nor a selective K-antagonist abolished the effects of Dyn (1-11), then the
interpretation would have to be that Dyn (1-11) acted via a non-opioid
pathway in day 70 fetal sheep hypothalamic cells.
As gestation proceeds in the fetal sheep, plasma glucocorticoid
4
levels increase concurrently with plasma ACTH (Norman et ah 1985).
Such data suggest that negative feedback regulation of the pituitary-
adrenal axis may be overcome near term (see Wood, 1988). This process
may be effected by rising fetal plasma Cortisol levels, which could act to
increase stimulatory input or decrease inhibitory input to the fetal
hypothalamus, so increasing the drive to pituitary ACTH secretion. In
4
the present study, the inhibitory effects of Dyn (1-11) on AVP secretion
were absent in cells treated with Cortisol, which supports the hypothesis
that Cortisol reduces the inhibitory input to the fetal hypothalamus.
The data do not reveal how the Cortisol effect was brought about. It
may be that Cortisol and Dyn (1-11) act through the same mechanism to
inhibit AVP release, and hence no further effect is observed when both
are added together. This is unlikely, as the principal action of
glucocorticoids is to decrease AVP mRNA levels (Davis et ah 1986;
Schilling et ah 1991), whereas opioids act at membrane-bound receptors to
regulate ion fluxes (see North, 1986). Nevertheless, glucocorticoids
acutely inhibit the secretion of ACTH-releasing factors from fetal sheep
hypothalami (Brooks et ah 1989). This effect has been attributed to
stabilisation of the cell membranes and inhibition of calcium fluxes
4
(Keller-Wood & Dallman, 1984). These are the same mechanisms by
which opioids reduce neuronal activity (North, 1986).
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Glucocorticoids may also act to attenuate neuronal responses to
opioids. Thus, the decrease in hypothalamic dopamine turnover caused
by morphine is diminished by pretreatment with glucocorticoids (Fekete,
Kanyicska, Szentendrai, Simoyi & Stark, 1984). Therefore, these data, in
concert with the present finding that Dyn (l-ll)-mediated inhibition of
AVP release is absent in cortisol-treated cells, suggest that increasing
plasma glucocortioids in the fetal sheep may be associated with a
reduction in the inhibitory effects of opioids on the fetal hypothalmao-
pituitary-adrenal axis.
In contrast to the modulatory effects of Cortisol, the present report
I
demonstrated that naloxone had no effect on AVP secretion from day 70
or day 100 fetal sheep hypothalamic cultures, under any of the
experimental conditions applied. In a recent study, Brooks & Challis
(1988) examined the effects of fetal naloxone administration on plasma
concentrations of ACTH between day 115-140 of gestation. An
intravenous bolus of the opioid antagonist did not alter fetal plasma
ACTH levels, whereas this treatment completely abolished the
stimulatory effects of die ^-agonist FK 33,824. According to these data, die
hypothalamo-pituitary-adrenal axis is not under tonic endogenous opioid
control in the fetal sheep. The present findings are in agreement with the
data of Brooks & Challis (1988), suggesting that there is no endogenous
opioid activity in fetal sheep hypothalamic cultures. What is more likely
is that opioids are. secreted by hypothalamic cultures, but that the
amounts of opioids secreted are in the low picomolar range (Sarkar &
Sakaguchi, 1990). The present report clearly shows that these
concentrations are ineffective in suppressing AVP secretion from fetal rat
hypothalamic cultures. Therefore, the fetal sheep hypothalamic cells may
well secrete opioid peptides, but not in sufficient quantity to exert effects
on AVP release.
%
Interestingly, the inhibitory effects of Dyn (1-11) on AVP secretion
from day 70 hypothalamic cells were not present in cells incubated with
I
56mM potassium-containing solution. In fetal rat hypothalamic cultures,
none of the opioid peptides shown to inhibit basal AVP release had any
efffect in the presence of 56 mM potassium. Therefore, the abolition of
the effects of opioids in 56 mM potassium solution was observed in
several hypothalamic cultures from two species, confirming that this was
4
+
Chapter 8 Opioid Regulation of AVP Secretion 158
not a random occurrence. This finding contrasts with reports that opioids
continue to inhibit hypothalamic ACTH-releasing factor secretion in the
presence of elevated potassium solutions (Tsagarakis et ah 1989;
Tsagarakis et al. 1990). Perhaps the difference between the present study
and those cited above is that the present experiments were carried out
with hypothalamic cell cultures, which lack the organotypic structure of
the hypothalamic fragments utilised by Tsagarakis and colleagues (1989;
1990). This suggests that the responses to opioids in elevated potassium
solutions are dependent on a specific presynaptic input. It would
certainly be interesting to repeat these studies using short term
incubations of hypothalamic pieces, to assess whether the responses to
opioids were different in organotypic explants.
It is possible that the presence of elevated potassium per se
interfered with the inhibitory actions of the opioids. Opioid peptides are
known to hyperpolarise cells by increasing potassium channel
conductivity (North, Williams, Surprenant & Christie, 1987). Williams,
Egan & North (1983) have shown that opioid-induced hyperpolarisations
#
are diminished or even reversed in elevated potassium solutions.
Therefore, opioid inhibition may disappear in the presence of 56 mM
potassium. Such data suggest that other forms of stimulation, such as
acetyl choline treatment (Clarke & Gillies, 1988), may be more appropriate
for investigations of opioid inhibition of AVP release.
In conclusion, the present report examined several variables which
may act at the fetal sheep hypothalamus during development to regulate
the fetal pituitary-adrenal axis. The studies indicated that the inhibitory
effects of opioids on the fetal sheep hypothalamus are diminished with
advancing gestational age, and that elevated Cortisol levels may act to
reduce any inhibitory effects of opioids. These results suggest a
progressive reduction in inhibitory influences acting on fetal
hypothalamic ACTH-releasing factors, and hence are consistent with an





There is a gradual increase in the activity of the pituitary-adrenal axis in
the fetal sheep in late gestation. Plasma ACTH and Cortisol levels rise
4
towards term, beginning around day 110-120 (Norman et al. 1985), and
increasing further at day 140 (Rose et al. 1978). Whilst direct
measurements have not been made of the concentrations of CRH and
AVP in the fetal sheep hypophyseal portal blood, available evidence
indicates that the increased pituitary-adrenal activity in the fetus in late
gestation is due to elevated hypothalamic stimulation of the anterior
pituitary (see Antolovich et al. 1991). These data are consistent with the
progressive increase in bioactive CRH and AVP present in the fetal
hypothalamus with advancing gestation (see chapter 6), which may be
secreted to stimulate ACTH release from the fetal pituitary.
9.2 Discussion
A general observation in the hypothalamic culture experiments
presented in this thesis was that secretion of ACTH-releasing factors was
decreased with advancing gestational age (see Chapters 5 and 7). To-
incorporate these observations into a unifying hypothesis, whereby the
net hypothalamic input to the anterior pituitary corticotropes is
stimulatory late in gestation, it is neccessary to suppose the existence of a
hypothalamic inhibitory factor, the secretion of which is also decreased in
late pregnancy. Recently, Antolovich and associates have provided
evidence for the existence of such a factor during fetal life (Antolovich et
al. 1991). These authors surgically disconnected the fetal sheep
hypothalamus from the pituitary gland (hypothalamo-pituitary
9
disconnection; HPD) at day 110 of gestation and noticed a marked and
sustained increase in circulating ACTH levels when compared to sham-
operated fetuses. These data suggest that ACTH release from the fetal
i
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anterior pituitary gland is under tonic inhibitory control, originating in
the fetal hypothalamus. Recently, evidence has accumulated to suggest
that atrial natriuretic peptide (ANP) may be such a physiological inhibitor
of ACTH release.
ANP is a 28 amino acid peptide originally isolated from the cardiac
atria (de Bold, Borenstein, Veress & Sonnenberg, 1981) which is detected
in the hypothalamus by immunocytochemistry and RIA (Kawata, Nakao,
Morii, Kiso, Yamashita, Imura & Sano, 1985). ANP neurones originate in
the PVN (Palkovits, Eskay, & Antoni, 1987), and project to the median
eminence where they release ANP into portal blood (Lim, Sheward,
Copolov, Windmill, & Fink, 1990). ANP is found to have little effect on
basal ACTH secretion, but to have potent inhibitory effects on stimulated
release of ACTH (Dayanithi & Antoni, 1990). If this factor is incorporated
into hypothalamic control of ACTH secretion in the fetus, then
decreasing hypothalamic ANP release in late gestation would permit the
full activity of CRH and AVP to stimulate ACTH secretion, resulting in
the preparturient activation of the fetal adrenal axis.
The chromatographic fractionation of fetal hypothalamic extracts
(chapter 6) provided good evidence for the presence of ACTH-releasing
factors in the fetal sheep hypothalamus, however, the findings did not
suggest the existence of a fetal corticotrophin release-inhibiting factor
(CRIF). ANP (1-28) has a molecular weight of 3062, therefore it would
have been expected to elute from the Sephadex column in between CRH
(M.Wt. 4671) and AVP (M.Wt. 1084). Re-examination of the data
presented in chapter 6 argues against the presence of such a CRIF in the
fetal sheep hypothalamus. However, the tissue extract which was applied
to the column was not purified, and so there was a good deal of
background ACTH-releasing activity in the chromatography fractions
which may have obscured an inhibitory effect of a putative CRIF. Future
studies to investigate a fetal hypothalamic CRIF should therefore utilise
an extract, purified initially, for example, by solvent extraction. The
peptide extract could then be fractionated by Sephadex chromatography
and the bioactivity of the various fractions measured in a pituitary cell
bioassay in which ACTH output is stimulated with CRH and AVP, in
order to detect inhibition of ACTH release (see Dayanithi and Antoni,
1990).
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Whilst the chromatographic purification of fetal hypothalamic
ACTH-releasing factors in chapter 6 did not reveal an ACTH release-
inhibiting factor, these studies provided evidence for an ACTH-releasing
factor, neither CRH nor AVP, which was present in apparently greater
quantities in late gestation. There are no previous reports of the
chromatographic purification of novel ACTH-releasing bioactivities in
the fetal sheep hypothalamus. Therefore, it would be neccessary to carry
out very thorough validation experiments in order to establish this
substance as a physiological ACTH-releasing factor. For example, the
chromatographic purification could be repeated with adult hypothalamic
extracts, to see if the factor was found only in the fetal hypothalamus. The
ACTH-releasing activity, which has an apparent molecular weight
between those of AVP and CRH (l-5kD), could then be dialysed against
water to remove residual chromatography buffer (0.1M HC1), which may
have intrinsic ACTH-releasing activity. If the ACTH-releasing bioactivity
is present after dialysis and is specific to the fetus, it is more likely to be a
physiological, fetal ACTH-releasing factor. The attractiveness of a specific,
ft
novel, fetal ACTH-releasing factor is that its synthesis and secretion may
not be negatively regulated by Cortisol, in contrast to CRH and AVP, and
so this factor could act to stimulate further ACTH release in the late
gestation fetus, when endogenous Cortisol levels are already elevated.
The reduction in the secretion of ACTH-releasing factors from
ft
hypothalamic cultures in vitro with advancing gestational age was in
contrast to the increased hypothalamic contents of bioactive AVP and
CRH in intact hypothalami (chapter 6). The simplest explanation for this
is that the hypothalamic cells from later in gestation were increasingly
unable to adapt to the culture system, which may be reflective of their
increased maturity and differentiation. However, the quantitative
immunocytochemical staining for Neurone-Specific Enolase (see chapter
5) suggested that there were relatively small differences between the
numbers of neurones in cultures from different fetal ages, relative to the
differences in peptide output. The possibility remains that a selective
reduction in CRH- and AVP-containing cells occurs in culture.
What is more likely is that the synthesis and secretion of AVP and
ft
ft
CRH in the fetal hypothalamus becomes dependent on trophic
presynaptic inputs, the contribution of which grows increasingly
1
ft
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significant as the fetal nervous system matures. In adult rats for example,
destruction of the catecholamine input to the PVN with the 6-hydroxy
dopamine results in a marked reduction in the numbers of CRH
immunopositive neurones in the PVN (Alonso, Szafarczyk, Balmefrezol
& Assenmacher, 1986), and a reduction in portal plasma CRH levels
(Assenmacher, Szafarczyk, Alonso, Ixart & Barbanel, 1987), suggesting that
these brainstem inputs maintain CRH synthesis and release. By contrast,
these inputs are not implicated in the development of hypothalamic CRH
in the rat fetus, as the catecholaminergic projections do not reach the
PVN until after birth (Plotsky et al. 1989).
The hypothetical trophic stimulus to the CRH and AVP neurones
may take the form of a excitatory amino acid input. Excitatory amino
acids are implicated in the increase in hypothalamic drive to the pituitary
at puberty (see Urbanski & Ojeda, 1990), a time when the negative
feedback actions of gonadal steroids are reduced. In chapter 4, cell cultures
from hypothalami removed at day 100 of gestation were treated with N-
methyl D-Aspartate (NMDA), a specific glutamate receptor agonist
(Cotman & Iversen, 1987). NMDA stimulation evoked AVP secretion
which was several fold greater than basal release. Interestingly, fetal
sheep hypothalamic cultures initiated at day 100 of gestation were later
shown to be insensitive to adrenal steroids. It is not clear whether the
NMDA response and the absence of steroid inhibition are linked.
Unfortunately, the experiments which would have permitted a
comparison of the NMDA responses in day 70 and day 100 hypothalamic
cultures were not carried out. In order to assess whether endogenous
*
glutamate is implicated in parturition, it would be very interesting to
examine the sensitivities of fetal hypothalami to NMDA stimulation at
different gestational ages. Possibly the best approach would involve
incubation of hypothalamic pieces over the short term in vitro, as
secretion of peptides from cultured hypothalami removed late in
gestation is too low to measure reliably.
As previously described, the studies in this thesis showed that AVP
secretion from day 70 hypothalamic cultures was inhibited by Cortisol,
whereas AVP release from day 100 hypothalamic cells was unaffected by
this adrenal steroid. The mechanism whereby day 100 cells do not
respond to Cortisol is unclear, as hypothalamic cells express greater
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Figure 9.1. Summary Diagram, indicating some
of the stimulatory and inhibitory influences on
hypothalamic drive to fetal pituitary ACTH secretion
at different stages of fetal development. Solid arrows
indicate results obtained in this thesis, and dashed
0
0
arrows represent the work of others, or as yet
hypothetical factors regulating ACTH release from
the fetal pituitary gland. Ultimately, various trophic
influences acting at central and hypophysial-sites
cause increased release of ACTH, which drives the
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quantities of glucocorticoid receptors at day 100 than at day 70 of gestation
(Yang et al. 1990). It may be that day 100 hypothalamic cells in culture no
longer express glucocorticoid receptors, in which case, it would be
interesting to immunostain hypothalamic' cultures with a monoclonal
anti-glucocorticoid receptor antibody (see Gustaffson et al. 1987) to
confirm the presence of the glucocorticoid receptor.
The studies reported in chapter 8 showed that Cortisol could abolish
the inhibitory effects of an opioid peptide on AVF secretion. There are
several reports in the literature which describe the interactions of
glucocorticoids and opioids, confirming the validity of these observations
(see Gustaffson et al. 1987; Fekete et al. 1984). However, in the fetal sheep
near term, Brooks & Challis (1991) have demonstrated a physiological
stimulatory opioid input to the fetal hypothalamus-pituitary unit, in spite
of the much elevated fetal plasma levels of Cortisol. This may suggest .
that Cortisol is not biologically active within the fetal hypothalamus
immediately before term.
Recently, evidence has accumulated to suggest that glucocorticoid
receptors interact with other factors within the cell to bring about their
biological effects (Akerblom, Slater, Beato, Baxter & Mellon, 1988). Schiile
and colleagues have suggested that an intracellular, transcription factor c-
jun antagonises the effects of glucocorticoids by binding to the
glucocorticoid receptor and preventing an action at the genome (see
Schiile, Rangarajan, Kliewer, Ransone, Bolado, Yang, Verma & Evans,
1990). Presumably, any stimulus which enhanced the synthesis of c-jun
could lead to a reduction in the inhibitory effects of glucocorticoids.
These data suggest that an investigation of c-jun at the molecular level in
the fetal sheep hypothalamus may clarify the mechanisms of
glucocorticoid negative feedback during development.
$
9.3 The Hypothalamic Cell Culture Model
This thesis has developed and exploited a fetal sheep hypothalamic cell
culture system in order to investigate fetal hypothalamic activity during
fetal development. A serum-free system was chosen to permit complete
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control over the chemical environment of the hypothalamic cells. In this
way, it was possible to minimise the confounding effects of batch-to-batch
variations in reagent quality on the characteristics of die cultured cells.
The cell culture system has permitted the detailed investigation of
fetal sheep hypothalamic cells over 5 weeks in vitro, an investigation
which would not have been possible using other techniques. During this
time, the secretion of neuropeptides from the hypothalamic cells was
measured in response to various experimental treatments. A limitation
of this technique became apparent when the secretion and culture content
of CRH and AVP was reduced with advancing gestational age, which was
at odds with the implications of data gathered using other methodologies.
Therefore, some properties of the cultured cells may not accurately reflect
the functions of the cells in vivo.
Cell culture is most effective as a component of the investigation of
fetal hypothalamic function. Other approaches could include short-term
hypothalamic tissue incubations in vitro and the use of the chronically
catheterised fetal sheep model. The main strengths of the cell culture
system are the degree of control over the cellular environment and the
ready accessibility of the hypothalamic neurones. This control has
permitted investigations of the neuropeptide secretion from the fetal
sheep hypothalmamus which have hitherto not been possible.
Furthermore, the culture system will permit future studies of the
molecular mechanisms of hypothalamic function in the fetal sheep.
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